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Abstract
Covariate-adjusted response-adaptive (CARA) randomization designs use the avail-
able responses to skew treatment allocation proportions towards the better performing
treatment, for a given patient’s covariate profile. Such designs have previously been
developed for two treatments assuming exponentially distributed survival responses.
Designs are obtained here considering Weibull distributed survival responses. The op-
timal treatment allocation proportions are targeted using biased coin procedures. These
sequentially estimated allocation proportions converge to the expected target values,
which are functions of the Weibull regression coefficients. CARA designs for Weibull
survival model are also studied using the distribution function of a Gumbel model as
a link between patient information history and the present allocation. Results show
that the proposed designs are a suitable alternative to balanced randomization designs
according to their powers and type I error rates.
To make CARA designs more applicable, they are developed assuming proportional
hazards of an event at a given time point. Optimal allocation proportions are derived
that are targeted similarly. The estimates of these proportions converge to the expected
target values, which are functions of the Cox regression coefficients. Other non-optimal
CARA designs are also investigated which compete in different characteristics with
the optimal CARA ones and the balanced designs. Simulation results show that the
optimal CARA designs outperform the other designs based on their powers and type I
error rates.
For the application of CARA designs in clinical trials with events due to multiple
causes, they are developed assuming proportional sub-distribution hazards at a given
time point. Optimal allocation proportions for the primary cause of interest are derived
that are targeted similarly. The sequentially estimated allocation proportions for these
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designs converge to the expected target values, which are functions of the Fine and
Gray model coefficients. Simulation results reveal the need of a theoretical procedure
for more complicated semi-parametric survival response models.
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Chapter 1
Introduction
1.1 Introduction
Clinical research is a branch of healthcare science that determines the safety
and efficacy of new interventions intended for human use. It is different from clinical
practice in the way that it collects evidence to establish a treatment, whereas in clinical
practice established treatments are used. A clinical research refers to any test article
from its inception in the lab to its introduction to the consumer market and beyond.
Clinical trials are experiments done in clinical research involving human partici-
pants, and are designed to answer specific questions about biomedical or behavioural
interventions, including new treatments. A clinical trial study can be categorized into
two broad categories:
Interventional study: This is a type of clinical study in which participants are
assigned to groups that receive one or more interventions so that researchers can eval-
uate the effects of the interventions on biomedical or health-related outcomes.
Non-Interventional study: Non-interventional studies refer to studies where the
medical products are prescribed in the usual manner in accordance with the terms of
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the marketing authorisation. The assignment of the patient to a particular therapeutic
strategy is not decided in advance by a trial protocol but falls within current practice
and the prescription of the medicine is clearly separated from the decision to include
the patient in the study. No additional diagnostic or monitoring procedures are applied
to the patients and epidemiological methods are used for the analysis of collected data.
The main focus of the entire thesis would be on developing advanced strategies in
order to aid healthcare industries design a Phase III interventional study where two
competing treatments are being compared in terms of its efficacy on human patients’
survival responses which are sequentially available during the course of the trial.
1.2 Journey of a test article during the process of
a Clinical Trial
After the discovery of a test article or a molecule in the laboratory, it goes through
different stages of experiments before being established as a final marketing product for
human well-being. Once the molecule is identified in the laboratory, it is subjected to
pre-clinical studies or animal studies where different aspects of the test article, including
its safety, toxicity if applicable, and efficacy if possible at this early stage, are studied.
Results obtained from the pre-clinical studies or other supporting evidence, are submit-
ted in support of an Investigational New Drug (IND) application to the Food and Drug
Administration (FDA) for review prior to conducting clinical studies that involve hu-
mans. A clinical research may require the approval of Institutional Review Board (IRB)
or Research Ethics Board (REB) and possibly other institutional committee reviews,
about prior submission of the research to the FDA. Clinical research review criteria
will depend on which federal regulations the research is subject to and will depend
on which regulations the institutions subscribe to, in addition to any more stringent
criteria added by the institution possibly in response to state or local laws/policies or
accreditation entity recommendations. This additional layer of review (IRB/REB in
particular) is critical to the protection of human subjects especially when one considers
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that often research subject to the FDA regulation for prior submission is allowed to
proceed, by those same FDA regulations, 30 days after submission to the FDA unless
specifically notified by the FDA not to initiate the study. Therefore ethics plays a very
significant role behind the sucess of any clinical research.
After the pre-clinical approval, the molecule enters the clinical phases of the re-
search. Clinical trials involving new drugs are commonly classified into five phases.
Each phase of the drug approval process is treated as a separate clinical trial. The drug-
development process will normally proceed through all the phases over many years. If
the drug successfully passes through phases 0, 1, 2, and 3, it will usually be approved by
the national regulatory authority for use in the general population. Each phase has a
different purpose and helps scientists answer a different question in relation developing
the new intervention. The phases of clinical trials are defined below. Each of the phases
definitions is a functional one and the terms are not defined on a strict chronological
basis.
Phase 0: Phase 0 is a recent designation for optional exploratory trials conducted in
accordance with the United States Food and Drug Administration’s (FDA) 2006 Guid-
ance on Exploratory Investigational New Drug (IND) Studies.This is the FDA(2006)
document often refered to by the clinicians and the biostatisticians. Phase 0 trials
are also known as human microdosing studies and are designed to speed up the de-
velopment of promising drugs by establishing very early on whether the drug behaves
in human subjects as was expected from preclinical studies. Distinctive features of
Phase 0 trials include the administration of single subtherapeutic doses of the study
drug to a small number of subjects (10 to 15) to gather preliminary data on the drug’s
pharmacokinetics (what the body does to the drugs).
A Phase 0 study gives no information on safety or efficacy, being by definition a
dose too low to cause any therapeutic effect. Drug development companies carry out
Phase 0 studies to rank drug candidates in order to decide which has the best phar-
macokinetic parameters in humans to take forward into further development. They
enable go/no-go decisions to be based on relevant human models instead of relying on
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sometimes inconsistent animal data.
Phase I: Formerly referred to as “first-in-man studies”, this phase comprises of
initial safety trials, side effects, best dose, and formulation method for a new medicine.
Since 1990s this phase of clinical research is being referred to as “first-in-human stud-
ies”. An attempt is made here to establish the dose range tolerated by volunteers for
single and for multiple doses. In order to achieve the objectives, a small group of 20 to
100 healthy volunteers are recruited in this phase of clinical trials. These trials are often
conducted in a clinical trial clinic, where the subject can be observed by full-time staff.
The subject who receives the drug is usually observed until several half-lives of the drug
have passed. Phase I trials are also sometimes conducted in severely ill patients (e.g.,
for patients with terminal cancer) or in less ill patients when pharmacokinetic issues are
addressed (e.g. metabolism of a new antiepileptic medicine in stable epileptic patients
whose microsomal liver enzymes have been induced by other antiepileptic medicines).
Pharmacokinetic and pharmacodynamics trials are usually considered Phase I trials re-
gardless of when they are conducted during a medicine’s development. These trials are
usually conducted in tightly controlled clinics called CPUs (Central Pharmacological
Units), where participants receive 24-hour medical attention and oversight.
Phase IIa: This is also referred to as ‘proof of concept’ studies. It involves pilot
clinical trials to evaluate efficacy ( and safety) in selected populations of patients with
the disease or condition to be treated, diagnosed, or prevented. Objectives here may
focus on dose-response, type of patient, frequency of dosing, or numerous other char-
acteristics of safety and efficacy.
Phase IIb: This is also referred to as ‘definite dose-finding’ studies. These are well
controlled trials to evaluate efficacy ( and safety) in patients with the disease or condi-
tion to be treated, diagnosed, or prevented. These clinical trials usually represent the
most rigorous demonstration of a medicine’s optimum dose at which shows biological
activity with minimal side-effects . Sometimes referred to as pivotal trials.
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Phase IIIa: Trials conducted after efficacy of the medicine is demonstrated, but
prior to regulatory submission of a New Drug Application (NDA) or other dossier.
These clinical trials are conducted in patient populations for which the medicine is
eventually intended. Phase IIIa clinical trials generate additional data on both safety
and efficacy in relatively large numbers of patients in both controlled and uncontrolled
trials. Clinical trials are also conducted in special groups of patients (e.g., renal failure
patients) , or under special conditions dictated by the nature of the medicine and dis-
ease. These trials often provide much of the information needed for the package insert
and labeling of the medicine.
Phase IIIb: Clinical trials conducted after regulatory submission of an NDA or
other dossier, but prior to the medicine’s approval and launch. These trials may supple-
ment earlier trials, complete earlier trials, or may be directed toward new types of trials
(e.g., quality of life, marketing) or Phase IV evaluations. This is the period between
submission and approval of a regulatory dossier for marketing authorization.
Phase IV: Studies or trials conducted after a medicine is marketed to provide ad-
ditional details about the medicine’s efficacy or safety profile. Different formulations,
dosages, durations of treatment, medicine interactions, and other medicine comparisons
may be evaluated. New age groups, races, and other types of patients can be studied.
Detection and definition of previously unknown or inadequately quantified adverse re-
actions and related risk factors are an important aspect of many Phase IV studies. If
a marketed medicine is to be evaluated for another (i.e., new) indication, then those
clinical trials are considered Phase II clinical trials. The term post-marketing surveil-
lance is frequently used to describe those clinical studies in Phase IV (i.e., the period
following marketing) that are primarily observational or non-experimental in nature, to
distinguish them from well controlled Phase IV clinical trials or marketing studies.
The usual process of drug development is depicted in Figure 1.1 .The entire process
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Figure 1.1: The Usual Process of Drug Development
of developing a drug from preclinical research to marketing can take several years and
involves a huge amount of money. Therefore the intention of any clinical research is
primarily on making the trial as ethical as possible without compromising much on the
efficiancy of statistical evaluation. An ethical and efficient design can also attract more
patients to paticipate in the clinical trial which can solve the problem of lack of patient
participation in a clinical trial which the pharmaceutical industries often face mainly
for late phase clinical trials. Therefore the role of a statistician becomes very significant
in the whole process of the drug development.
1.3 Role of a Trial Statistician During the Process
of Clinical Research
While performing a clinical research, the team involved in the process of drug develop-
ment is called the clinical trial team (CTT). This team is responsible for the successful
planning, conducting and execution of the trial. The team consists of many functions
such as global trial leader, clinical managers, clinical scientist, data manager, trial
statistician and statistical programmer. The statistical representative on the CTT is
called the Trial Statistcian who would primarily be responsible for creating the Statisti-
cal Analysis Plan, protocol writing, concept sheet writing, inputs to data management
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documents, preparing the Trial Design module which outlines the inclusion and exclu-
sion criteria and also the visit schedule, as well as work on efficient dry run deliveries
and writing of the final clinical study report. When a clinical objective is presented to
a Trial Staitstician, he/she has to develop an appropriate trial design, decide on appro-
priate study endpoints and suggest a suitable analysis method to achieve the objectives.
It is also the responsiility of the trial statistician to calculate appropriate sample size in
the concept sheet to initiate the trial process. This is further documented in the sample
size documentation. This is then further developed in the Protocol and then detailed
in the Statistical Analysis Plan. For an interventional study, the Statistical Analysis
Plan needs to be prepared before the First Patient First Visit (FPFV) date. Based on
the Statistical Analysis Plan, the Trial Statistician then prepares the TFL shells which
outlines all the Tables, Figures and Listing based on the requirement of a medical lead.
The TFL shells play the pivotal role in the dry run delivery of the output and the final
delivery of the efficacy or safety related outputs prior to the database lock, because
the Trial Programmer programs the outputs based on the structure of the reports in
the TFL shell prepared by the Trial Statistician. The TFL shells need to be finalized
by the trial statistician no later than 6 months after the FPFV, whereas the dry run
analysis outputs need to be finally reviewed by the trial statistician atleast 2 months
prior to the Last Patient Last Visit (LPLV) date. In all these processes the design of
the clinical trial plays a very important role as this is the process that generates the
data which answers the primary and secondary objectives of a clinical research. While
preparing all these regulatory documents, the Trial Statistician needs to maintain the
Clinical Data Interchange Standards Consortium (CDISC) standards.
The CDISC is an open, multidisciplinary, neutral, non-profit standards developing
organization (SDO) that has been working through productive, consensus-based col-
laborative teams, since its formation in the year 1997, to develop global standards and
innovations to streamline medical research data and ensure a link with healthcare. The
CDISC vision is “informing patient care and safety through higher quality medical re-
search”. The CDISC suite of standards supports medical research of any type from
protocol through analysis and reporting of results in the clinical study report.
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In parallel to keeping the CDISC vision while preparing the regulatory documenta-
tion, the Trial Staitistician also tries to follow the statistical methods under research
according to the International Council for Harmonisation of Technical Requirements
for Pharmaceuticals for Human Use (ICH). The ICH is unique in bringing together the
regulatory authorities and pharmaceutical industries to discuss scientific and technical
aspects of drug registration. Since its inception in 1990, ICH has gradually evolved,
to respond to the increasingly global face of drug development. ICH’s mission is to
achieve greater harmonisation worldwide to ensure that safe, effective, and high qual-
ity medicines are developed and registered in the most resource-efficient manner. The
efficacy and safety of medicinal products should be demonstrated by clinical trials
which follow the guidance in ’Good Clinical Practice: Consolidated Guideline’ (ICH
E6) adopted by the ICH, 1 May 1996. The role of statistics in clinical trial design
and analysis is acknowledged as essential in that ICH guideline. The proliferation of
statistical research in the area of clinical trials coupled with the critical role of clinical
research in the drug approval process and health care in general necessitate a succinct
document on statistical issues related to clinical trials. The ICH E9 document gives
direction to sponsors in the design, conduct, analysis, and evaluation of clinical trials
of an investigational product in the context of its overall clinical development. The
document also assists scientific experts charged with preparing application summaries
or assessing evidence of efficacy and safety, principally from clinical trials in later phases
of development.
Recognizing the challenges for research and development and trends for productiv-
ity decline, in 2004 the US Food and Drug Administration (FDA) released the Critical
Path Initiative (CPI) and in 2006 they released the Critical Path Opportunities Report
(CPO) . These are two strategic documents that encourage innovation in drug devel-
opment. One aspect of innovation is adaptive designs which are clinical trial designs
that facilitate efficient learning from data in an ongoing trial and allow modification
of certain aspects of the study according to pre-specified criteria to achieve some pre-
determined experimental objectives. This is where the application of sequential and
adaptive randomization procedures has long been an area of active research. The FDA
are now looking forward to a suitable adaptive randomization procedure which can be
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fruitfully applied in real clinical trials as well as one which addresses the ethical objec-
tives of a clinical study without compromising on the statistical efficiency of treatment
comparison.
1.4 Adaptive Design in Clinical Trials
An adaptive design is defined as a clinical trial design that allows for prospectively
planned modifications to one or more aspects of the design based on accumulating data
from subjects in the trial. It can provide a variety of advantages over non-adaptive
designs. These advantages arise from the fundamental property of clinical trials with
an adaptive design: they allow the trial to adjust to information that was not available
when the trial began. The specific nature of the advantages depends on the scientific
context and types of adaptation considered, with potential advantages falling into the
following major categories:
• Statistical efficiency: In some cases, an adaptive design can provide a greater
chance to detect a true drug effect with greater statistical power than a com-
parable non-adaptive design.This is often true, for example, of group sequential
designs and designs with adaptive modifications to the sample size. Alternatively,
an adaptive design may provide the same statistical power with a smaller expected
sample size or shorter expected calendar time than a comparable non-adaptive
design.
• Ethical considerations:There are many ways in which an adaptive design can
provide ethical advantages over a non-adaptive design. For example, the ability
to stop a trial early if it becomes clear that the trial is unlikely to demonstrate
effectiveness can reduce the number of patients exposed to the unnecessary risk
of an ineffective investigational treatment and allow subjects the opportunity to
explore more promising therapeutic alternatives.
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• Advantages in generalizability and improved understanding of drug ef-
fects: An adaptive design can make it possible to answer broader questions than
would normally be feasible with a non-adaptive design. For example, an adaptive
enrichment design may make it possible to demonstrate effectiveness in either a
given population of patients or a targeted subgroup of that population, where a
non-adaptive alternative might require infeasibly large sample sizes. An adaptive
design can also yield improved understanding of the effect of the experimental
treatment. For example, a design with adaptive dose selection may yield better
estimates of the dose-response relationship, which may also lead to more efficient
subsequent trials.
• Acceptability to stakeholders: An adaptive design may be considered more
acceptable to stakeholders than a comparable non-adaptive design because of the
added flexibility. For example, sponsors may be more willing to commit to a
trial that allows planned design modifications based on accumulating informa-
tion. Patients may be more willing to enroll in trials that use response-adaptive
randomization because these trials can increase the probability that subjects will
be assigned to the more effective treatment.
Example: A clinical trial was conducted to evaluate Eliprodil for treatment of pa-
tients suffering from severe head injury (Bolland et al. 1998). The primary efficacy
endpoint was a three category outcome defining the functional status of the patient
after six months of treatment. There was considerable uncertainty at the design stage
about the proportions of patients in the placebo control group who would be expected
to experience each of the three different functional outcomes. An interim analysis was
prespecified to update estimates of these proportions based on pooled, non-comparative
data in order to potentially increase the sample size. This approach was chosen to avoid
a trial with inadequate statistical power and therefore helped ensure that the trial would
efficiently and reliably achieve its objective. The interim analysis ultimately led to a
sample size increase from 400 to 450 patients.
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Dragalin’s (2006) classification of adaptive designs distinguishes four major types of
adaptation:
• Adaptive allocation rule: change in the randomization procedure to modify
the allocation proportion or the number of treatment arms.
• Adaptive sampling rule: change in the number of study subjects or change in
study population.
• Adaptive stopping rule: early stopping due to efficacy, futility, or safety.
• Adaptive decision rule: change in the way decisions will be made about the
trial (e.g., change of endpoint, change of test statistics, etc.).
The current thesis deals with adaptive randomization designs, i.e, the designs that
fall in the first category of Dragalin’s (2006) classification. A general adaptive random-
ization procedure is defined by specifying conditional randomization probabilities of
treatment assignments as follows: Let X(m+1) be a treatment assignment indicator such
that X(m+1) = (1, 0) according to the assignment of the (m+ 1)
th patient to treatment
k = (A,B). Let Dm be the data structure that forms the basis for design adaptations.
A general adaptive randomization procedure is defined by specifying conditional ran-
domization probabilities of assignments of patients to a particular treatment arm eg:
Arm A, as follows:
P(m+1),A = P{X(m+1) = 1|Dm}, (1.1)
Depending on the trial objectives, one can distinguish four types of adaptive ran-
domization designs:
• Restricted randomization:
This is the randomization procedure when Dm = {χ1, ..., χm}, the history of
previous patients’ treatment assignments. The goal is to prospectively balance
treatment numbers in the trial.
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• Covariate-adaptive randomization:
This is the randomization procedure when Dm = {(χ1, z1), ..., (χ1, zm), zm+1},the
history of previous patients’ treatment assignments and covariates, and the covari-
ate vector of the current patient. The goal is to prospectively balance treatment
assignments overall in the trial and across selected covariates.
• Response-adaptive randomization:
This is the randomization procedure when Dm = {(χ1, υ1), ..., (χm, υm)}, the his-
tory of previous patients treatment assignments and responses. The most common
goal is to increase the chance for a patient to be assigned to a potentially better
treatment. Other possible goals may include increasing estimation efficiency of
the desired treatment effect or maximizing the power of a statistical test.
• Covariate-adjusted response-adaptive randomization
This is the randomization procedure whenDm = {(χ1, z1, υ1), ..., (χm, zm, υm), zm+1},
the history of previous patients treatment assignments, responses and covariates,
and the covariate vector of the current patient. The most common goal is to
increase the chance for a patient to be assigned to a potentially better treatment
given the patients covariate profile while maintaining the power of a statistical
test.
The class of adaptive randomization procedures can be extended further by including
adaptive designs with treatment selection for which randomization probabilities for
some treatment arms can be set to 0 throughout the trial.
This thesis is dedicated towards discussing the development of Covariate-adjusted
response-adaptive randomization designs when the response of patients to a particular
treatment arm follow a survival model. Very limited discussion can be found in the lit-
erature about the development of Covariate-adjusted response-adaptive randomization
procedures for survival trials. This is because considering survival responses does not
allow the priviledge of handling independent and identically distributed observations.
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1.5 Survival Responses
Survival responses are concerned with obsevations relating to times to some critical
event, starting from some specific time origin. For example, oncology studies are often
concerned with cancer survival from treatment to death. Here a major objective is to
compare the effectiveness of treatments allowing for the effects of explanatory variables
or factors. Random variables representing time to event outcomes do not always record
a random sample of completed observations. For example, when the survival of patients
following treatment for cancer is being measured, starting in each case with the date of
treatment, some patients who live for a long time, do not have their completed survival
times at the end of the study period. Omitting such observations from the analysis
would clearly introduce a serious bias into the estimation of how long such patients do
in fact survive. Such observations are said to be right-censored and their inclusion in
the analysis in appropriate form is crucial.
There are three different forms of censoring: right-censoring, left-censoring and
interval-censoring; truncation is a somewhat different phenomenon.
• Right-Censoring : This is the most frequently encountered type, at least in
medical applications. Some subjects leave the study before the event occurs, so
one only knows that their survival time X lies in an interval (t,∞). If X is the
survival time, and C is the time until the subject left the study, then in the case
of right-censoring for the ith subject, Ti = min(Xi;Ci) is only observed.
• Left-Censoring : This is much more rarely encountered. Sometimes some sub-
jects have experienced the event before detailed observation commences. Thus
their time to the event lies in the interval [0, T ). It is possible for both right and
left censoring to occur in the same dataset.
• Interval-Censoring :Interval-censoring occurs when it is not clear when the
event occurred. All that is known is that the time to event occurred within
some interval (t1, t2]. This form of censoring often arises when observations are
infrequent, and the event has occurred between two observation times.
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• Left-Truncation : In left-truncation subjects enter the study at times after the
origin for the events of interest and are followed up until the event of interest
occurs or they are lost to followup. Subjects only contribute to the likelihood
once they have entered the study, which will be at particular times greater than
zero, even on their personal time origin bases. If they experience the event before
their observation period starts they will not appear in the study.
• Right-Truncation : Right-truncation refers to studies where subjects are only
observed if they experience the event. Studies based on death records are an
example of this.
Throughout this thesis Covariate-adjusted response-adaptive (CARA) designs are
developed for survival responses which are right-censored, assuming independence be-
tween survival times and censored times. Numerous real-life clinical trials, specially in
the oncology theraputic area, deal with survival endpoints. However there has been very
limited discussion about developing CARA designs for such trials. Sverdlov, Rosen-
berger and Ryzenik (2013) discussed development of CARA designs for exponential
survival responses which are right-censored. Biswas, Bhattacharya and Park (2016)
considered informative random censoring while developing CARA designs for exponen-
tial survival responses. An attempt has been made throughout this thesis to develop
CARA designs further in order to enhance their applicability in real-life survival trials
when observations are right-censored.
1.6 Outline of the Thesis
Chapter 2 of this thesis enhances the scope of applications of CARA designs beyond ex-
ponential survival responses, by considering Weibull distributed survival responses. In
real clinical trials however the response of patients to a treatment infrequently follows
a paramertic model, the scope of application of CARA designs is enhanced further in
Chapter 3 by relaxing any parametric distributional assumption for survival responses
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but considering the hazard of patients at a given time-point to be proportional. Often
in clinical trials especially in the oncology therapeutic area, people are interested in
survival endproints where events occur due to multiple causes. Trial protocols consid-
ering progression free survival as the primary endpoint often encounters such scenario.
CARA designs are developed in Chapter 4 for such specific type of survival trials. This
is followed in Chapter 5 by detailing the summary of the research findings in this thesis
along with its critical evaluation and suggestion on few areas in which CARA designs
can be developed further considering survival responses of patients who are arriving
sequentially in the trial.
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Chapter 2
Covariate-Adjusted
Response-Adaptive Designs for
Weibull Survival Models
2.1 Introduction
There is great interest in the possibility that clinical trials can be designed with
adaptive features that may make the studies more efficient. An adaptively random-
ized clinical trial evaluates a treatment by observing patient responses on a prescribed
schedule and modifies the parameters of the trial protocol in accordance with those
observations. The adaptation process generally continues throughout the trial. Clinical
trials are often designed with adaptive features to force balance in the sequential allo-
cation of patients across two or more competing treatment arms. It is also used to force
imbalance by allocating a greater number of study subjects to the better-performing
treatment arm.
A clinical trial is a complex experiment on humans with multiple and often compet-
ing experimental objectives. Here, several treatments for a disease are compared with
the purpose of obtaining information on their performance. Since human patients are
involved, there is an ethical concern to treat as many patients as possible with the best
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treatment. At the same time, there must be some allocation of patients to the worse
treatment arm for making useful statistical inferences about treatment comparisons.
An increase in the number of patients receiving better treatments leads to sequential
experiments in which data are analysed and new allocations are made in the light of
the estimated parameters. However, the advocates of traditional balanced randomized
designs argue that having a balanced allocation of patients across the treatment arms
helps estimate treatment effects efficiently. Since clinical trials involve human patients,
balanced allocation can be a serious problem as one would be more inclined to be treated
with the better treatment and such balanced allocation leads to almost one half of the
patients on the worse treatment arm. To balance these competing goals of ethics and
statistical efficiency in a clinical trial, response-adaptive designs have been developed
and used. A response-adaptive design uses the available response and treatment alloca-
tion histories to skew the treatment allocation probabilities in favour of the treatment
arm found best at an interim stage in the trial. However, human patients are heteroge-
neous and therefore one needs to take into account such concomitant information when
allocating a particular patient to a treatment arm.
Covariate-adjusted response-adaptive designs balance the competing goals of as-
signing a greater number of study subjects to the better treatment and achieving high
statistical efficiency in estimating treatment effects. This is done in the presence of
covariates, while maintaining randomness in treatment assignments. Investigators are
often aware of important baseline covariates that may have a strong influence on patient
responses and they may wish to adjust the randomization procedure for these covariates.
Rosenberger and Sverdlov (2008) gave an overview of different techniques for handling
covariates in the design of clinical trials and distinguished between two main approaches.
These are covariate-adaptive randomization and covariate-adjusted response-adaptive
randomization (CARA) procedures. CARA randomization is applicable to clinical tri-
als where non-linear and heteroscedastic models determine the relationship between
responses, treatments and covariates, and when multiple experimental objectives are
pursued in the trial. The goal of a CARA procedure in a phaze III clinical trial may
be to skew allocation in the direction of the better performing treatment arm, for a
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given patient’s covariate profile, while maintaining the power of a statistical test for
treatment comparisons. These designs rely on correctly specified parametric models.
Although the exponential model for survival responses has been previously considered
by Sverdlov, Rosenberger and Ryzenik (2013) for developing CARA designs, to extend
the scope of application of such designs in real-life clinical trials, the Weibull survival
model has been considered here, which includes the exponential model as a special case.
The memoryless property of the exponential survival model due to its constant hazard
property limits its application in real-life clinical trials involving humans. Therefore
to enhance the scope of the application of such designs a step further, methods are
developed here considering survival responses following a Weibull model. The shape
parameter for the Weibull survival model determines the shape of the density function
as well as the hazard function of the responses. The exponential model is a special
case when the shape parameter is unity which makes the hazard function of the time
to an event a constant. A CARA design based on the Weibull model for the survival
responses of the patients therefore extends the scope of application of such designs to
scenarios beyond constant hazard. Extensive simulation study of the operating charac-
teristics suggest that the proposed CARA procedure can certainly be considered as a
suitable alternative to the traditional balanced randomization designs in survival trials,
provided that sufficient responses are available during the interim stage of the trial to
enable adaptations in the design.
The outline of this chapter is as follows. Section 2.2 explains the basic background
relating to the Weibull survival model . The discussion in Section 2.3 focuses on the
idea of obtaining parameter estimates using the maximum likelihood approach when
survival times conform to a Weibull model and the right-censored times are independent
of the event times. This is followed by Section 2.4 that proposes the various target
allocation proportions to a treatment arm, for Weibull distriuted survival times and
the CARA randomization procedures to achieve the derived allocation proportions.
The derivation of the asymptotic properties of the CARA designs using a Taylor series
expansion of the non-centrality parameter for the Wald test is detailed in Section 2.5.
The findings of Section 2.4 have been validated using extensive simulations in Section
2.6. In Section 2.7, the applicability of the proposed CARA designs is further explained
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through the results obtained from applying them to redesign a real-life clinical trial.
A critical evaluation of some of the derived CARA designs for Weibull distributed
survival responses is provided in Section 2.8. Section 2.9 concludes with a discussion of
the overall findings and an outline of some future research in this direction.
2.2 The Weibull Model
The exponential model used by Sverdlov, Rosenberger and Ryeznik (2013) to
develop CARA randomization procedures for survival trials is often referred to as a
purely random failure pattern. It is useful for its mathematical simplicity, but the fact
that the exponential distribution corresponds to a lack of memory model and that it
has only one parameter make it less likely to fit data in practice.
Let T be a non-negative random variable representing the time to a critical event.
The lack of memory property of the exponential distribution means that P (T > t +
z|T > t) = P (T > z), which leads to its mathematical tractability but also reduces
its applicability to many realistic applied situations. It is because of this distributional
property that E(T − t|T ≥ t) = E(T ) = µ; that is, the mean residual life or the
expected remaining lifetime for a patient is constant at any point in the study. This
shows that the time until the future occurrence of an event does not depend upon past
history, and therefore this property is sometimes called the “no-aging” property. This
property is also reflected in the exponential distribution’s constant hazard rate which
is independent of t. Although the exponential distribution has been historically very
popular, its constant hazard rate appears to make it too restrictive in both health and
industrial applications.
The Weibull distribution can be regarded as a generalization of the exponential, with
an extra shape parameter, γ > 0 . Being the only parametric survival distribution which
has both a proportional hazards representation and an accelerated life representation, it
is the most popular distribution used in reliability and survival analysis. Let xi denote
the treatment indicator for the ith patient such that xi = 1 if the patient is assigned
to treatment A, and xi = 0 if the patient is assigned to treatment B. Associated with
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patient i = 1, 2, ..., n is a vector of baseline covariates zi = (1, z1i, ...., zpi)
T . Let γk
be the shape parameter that determines the shape of the distribution of the responses
for treatment k as well as that of the hazard function, βk = (βk0, βk1, ...., βkp)
T be the
vector of unknown model parameters and µk(zi) = exp(β
T
k zi) > 0, the scale parameter
for treatment k given the ith covariate zi. Conditional on zi, patient’s survival time on
treatment k, Tik, follows a Weibull distribution with probability density function
fk(t|zi;βk, γk) =
{
γk
µk(zi)
}{
t
µk(zi)
}γk−1
exp
[
−
{
t
µk(zi)
}γk]
(2.1)
for t > 0.
Let Sk(t|zi) = Pk(T ≥t |zi) be the survivor function measuring the probability of
a patient with covariate zi at treatment k surviving beyond a given time point t. The
survivor function of the Weibull model is Sk(t|zi;βk, γk) = exp [−{t/µk(zi)}]γk . Let
hk(t|zi) = fk(t|zi)Sk(t|zi) be the hazard function representing the instantaneous failure rate of
a subject with covariate zi at time t. Therefore, the hazard function for the Weibull
model can be expressed as hk(t|zi;βk, γk) = {γk/µk(zi)}{t/µk(zi)}γk−1. It is also known
that Sk(t|zi;βk, γk) = exp{−
∫ t
0
hk(u|zi;βk, γk)du} where,∫ t
0
hk(u|zi;βk, γk)du = Hk(t|zi;βk, γk) = − log{Sk(t|zi;βk, γk)}
is called the cumulative hazard or the integrated hazard. The cumulative hazard for the
Weibull distribution therefore is Hk(t|zi;βk, γk) = {t/µk(zi)}γk . The hazard function
for a Weibull model is always monotonic, but can be increasing if γk > 1, decreasing
if 0 < γk < 1 or constant if γk = 1. Therefore, the Weibull distribution with shape
parameter γ = 1 corresponds to the exponential distribution. The mean and the
median survival times for the Weibull model are λk(zi) = µk(zi)Γ{(γk + 1)/γk} and
φk(zi) = {log(2)}1/γkµk(zi) respectively, where Γ denotes the gamma function.
When comparing the survival experience of two arms, if an additional assumption is
made about the shape parameter γk being constant between the arms, then the hazard
at any given time for an individual in one treatment group is proportional to the hazard
at that time for an individual from the other treatment group. The hazard ratio ψ of
the two treatment groups satisfies
hA(t|zi;βA, γ) = ψhB(t|zi;βB, γ). (2.2)
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Here, ψ does not depend on t and the responses for the two treatment groups follow
Weibull distributions with the same shape parameter γ. The assumption of the response
following a Weibull model with equal shape parameter can be checked by plotting the
log cumulative hazard function marginalized over the covariate profile zi of the patients,
against the log time for both treatment arms. If the plot yields parallel lines then the
assumption of a constant γ between the treatment groups can be considered to have
been satisfied. The intercept of the log cumulative hazard plot for patients receiving
treatment k against the log time is −γ log(µk). If the survival times conform to a
Weibull distribution with a constant shape parameter, the hazard function for patients
at the two treatment arms will be
ψ =
hA(t|βA, γ)
hB(t|βB, γ) =
{
µB
µA
}−γ
(2.3)
and
log(ψ) = −γ log
{
µB
µA
}
. (2.4)
This shows that the hazard ratio between the treatment arms is constant if the responses
of the patients to the treatments follow a Weibull distribution with the same shape
parameter. It can also be seen from (2.4) that a crude estimate of the hazard ratio
can be obtained by exponentiating the difference between the intercepts when the log
cumulative hazard function for each treatment arm is plotted against log time. This
model is called the Weibull proportional hazards model.
It is sometimes useful to work with the logarithm of the survival times. If Yik =
log(Tik), where Tik follows a Weibull distribution, then Yik has a Gumbel distribution
with density function given by
fk(y|zi;βk, γk) = γk exp ([y − log{µk(zi)}γk]) exp(−e[y−log{µk(zi)}γk]), (2.5)
for −∞ < y < ∞. This distribution will frequently be referred to in this chapter
while constructing the likelihood for the Weibull model and the CARA randomization
procedure.
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2.3 Construction of the Likelihood
In survival trials, observations are likely to be censored. Therefore in such trials one
cannot observe a random sample of complete independent and identically distributed
random variables. A critical assumption is that the survival times and the censoring
times are independent. For construction of a likelihood function for censored data,
one needs to carefully consider the information conveyed by each observation. Right
censoring is the most frequently encountered type of censoring, which could happen
when the patient followed does not experience the event or when the study is stopped
before the event occurred. For example, when the data are measured from different
start times, some patients who are recruited late to the study are likely to be alive at
the time of analyzing the data. Therefore, the survival times for these patients would be
unavailable. All that would be known about the survival times for these patients is that
they exceed a certain time.When some subjects are right censored, all that is known
is that their survival time lies in an interval (t,∞). Let Tik be the random variable
representing the survival time for the ith patient with treatment k and Cik be the one
representing the censoring time for that patient.The survival times are assumed to be
independently and identically distributed. For the ith patient, the observed outcome is
a bivariate random vector (Tik,δik), where Tik = min(Tik,Cik) and
δik =
0 if Tik is a right-censored time,1 if an event occured at time Tik. (2.6)
When subjects join a study at different times and are all observed until a fixed
moment in time, we have generalized type I right censoring. Here time is measured
from a different origin for each subject, who has an individual specific fixed censoring
time. Figure 2.1 shows this for five patients.
For right-censored observations, the event time is larger than the observed time.
So the information is the survivor function evaluated at the on study time. It can be
seen from Figure 2.1 above that each of the five patients in the trial enter the study at
different times but are observed for a predetermined study period. The blank circles
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Figure 2.1: Generalized type I right censoring
in the figure represents censoring observations and the dark squares represent patients
who have experienced the event. The patients who enter the study late are more likely
to be censored. Censoring in such cases may occur if the patients did not experience
the event until the end of the study period or if they have been lost to follow-up before
the end of the study period. It can be seen from Figure 2.1 that patients A survive
until the end of the study period and therefore their actual survival times Tik are not
known. All that is known is that they survive beyond a certain time period. Also
the time to event for patient B and patient D is censored as he/she has been lost to
follow-up before the end of the study period. Therefore, Tik = Cik for patients A,B and
D. However, for patients C and E, it can be seen that they have experienced the event
and therefore their actual event times Tik = Tik are known.
In this chapter, a CARA randomization procedure has been developed for survival
responses where the event times follow a Weibull model. Since patients arrive sequen-
tially in the clinical trial and are observed until the end of the trial, the type of censoring
considered here is generalized type I right censoring. With such a model, the outcome
for the ith patient is given by (tiA,δiA) if xi = 1 or (tiB,δiB) if xi = 0. Any of the com-
plications of the data such as censoring or truncation will affect the likelihood as this
leads to a data which is not indenpendent and identically distributed. The likelihood
may be written down by incorporating the exact event times through the density func-
tion fk(tik|zi;βk, γk) and the right censored observations through the survivor function
Sk(cik|zi;βk, γk). Here, cik is a realization of the random variable Cik and censoring is
assumed to be independent of the survival. Note that the functions are being adjusted
for the effects βk of the covariates zi and also for the shape parameter γk of the Weibull
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model which scales the theoretical errors of the accelerated life model.
For the survival times from the patients on treatment k, the likelihood function is,
Lk =
∏
δik=1
fk(tik|zi;βk, γk)
∏
δik=0
Sk(cik|zi;βk, γk) (2.7)
Now, it can be seen that, for δik = 0,
P (Tik = cik, δik = 0) = P (Tik = cik|δik = 0)P (δik = 0).
Therefore, this can also be written as
P (Tik = cik, δik = 0) = P (δik = 0) = P (Tik > cik),
which is the survivor function at time cik. Similarly for δik = 1,
P (Tik = tik, δik = 1) = P (Tik = tik|Tik < cik)P (Tik < cik),
which can also be written as
fk(tik|zi;βk, γk)
1− Sk(cik|zi;βk, γk){1− Sk(cik|zi;βk, γk)} = fk(tik|zi;βk, γk).
Thereofore, for a random sample of pairs (tik,δik) of nk patients, the likelihood function
is given by
Lk =
nk∏
i=1
{fk(tik|zi;βk, γk)}δik{Sk(tik|zi;βk, γk)}1−δik . (2.8)
It is well known from the distribution theory of survival analysis that fk(tik|zi;βk, γk) =
Sk(tik|zi;βk, γk)hk(tik|zi;βk, γk). Thus, (2.8) can be further simplified to be
Lk =
nk∏
i=1
{hk(tik|zi;βk, γk)}δikSk(tik|zi;βk, γk), (2.9)
so that the combined likelihood function is
L =
B∏
k=A
n∏
i=1
{hk(tik|zi;βk, γk)}δikSk(tik|zi;βk, γk).
For a random sample of observations (tik, δik), from the Weibull distribution with
independent right censoring, let yik = log(tik). It was seen earlier that the density of
Yik is given by (2.5). Therefore, the likelihood function in this case is
Lk =
nk∏
i=1
(γk e
[yik−log{µk(zi)})γk])δike− exp [yik−log{µk(zi)}γk]. (2.10)
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So the log-likelihood function here is given by
lk = − log(γk)
nk∑
i=1
δik +
nk∑
i=1
(δik[yik − log{µk(zi)}γk]− e[yik−log{µk(zi)}γk]). (2.11)
Maximising the log-likelihood in (2.11) separately for 1/γk and log{µk(zi)}, the
maximum likelihood estimators for these model parameters can be obtained, which in
turn give the maximum likelihood estimators of the regression parameters. This is
because, for the Weibull accelerated life model, the linear predictor βTk zi is considered
to be identical to log{µk(zi)} and not µk(zi). Also the theroretical errors follow a
two parameter Gumbel distribution that is scaled by the factor 1/γk. The first partial
derivatives of the log likelihood function (2.11) with respect to log{µk(zi)} and 1/γk
are
∂lk
∂ log{µk(zi))} =
n∑
i=1
(
δik − e[yik−log{µk(zi)}γk]
)
(−γk), (2.12)
and,
∂lk
∂(1/γk)
= −
(
nk∑
i=1
δikγk +
nk∑
i=1
(δik − e[yik−log{µk(zi)}γk])
)
[yik − log{µk(zi)}]γ2k. (2.13)
Equating the score functions in (2.12) and (2.13) to zero and solving for 1/γk and
log{µk(zi)} gives the maximum likelihood estimates for 1/γk and log{µk(zi)}. The
variances of the estimated parameters can be obtained by calculating the second patial
derivatives of the log-likelihood function (2.11) with respect to 1/γk and log{µk(zi)} .
The details are in Appendix A.
An important practical feature of Weibull accelerated life models is that they can be
fitted to data using an algorithm which is a form of iteratively re-weighted least squares.
The maximum likelihood estimate of βk is obtained by this method. The maximum
likelihood estimates of log{µk(zi)} and 1/γk are also obtained by equating (2.12) and
(2.13) to zero and numerically solving them using the method of iteratively re-weighted
least squares. McCullagh and Nelder (1989) proved that this algorithm is equivalent to
the Fisher scoring method and leads to the maximum likelihood estimates.
Given an initial trial estimate βˆk, the estimated linear predictor ηˆik = βˆ
T
k zi is cal-
culated. This is used to obtain µˆk(zi) = r
−1(ηˆik), where r(.) is the necessary one-to-one
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continuous link function selected on the basis of the distribution of the responses. In
the Weibull regression model, r(.) is the natural log link function. These quantities are
further used to calculate the working dependent variable
bi = ηˆik + {yik − µˆk(zi)} ∂ηˆik
∂µˆk(zi)
,
where the rightmost term is the derivative of the link function evaluated at the trial
estimate. Next, the iterative weights are calculated. The ith weight is inversely propor-
tional to the variance of the working dependent variable bi, given the current estimates
of the parameters. The iterative weights here are given by
ik(βk, γk, zi) = P (Tik ≤ Ci|zi;βk, γk), (2.14)
for i = 1, 2, ..., nk , and k = A, B.
For the ith patient, (2.14) is the probability of observing an event before censoring
conditional on βk, γk and the covariates for that patient.This quantity will depend on
the censoring mechanism in the trial. Finally, an improved estimate of βk is obtained
by regressing the working dependent variable bi on the covariates zi using the weights.
This means that a weighted least squares estimate is approximated using
βˆk = (Z
T
nk
WkZnk)
−1ZTnkWkb, (2.15)
where b is a response vector with entries given by the working dependent variable bi,
Znk is the model matrix for the patients on treatment k, Wk is an nk × nk diagonal
matrix with the ith diagonal element as ik(zi;βk, γk) given in (2.14) and Z
T
nk
WkZnk is
the approximate Fisher Information matrix for βk which is scaled by γk. The procedure
is repeated until successive estimates change by less than a specified small amount.
2.4 The Proposed Allocation Designs
The main goal of a CARA procedure is to use the accumulated data to skew the
treatment allocation probabilities in favour of the treatment that is most efficacious
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for a given patient. This is done for ethical considerations and also for enhancing the
efficiency in estimating the treatment effects. This represents an advancement in the
field of personalized medicine or theranostics, which is a medical model that separates
people into different groups based on medical decisions, practices, interventions and/or
products being tailored to the individual patient after taking into account the informa-
tion related to their predicted response or risk of disease. The CARA randomization
procedure is applicable when the responses of the patients to the treatment follow a
non-linear and heteroscedastic model and when multiple experimental objectives are
being pursued in the clinical trial. It relies on correctly specified parametric models.
The censoring scheme assumed throughout this chapter is a combination of uniform
and generalized type I censoring. This has been described as administrative censoring
in Latta (1981). Patient arrival times follow an independent uniform distribution on
(0,R). The clinical trial has a recruitment period of length R > 0. The survival times of
the patients follow a Weibull distribution with parameters µk(zi) and γk, and the right
censored times, Cik, are uniformly distributed over (0,D), where D is the duration of the
clinical trial. At time D, the subjects who have not experienced an event or have not
yet been lost to follow-up are considered to be generalized right censored of type I. Such
assumptions can be considered to be reasonable in a real-life clinical trial. In the subset
of survival trials where the recruitment phase is long enough to accumulate a substantial
amount of response data, the CARA randomization procedure is applicable.
The βA and the βB are population characteristics representing the covariate adjusted
treatment effects of A and B, respectively. During the initial phase of the trial, one
uses some balanced randomization procedure to allocate the initial 2m0 patients equally
among treatments A and B, where m0 is a positive integer. This ensures that at least
m0 patients are allocated to each treatment arm, and m0 is chosen so that estimates of
the parameters (βA , βB) can be obtained from this initial sample. At stage m = 2m0,
one computes the maximum likelihood estimates (βˆA,m, βˆB,m) based on the responses
of the first 2m0 patients, eliminating the effects of the prognostic factors. At stage m ≥
2m0 + 1, when the (m+ 1)
th patient enters the clinical trial with covariate vector zm+1,
this patient is randomized to treatment A with probability c(βˆA,m, βˆB,m,γˆ, zm+1) where
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0 ≤ c(.) ≤ 1 is an allocation function which bridges the past allocation pattern, response
histories and the covariate vectors of the m patients through the sufficient statistics
which the fittel model is a function of, to the (m + 1)th allocation with the covariate
vector zm+1. This allocation is chosen with the intention of skewing the treatment
allocation probability in favour of the better treatment arm. This section discusses
the method of derivation of this allocation function using two different approaches.
One of these uses two different types of allocation function to target a derived optimal
allocation proportion with the aim of achieving the ethical objective in a clinical trial
while keeping the asymptotic variance of the treatment difference to be constant, and
the other one uses a link function to skew the treatment allocation probabilities in favour
of the better treatment arm after adjusting for the effects of the covariate profiles of
the patients.
2.4.1 CARA Design using the Optimal Allocation Approach
One of the approaches to develop CARA randomization procedures is to derive
the optimal allocation proportion for a model without covariates and use its covariate-
adjusted version for the sequential allocation of patients (Zhang et al., 2007). For a
clinical trial, where the survival times of the patients are right censored and follow a
Weibull distribution, the optimal allocation proportion can be found using the maxi-
mum likelihood approach presented in Section 2.3. Now, the variance of the logarithm
of the estimated Weibull scale parameter is shown, in Appendix A to be
σ2k = var[log{µˆk(z)}] =
Gk
nkγ2k
for k = A,B, where Gk is defined in (2.16) and nk denotes the number of patients on
treatment k. Let ςk = γk[Yk − log{µk(z)}] and k(z;βk, γk) be the probability of an
event, where Yk = log(Tk) is the logarithm of the survival time on treatment k. Then
Gk =
k(z;βk, γk) + E(ς
2
ke
ςk)
2k(z;βk, γk) + k(z;βk, γk)E(ς
2
ke
ςk)− {E(ςkeςk)}2 (2.16)
where k(z;βk, γk) = P (Tk ≤ C|z;βk, γk). The derivation of a formal analytical form
for k(z;βk, γk) is shown in Appendix B.
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Zhang and Rosenberger (2007) derived an optimal allocation proportion by mini-
mizing the average hazard in the trial subject to the constraint that the asymptotic
variance of the difference in the estimated scale parameters is a constant. This would
ensure that for any choice of the number of patients allocated to each treatment arm,
the power for testing the significance of the difference in the treatment effects would
remain fixed. For a survival trial with two treatment arms of overall duration D, if
µk > 0 is the scale parameter and γk > 0 is the shape parameter of a Weibull distribu-
tion, then the cumulative hazard at time D will be (D/µk)
γk . Therefore, minimizing
the total cumulative hazard nA(D/µA)
γA +nB(D/µB)
γB for the two treatments subject
to the constraint that the asymptotic variance GA/(nAγ
2
A)} + GB/(nBγ2B) is constant,
the optimal allocation proportion for treatment A is given by
%A0 =
γB
√{D/(µB)}γBGA
γB
√{D/(µB)}γBGA + γA√{D/(µA)}γAGB . (2.17)
The corresponding covariate-adjusted target allocation proportion is therefore ex-
pressed as
piWA0(βA,βB, γA, γB, z) =
γB
√{D/µB(z)}γBGA
γB
√{D/µB(z)}γBGA + γA√{D/µA(z)}γAGB . (2.18)
Its derivation is detailed in Appendix D. An important feature of (2.18) is that, irre-
spective of the value of z, the allocations are skewed towards the better treatment arm,
but the degree of skewing is dependent on the parameters of the Weibull distribution.
Other functions could also be minimized to obtain different optimal allocation pro-
portions. For instance, one could use the relationship between the expected survival
time and the hazard in the exponential distribution case, and obtain an average haz-
ard for the Weibull distribution. Maximizing the total expected survival time for the
Weibull distribution, subject to a constraint on the asymptotic variance of the treat-
ment difference similarly gives the optimal allocation for treatment A as
%A1 =
γB
√
µAΓ{(γA + 1)/γA}GA
γB
√
µAΓ{(γA + 1)/γA}GA + γA
√
µBΓ{(γB + 1)/γB}GB
. (2.19)
The corresponding covariate-adjusted target allocation proportion is therefore;
piWA1(βA,βB, γA, γB, z) =
γB
√
µA(z)Γ{(γA + 1)/γA}GA
γB
√
µA(z)Γ{(γA + 1)/γA}GA + γA
√
µB(z)Γ{(γB + 1)/γB}GB
.
(2.20)
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This approach does not take into account the fact that the hazard of a Weibull distri-
bution depends on the survival times. It would be more appropriate when patients do
not have a common follow-up time.
Apart from minimizing the total average hazard, one can consider other metrics
to optimize and obtain a different allocation function when the survival times fol-
low a Weibull distribution. For instance, minimizing the overall trial size subject to
the asymptotic variance of the covariate-adjusted treatment difference remaining fixed,
produces the Neyman allocation function. This allocation proportion is directly propor-
tional to the standard deviation of the logarithm of the estimated scale parameter. The
Neyman allocation function results in the maximum power of the CARA procedure for
a given randomization function. The allocation proportions piWA2(βA,βB, γA, γB, z) and
piWA3(βA,βB, γA, γB, z) given below are considered here as an alternative to (2.18) and
(2.20). The first is the Neyman allocation that maximizes the power of the Wald test
for treatment comparisons, for a given sample of size n. Minimizing the overall trial
size subject to the asymptotic variance of the covariate-adjusted treatment difference
remaining fixed, the Neyman allocation is obtained as,
piWA2(βA,βB, γA, γB, z) =
γB
√
GA
γA
√
GB + γB
√
GA
. (2.21)
For ethical considerations in CARA randomization procedures, it is desired to target
an allocation proportion which is optimal in some sense. Biswas and Mandal (2004)
proposed a procedure that results in an allocation which is a generalization of opti-
mal allocation for normal responses. They generalized the binary optimal allocation
for normal responses in terms of failures. Zhang and Rosenberger (2007) applied their
approach in the case of exponentially distributed survival times to develop the response
adaptive randomization (RAR) approach. This approach can also be applied to develop
the CARA randomization procedure when the survival times conform to a Weibull dis-
tribution. The survivor function for Weibull distributed survival times can be obtained
from (2.1). If the survival times are dichotomized based on some threshold constant κ,
that is, a survival time less than the threshold κ is considered a failure, and otherwise
a success, then the function
nA[1− e−{κ/µA(z)}γA ] + nB[1− e−{κ/µB(z)}γB ],
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can be minimized subject to the contraint on the asymptotic variance ;
GA
nAγ2A
+
GB
nBγ2B
= k,
where k > 0 is a constant, to obtiain the allocation proportion
piWA3(βA,βB, γA, γB, z) =
γB
√
GA[1− e−{κ/µB(z)}γB ]
γB
√
GA[1− e−{κ/µB(z)}γB ] + γA
√
GB[1− e−{κ/µA(z)}γA ]
.
(2.22)
As pointed out earlier, the CARA designs are desirable for ethical and efficiency
reasons, without undermining the validity of the trial results and maintaining the ran-
domized nature of the experiment. Rosenberger and Hu (2004) showed that, in the
case of binary responses, using the doubly-adaptive biased coin design (DBCD) to ran-
domize an incoming patient to a particular treatment arm, results in a very useful
randomization procedure in terms of maintaining power while targeting any specific
allocation proportion which considers only the responses and the treatment allocation
history. Zhang and Rosenberger (2006) further established this in the same settings
in the case of continuous outcomes using the normal responses as the special case.
A suitable randomization procedure is therefore needed to target the derived CARA
allocation proportions based on the Weibull accelerated life model.
2.4.2 Targeting the Derived Allocation Proportion
Various randomiation procedures can be used to target a specific derived allocation
proportion. Each of the randomization procedures consists of a probability allocation
function whose arguments approach the derived allocation proportion. A response-
adaptive design is said to be efficient of the first-order if it attains a lower bound on
the asymptotic variance of the observed allocation proportion. The DBCD procedure
along with most of the other randomization procedures in the literature are not first
order efficient. One of the exceptions is the drop-the-loser rule of Ivanova (2003). This
rule considers balls of three types : type A, type B, and type 0. A ball is drawn at
random. If it is type A or type B, then the corresponding treatment is assigned, and
the patient’s response is observed. If it is a suc-cess, then the ball is replaced and the
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urn remains unchanged. If it is a failure, then the ball is not replaced. If a type 0 ball is
drawn, then no subject is treated, and the ball is returned to the urn together with one
ball of type A and one ball of type B. Even though this rule is asymptotically efficient
of the first order, its applications are limited to urn allocation proportions and binary
responses.
Hu, Zhang and He (2009) proposed a family of randomization procedures that attain
the Cramer-Rao lower bound on the allocation variances for any allocation proportion
but the allocation function for this procedure is discontinuous. The asymptotic theory
for adaptive designs that relies on a Taylor series expansion for the allocation func-
tions, is not applicable to non-differentiable cases. This family of efficient randomized-
adaptive designs (ERADEs) can adapt to any desired allocation proportion and is easy
to implement in practice for both discrete and continuous responses. Under certain
mild conditions, the asymptotic normality and strong consistency of both the alloca-
tion proportions and the estimators of the population parameters have been obtained
by Hu, Zhang and He (2009). However, their work ignores the fact that the patients in
clinical trials are heterogeneous and therefore does not take into account the informa-
tion related to the covariate profiles of the patients. Now, when the allocation function
is disccrete, the commonly used techniques do not work anymore. The allocation prob-
abilities of the ERADE randomization procedures are discrete functions. Introducing
a stopping time of a martingale process as shown in Hu, Zhang and He (2009), one can
overcome the difficulties arising out of discontinuity.
After the allocation of the two treatments to m patients and observing their re-
sponses, let NA(m) and NB(m) = m−NA(m) denote the numbers of patients assigned
to each of the two treatments. When the (m+ 1)th patient enters the clinical trial with
covariate vector zm+1, let pˆim = pˆi
W
A (βˆA,m, βˆB,m, γˆAm, γˆBm, zm+1) represent the estimate
of piWA (βA,βB, γA, γB, z) based on the responses observed from the m patients, adjusted
for the covariate zm+1 of the incoming patient. Using the covariate-adjusted ERADE
(CAERADE) procedure, the (m+1)th patient can be assigned to treatment A with prob-
ability jm+1{NA(m)/m, pˆim, ρˆAm}. Let ρˆAm =
∑m
i=1{pˆiWA (βˆA,m, βˆB,m, γˆAm, γˆBm, zi)}/m
be an estimate of the average target allocation for treatment A based on the data for
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the first m patients. Therefore, the mathematical form of the allocation rule for the
(m + 1)th patient entering the clinical trial with covariate vector zm+1 to be assigned
to treatment A is
jm+1
{
NA(m)
m
, pˆim, ρˆAm
}
=

α′pˆim if
NA(m)
m
> ρˆAm,
pˆim if
NA(m)
m
= ρˆAm,
1− α′(1− pˆim) if NA(m)m < ρˆAm,
(2.23)
where 0 ≤ α′ < 1 is a constant that reflects the degree of randomization. Hu, Zhang and
He (2009) recommended a value of α′ to be between 0.4 and 0.7. This gives a family of
CARA designs that are fully randomized and also asymptotically efficient as it attains
the Cramer-Rao lower bound on the asymptotic variance of the observed allocation
proportion. The ERADE can be viewed as a generalization of Efron’s biased coin design,
an asymptotically efficient restricted randomizaton procedure, for any desired allocation
function, which may depend on the unknown parameters. If the response distribution
belongs to the exponential family, the CAERADE for any α′ ∈ [0,1) is efficient of
the first-order. When the survival outcomes conform to a Weibull distribution, the
CAERADE also generates a first-order efficient allocation design for patients.
When the allocation probability function is a continuous and differentiable function
of ρˆAm, pˆim and the current sample proportion, the asymptotic properties of adaptive
designs are obtained using a Taylor series expansion. In such cases, the expected sample
proportions cannot be efficiently approximated by ρˆkm. Therefore, the variances of the
allocation proportions do not attain the Cramer-Rao lower bound.
The covariate-adjusted doubly-adaptive biased coin design (CADBCD) procedure
(Zhang and Hu, 2009) can also be used to construct CARA randomization procedures.
The CADBCD is a randomization procedure which is used to target the allocation
proportions. This is a randomization procedure with low variability and follows in
the path of Efron’s biased coin design. It applies to cases where the desired allo-
cation proportions are unknown, but estimated sequentially. The key component of
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this procedure is an allocation function jm+1{NA(m)/m, pˆim, ρˆm}, which is defined on
[0,1]×[0,1]×[0,1]. If NA(m) and NB(m) = m - NA(m) represent the numbers of pa-
tients assigned to treatments A and B, respectively, after m allocations and pˆim =
piWA (βˆA,m, βˆB,m, γˆAm, γBm, zm+1) denotes an estimate of the derived target allocation
proportion based on the data from those m patients, adjusted for the covariate zm+1,
then, according to the CADBCD allocation rule, the probability of the (m+1)th patient
with covariate vector zm+1 being assigned to treatment A is given by
jm+1
{
NA(m)
m
, pˆim, ρˆAm
}
=

pˆim{ρˆAm/NA(m)m }α
pˆim{ρˆAm/NA(m)m }α+(1−pˆim)[(1−ρˆAm)/{1−
NA(m)
m
}]α if 0 <
NA(m)
m
< 1,
1− NA(m)
m
if NA(m)
m
= 0 or 1.
(2.24)
Here α is a non-negative parameter controlling the degree of randomness of the
CADBCD procedure. A value of α = 0 corresponds to the procedure being most ran-
dom and a value of α = ∞ corresponds to it being most deterministic. The allocation
function jm+1{NA(m)/m, pˆim, ρˆm} is strictly decreasing in {NA(m)/m} and strictly in-
creasing in (pˆim, ρˆm) on [0,1]×[0,1].
The allocation function given in equation (2.24) is the probablity of an incoming pa-
tient, being assigned to treatment A. Following Theorem 3.1 of Zhang and Hu (2009),
under mild conditions, NA(m)/m and pˆim are strongly consistent and follow an asymp-
totic bivariate normal distribution with the asymptotic means being the expected value
of the target alloation proportion. Also,
√
m(βˆk,m−βk) is asymptotically multivariate
normal with zero mean vector and asymptotic covariance matrix I−1k (βk, γk). How-
ever, since the survival times conform to a Weibull distribution and there is no closed
form for the maximum likelihood estimators of the scale and shape parameters, an
explicit asymptotic variance for the CADBCD procedure cannot be obtained. If some
knowledge about the shape parameter is available, then the derivation of the asymp-
totic variance of the procedure can proceed as in the exponential case as described in
Zhang and Rosenberger (2007). When α → ∞, the allocation function is the most
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deterministic and thus achieves the Cramer-Rao lower bound in terms of its asymptotic
variance.
2.4.3 The Effect of Delay in Survival Responses
Survival time or censoring time cannot be observed until an event or censoring has
happened. Therefore, there is an inherent delay in measuring the survival responses
which in turn delays the estimation process of the model parameters. Zhang and Rosen-
berger (2006) demonstrated by using extensive simulation that a moderate delay has a
marginal effect on the asymptotic properties of response-adaptive randomization pro-
cedures. Zhang and Rosenberger (2007) provided a theoretical treatment for handling
the problem of delay in survival responses. They showed that, if τm is the delay in the
response of the mth patient and η′m his/her arrival time, then, under the assumption
P{τm > η′(n+m) − η′(m)} = o(n−c), (2.25)
for some constant c > 0, the asymptotic results of the DBCD procedure still hold. Note
that (2.25) implies that the probability that a patient will respond before n additional
patients arrive is of the order n−c. The delay in response in this case is exactly the sur-
vival time or censoring time of the patient. The asymptotic properties of the CADBCD
procedure when the survival times conform to a Weibull distribution, can be justified
if the assumption in (2.25) holds.
2.4.4 Using a Link Function to Develop a Suitable Alternative
An alternative approach presented by Bandyopadhyay and Biswas (2001) used a suit-
able probit link function to develop adaptive designs in clinical trials which take into
account the heterogeneity of patients due to the presence of concomitant information.
In their approach, they assumed that the response from each patient to a treatment
is a continuous random variable and follows a normal linear model but does not ac-
count for the covariate information of the incoming patient while doing the adaptation.
The method provided is further developed in this chapter in the context of Weibull
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distributed survival outcomes of patients which take the information of right censoring
into account.
If m patients have been enrolled in a clinical trial and NA(m) patients have been
allocated to treatment A, the observed treatment allocation proportions for m patients
are given by NA(m)/m for treatment A and NB(m)/m = 1−NA(m)/m for treatment B.
A suitable link function bridges the past history about treatment allocation, responses
and the covariates of the patients to the (m + 1)th allocation. Bandyopadhyay and
Biswas (2001) suggested this to be a suitable cumulative distribution function F (.)
which is symmetric about zero. This means that F (0) = 1/2 and F (−x) = 1- F (x).
Since they assumed that the responses of the patients conform to a normal linear model,
a natural choice for F was the probit link function Φ(.), which is the quantile function
associated with the standard normal distribution. In the context of survival models,
where the survival times of the patients to a treatment are right censored and conform
to a Weibull distribution, there are other link functions which can address the ethical
criteria of a clinical trial more effectively. An alternative link function considered here
for the purpose of developing the CARA randomization procedure is
F (x) = g
{
x
ŜE(X) + ĤR(z)
}
,
where g(.) is the cumulative distribution function of a random variable following the
Gumbel distribution, x represents the value of a random variable X,
ĤR(z) = {hˆA(t|z)/hˆB(t|z)}
is the ratio of the estimated hazards of the two treatment groups at the time t after
adjusting for the effects of the other significant covariates and ŜE(X) is the estimated
standard error of X . The quantity {ŜE(X) + ĤR(z)} is used as a scaling factor to
control the variability of the design. In this case, ŜE(X) is based on the magnitude and
the direction of the treatment difference, depending on the observed covariate values of
the patients.
Bandyopadhyay and Biswas (2001), had used an arbitrary tuning parameter T to
scale the estimated covariate-adjusted treatment difference and showed that the power
of the design as well as its variability and the degree of skewness depends on the value
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of T which is chosen by the experimenter. However, because of the arbitrariness of
the user defined value of T on which the variability of the design solely depends on,
this design has been widely criticised over the past decade, and, therefore, even though
the design is ethically attractive, it has hardly been used in practice. To address this
arbitrariness, Bandyopadhyay and Biswas (2001) stated a rule for selecting the value
of this tuning parameter. They explained that one can start with a large value of T
at the intial stage of the trial and then switch to progressively smaller values at later
stages. The link function g(.) is referred to as the glink function. Here, instead of using
an arbitrary value of the tuning parameter T, scaling the value x by a more defined
quantity, {ŜE(X) + ĤR(z)}, makes the design less arbitrary and also addresses the
issue of statistical efficiency more consistently. Moreover, the Gumbel cumulative dis-
tribution function being light tailed and steeper compared to that of a standard normal
distribution increases the chance of assigning more patients to the better-performing
treatment thus far in the clinical trial.
At the beginning of the trial, one uses some restricted randomization procedure to
randomize the initial 2m0 patients, where m0 is a small positive integer, equally be-
tween treatment arms A and B. This is performed in order to collect initial data at
beginning of the trial to estimate the unknown model parameters. In any survival trial,
outcomes are inherently delayed. Therefore, it will take a significant amount of time
until the model parameters can be accurately estimated. Let ∆Am = log{µA(m)(z)} −
log{µB(m)(z)} represent the difference between the log transformed Weibull scale pa-
rameters for the two treatments upto the mth patient after adjusting for the effect of the
covariates. . After m allocations to the two treatment arms, the rule for each incoming
patient is that they would be allocated to treatment A with probability
piWA4{µˆA(m)(z), µˆB(m)(z), γˆ, z} = F (∆ˆAm) = g
{
∆ˆAm
ŜE(∆ˆAm) + ĤR(zm)
}
, (2.26)
and to treatment B with probability
F [∆ˆBm = log{µˆB(m)(z)} − log{µˆA(m)(z)}] = g
{
∆ˆBm
ŜE(∆ˆBm) + ĤR(zm)
}
, (2.27)
Unlike Bandyopadhyay and Biswas (2001) who used the cumulative distribution
function of a standard normal distribution, the cumulative distribution function of
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the Gumbel model is based on a location parameter and a non-zero scale parameter.
The scale considered here for the glink function is (1/γ) and the location parameter
depends on the covariates of the incoming patients. The proportional hazard Weibull
accelerated life model assumes equal shape parameter for the two treatment groups. Let
γˆm be the common shape parameter which is estimated from the Weibull accelerated
life model fitted based on the information related to the previous m patients. Therefore
(1/γˆm) is used here as the scale parameter for the glink function at every step of the
adaptation process. It has been seen using simulated trial and error method that
using {1/µˆ(zm+1)} as the location parameter for the glink function where zm+1 are the
covariate information of the incoming patients, gives an ethical design.
This allocation rule favours the better-performing treatment at a given stage of the
trial after accounting for the concomitant information of the previous patients as well as
that of the incoming patient. If ∆ = log{µA(z)} − log{µB(z)}, using (2.26) and (2.27)
the probability of allocating an incoming patient to treatment A is being forced towards
F (∆), an increasing function of ∆, provided that the estimators of the treatment effects
are consistent.
Let Xm, Ym , Zm denote, respectively, the sigma fields for the past treatment allo-
cation history, the response history, the prognostic factors for the first m patients and
let zm+1 be the covariates of the incoming patient. Based on the glink, the conditional
probability that the (m + 1)th patient with covariate vector zm+1, will be assigned to
treatment A is given by
P (X(m+1) = 1|Xm,Ym,Zm, zm+1) = g
{
∆ˆAm
ŜE(∆ˆAm) + ĤR(zm)
}
. (2.28)
where, conditional on Xm,
∆ˆAm
d−→ N(∆Am, σ2)
as m → ∞. The variance σ2 is calculated by inverting the Fisher information matrix
obtained from the log likelihood function (2.11) as shown in Appendix A. Let ζ(m) =
P (X(m+1)= 1). Then the sequence {ζ(m) : m ≥ 2m0 + 1} converges to g
{
∆Am
HR(zm)
}
.
The limiting proportion of the allocation of patients to treatment A is also g
{
∆Am
HR(zm)
}
.
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The glink function puts more weight on the available data to develop the CARA
randomization procedure. The cumulative distribution function of a Gumbel random
variable is light-tailed, and therefore gives more weight to the available data compared
to its heavy-tailed counterparts like the Cauchy. The main advantage of using the glink
function for developing the CARA randomization procedure is that it tends to allocate
more patients to the better treatment arm as compared to the design based on the
probit model. Thus, it fulfils the ethical considerations of adaptive designs more than
that of Bandyopadhyay and Biswas (2001).
2.5 Asymptotic Properties of CARA Designs
An important aspect of the design of phase III clinical trials is the use of appro-
priate methods of randomization. The previous section gave a detailed explanation
about various target allocation proportions and the discrete and continuous CARA
randomization procedures targeting these allocation proportions in the design of phase
III clinical trials. It would, however, be useful to compare the performance of these
target allocations and the CARA randomization procedures to find out which random-
ization procedure targeting a specific allocation proportion outperforms the others. Hu
and Rosenberger (2003) provided a theoretical template for the comparison of different
response-adaptive randomization procedures and different target allocations in terms
of power and expected failure rates when the response of the patients to a treatment
is binary. Zhang and Rosenberger (2006) further developed this idea for continuous re-
sponses following a normal distribution. In this section a theoretical template is given
for the comparison of different CARA designs and different target allocation proportions
when the survival responses conform to a Weibull distribution.
The optimal allocation proportions are largely dependent on the choice of measure
of difference between the treatment. In this chapter, the focus has been on the simple
difference [∆ = log{µA(z)}− log{µB(z)}]. The entire theory behind covariate-adjusted
response-adaptive designs for phase III clinical trials rely on asymptotic approximation
of the observed allocation proportion and the estimated target allocation proportion.
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Asymptotically the Wald test, score (Rao) test, and the likelihood ratio test are equiv-
alent in the sense that the probability limit of the test statistic for all the three tests
are equal. Moreover in real clinical trials the Wald tests are frequently used for treat-
ment comparison. Thus the Wald test is used here to test for the significance of this
difference, ∆, between the treatment effects.
Using a Taylor series expansion of the non-centrality parameter of the usual chi-
squared test for testing the effect of the treatments, an explicit relationship can be
derived between the target allocation proportion, the bias of the randomization pro-
cedure from the target and the variability induced by the randomization procedure
for any allocation proportion. When there are random samples (tik,δik), (k = A,B)
from Gumbel distributions with parameters [log{µk(z)}, 1/γk], the Wald test statistic
is given by
Tn =
log{µˆA(z)} − log{µˆB(z)}√
GA
nAγˆ
2
A
+ GB
nB γˆ
2
B
, where Tn
d−→ N(0,1),
as n→∞, for testing the hypothesis
H0 : ∆ = 0
against,
HA : ∆ 6= 0
For a design with nA and nB fixed and the times to events independent Weibull
survival outcomes, T 2n is asymptotically chi-squared with one degree of freedom. Under
the alternative hypothesis, power can be expressed as an increasing function of the
non-centrality parameter of the chi-squared distribution for a fixed target allocation
proportion pi. Using the simple difference measure, the non-centrality parameter can
be expressed as
Λ =
[log{µA(z)} − log{µB(z)}]2
GA
nAγ
2
A
+ GB
nBγ
2
B
,
which can be re-written as,
Λ(x)
n
=
[log{µA(z)} − log{µB(z)}]2
GA
(pi+x)γ2A
+ GB
(1−pi−x)γ2B
,
40
where x = (nA/n) - pi, and pi is the target allocation proportion on treatment A.
Expanding Λ(x)
n
in a Taylor series about pi yields
Λ(na/n)
n
=
[log{µA(z)} − log{µB(z)}]2
GA
piγ2A
+ GB
(1−pi)γ2B
+[log{µA(z)} − log{µB(z)}]2
(1− pi)2GA
γ2A
− pi2GB
γ2B
{(1− pi)GA
γ2A
+ piGB
γ2B
}2
(
nA
n
− pi
)
−[log{µA(z)} − log{µB(z)}]2
(GA
γ2A
GB
γ2B
)
{(1− pi)GA
γ2A
+ piGB
γ2B
}3
(
nA
n
− pi
)2
+ o
{(
nA
n
− pi
)2}
or,
Λ(na/n)
n
= (I) + (II) + (III) + o
{(
nA
n
− pi
)2}
(2.29)
The first term (I) is determined by pi and represents the non-centrality parameter for
a fixed design. The Neyman allocation for patients with a given set of covariates z
as in (2.21) maximizes this term. This term can be used to compare different target
allocation proportions in terms of their powers. The second term (II) represents the
bias of the actual allocation from the target allocation. With the design shifting to
different sides from the target allocation proportion pi, the non-centrality parameter
will increase or decrease according to the coefficient
[log{µA(z)} − log{µB(z)}]2
(1− pi)2GA
γ2A
− pi2GB
γ2B
{(1− pi)GA
γ2A
+ piGB
γ2B
}2 ,
and this coefficient equals 0 if and only if (1− pi)2GA
γ2A
− pi2GB
γ2B
= 0 , that is
pi = piWA2(βA, βB, γA, γB, z) =
γB
√
GA
γA
√
GB + γB
√
GA
,
the Neyman allocation given in (2.21).
In a real-life scenario, especially in the field of personalized medicine, people may
be interested to know the proportion of patients on a particular treatment for a given
set of covariates z. CARA randomization procedures involve, NA|z(m), the number
of patients with covariate z allocated to treatment A after m allocations. Given a
covariate z, the proportion of patients allocated to treatment A is NA|z(m)/Nz(m),∑n
m=1XA(m)I{zm=z}∑n
m=1 I{zm=z}
=
NA|z(m)
Nz(m)
,
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where Nz(m) is the total number of patients with covariate z . Replacing nA/n and
nB/n with NA|z(m)/Nz(m) and NB|z(m)/Nz(m) in (2.31), the test statistic T 2n still has
an asymptotic chi-squared distribution. The specific procedures for which the asymp-
totic properties hold and the necessary conditions are well described in the response-
adaptive randomization literature. The justification for the asymptotic chi-squared
distribution of the test statistic can be deduced from Hu and Zhang (2004). A very
general form of the asymptotic variance of the observed allocation proportion was given
by Eisele and Woodroofe (1995) and Hu and Zhang (2004); actual computation depends
on specific values of the target allocation proportion and the allocation rule, which is
straightforwarward but tedious. The critical condition to ensure the chi-squared limit
is that the covariate-adjusted allocation proportion on each treatment converges almost
surely to a constant between 0 and 1 for the specific procedure. This substitution makes
Λ{NA|z(m)/Nz(m)} a random non-centrality parameter, and therefore its expectation
can be considered. For example, since NA|z(m)/Nz(m) is asymptotically unbiased for
pi, E[{NA|z(m)/Nz(m)} - pi ] → 0. Therefore, the average power of the test directly
relates to the variance E[{NA|z(m)/Nz(m)} − pi]2 of the CARA procedure. It is this
explicit relationship that would be mostly used to evaluate the power performances of
different CARA randomization procedures.
2.6 Simulation Study
2.6.1 Choice of Design Parameters
In the experimental setup to compare the different CARA randomization procedures,
a two-arm survival trial with 400 patients has been considered. A patient’s arrival time
here is simulated from a uniform (0,365) distribution. The response time of a patient
is added to the recruitment time of the patient and those whose outcomes have not
been observed by specified time D > R are said to be generalized type I right censored.
The length of the recruitment period is considered to be R = 365 days and the overall
trial duration is taken to be D = 581.66 days. The censoring time of the patients is
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simulated from a uniform (0,581.66) distribution.
Following Rosenberger, Vidyashankar and Agarwal (2001), a covariate structure
of three independent covariates has been generated. These are gender (Bernoulli, p =
0.5), age (Uniform(30,75)) and cholestrol level (Normal (200,400)). Treatment-covariate
interactions are not considered during the simulation stage, as the covariate-adjusted
treatment effects can be quite effective as compared to the individual treatment effects,
even in the absence of such interaction terms. The survival time of a patient with
covariate vector z = (1, z1, z2, z3)
T in treatment group k is simulated from the Weibull
distribution with scale parameter µk(z) =exp(β
T
k z) and shape parameter γk = 2.07527
when assessing the situation for a monotonic increassing hazard and γk = 0.57527
when assessing for a monotonic decreasing hazard. The values of shape parameters were
chosen by trial and error, taking into account the three covariate structures with known
distributions, Weibull distributed time to event outcomes, and to have approximate
values of hazard ratio in the population as per the model parameters given in Table
2.1. The values of hazard ratio will vary across individual patients depending on their
covariate values. Three choices of the treatment effects vector have been considered in
this case, which are neutral effect of either treatment, positive effect of treatment A
and negative effect of treatment A. The effects of the corresponding covariates for the
simulation model µk(z) =exp(β
T
k z) are summarized in Table 2.1.
Model Treatment Covariate Effects
β0 β1 β2 β3
Neutral A 1.896 0.810 0.038 0.001
B 1.896 0.810 0.038 0.001
Positive A 5.5042 0.810 0.038 0.001
B 1.896 0.810 0.038 0.001
Negative A -1.7112 0.810 0.038 0.001
B 1.896 0.810 0.038 0.001
Table 2.1: Values of model parameters
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In Table 2.1, the neutral treatment effect refers to the hypothetical experimental sce-
nario where treatments A and B are equally effective. In the case of comparing a new
treatment with a control, this scenario refers to the situation where the new treatment
is as good as the existing control. The positive treatment effect refers to the hypotheti-
cal experimental scenario where treatment A is more effective than treatment B, or the
new treatment performs better than the control. The negative treatment effect refers
to the hypothetical experimental scenario where treatment B is more effective than
treatment A, or in the case of comparing a new treatment with a control, this means
that the new treatment is not as effective as the control. The procedure used here is a
fully sequential one that recalculates the randomization probabilities after the arrival of
each patient and there are 5000 such simulation runs. Since there are three predictive
covariates in the model, the direction and magnitude of the treatment difference will
vary for the patients, depending on their observed covariate values.
In order to compare the different competing designs, two response adaptive rules
have also been considered for which the covariates are ignored at the design stage,
but the final estimates of the treatment effects can be adjusted for all covariates. The
competing randomization procedures and the corresponding design numbers are listed
in Table 2.2.
In survival trials, the delay time for a patient is the patients’ survival or censoring
time. To facilitate CARA designs with delayed responses, it is required that, at the
ith patient′s randomization time, only data from those patients who have responded
before the ith patient’s arrival are used in computing the randomization probability for
the ith patient. In practice, the assumption of immediate responses is not feasible due
to the inherent delay in time-to-event outcomes. For the implementation of the CARA
and the response adaptive designs given in Table 2.2 above, initially 2m0 patients have
been equally allocated to the two treatment arms using Efron’s biased coin design.
This is a restricted randomization procedure which allocates a patient to a treatment
arm based on the history of the treatment assignment with the aim of achieving balance
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Design Competing Randomization Procedures
I Completely randomized design
II Efron’s biased coin design with p = 2/3
III Pocock and Simon design with p = 3/4
IV CARA CADBCD with (2.18) as the target
V CARA CADBCD with (2.22) as the target
VI CARA CADBCD with (2.21) as the target
VII CARA CADBCD with (2.20) as the target
VIII CARA CAERADE with (2.18) as the target
IX CARA CAERADE with (2.22) as the target
X CARA CAERADE with (2.21) as the target
XI CARA CAERADE with (2.20) as the target
XII Response Adaptive DBCD with (2.17) as the target
XIII Response Adaptive ERADE with (2.17) as the target
XIV CARA design based on the g-link function
Table 2.2: List of the Competing Designs
without introducing biases which are usually avoided by using a completely randomized
design. At a given stage, one computes the treatment imbalance and with probability
2/3 an incoming patient is assigned to the underrepresented treatment arm to reduce
the overall imbalance. This design represents a class of biased coin procedures for
the comparison of two treatments in which allocation of the treatment is determined
probabilistically, but with a bias towards the underrepresented one. Permuted block
design is another restricted randomization approach which is commonly used in practice
and also achieves balance across treatment arms. This randomization scheme consists of
a sequence of blocks such that each block contains a pre-specified number of treatment
assignments in random order. The purpose of this is so that the randomization scheme
is balanced at the completion of each block. Permuted blocks can be quite effective
in achieving balanced designs but they suffer from the disadvantage that at certain
points in the experiment, the experimenter knows for certain whether the next subject
will be assigned as a treatment or as a control. For example, if the block size is
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5, the probability is 1/6 that the experimenter will know for certain the assignment
of units 8, 9 and 10, and 4/9 that he will know for certain the assignment of units
9 and 10. Efron’s biased coin design is asymptotically the most efficient restricted
randomization procedure and therefore enables one to achieve an allocation procedure
with high power for treatment comparison. Here, m0 is a positive number and using
Sverdlov, Rosenberger and Ryeznik (2013) as a guidance, 2m0 is chosen to be 110 for the
CARA designs and 80 for the response-adaptive designs, which are sufficiently large for
accurate estimation of the model parameters. It must be noted that unlike the designs
based exponential regression model, the designs here needs a longer time to start the
adaptation process. This is because of having the number of patients to efficiently
estimate models parameters which includes the extra shape parameter in this case.
At a given step, the Newton-Raphson method for fitting the Weibull regression
model to the data may not converge and maximum likelihood estimate are not attain-
able. In that case, the treatment assignment for the patient is determined using an
Efron’s biased coin design. After the model parameters are estimated from the initial
stage of the design, a randomization probability is calculated after each new patient
who arrives sequentially into the trial. This randomization probability can be based
on any one of the derived allocation functions. A pseudo random number generator
(PRNG) is then used to draw a random number between 0 and 1. If the derived ran-
domization probability is greater than or equal to this generated random number, the
patient is assigned to treatment A or else the patient is assigned to treatment B. The
procedure described is repeated for the subjects entering the trial in the future. The
randomization procedures which are being compared with the derived CARA designs
are as follows :
• A completely randomized design, for which every patient is randomized to treat-
ment A or B with probability 0.5.
• Efron’s (1971) biased coin design in which allocation of the treatment is deter-
mined with a probability of 2/3 towards the underrepresented treatment.
• Pocock and Simon’s (1975) covariate-adaptive randomization procedure. For its
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implementation, all covariates must be categorical. Therefore, the continuous
covariate age has been dichotomized according to age < 53 years and age ≥ 53
years, whereas the covariate cholestrol level has been dichotomized to level < 200
and level ≥ 200. For an incoming patient, one computes the treatment imbalance
at each level of the patient’s covariates and with probability 3/4 the patient is
assigned to the treatment arm that reduces the overall covariate imbalance. If
the imbalance is zero, the patient is randomized to treatment A or B with equal
probability.
• A response-adaptive rule with (2.17) as its target, for which only the covariates
are ignored at the design stage but the final estimates of the treatment effects
can be adjusted for all covariates. The response-adaptive rule is implemented by
means of the doubly adaptive biased coin design with α = 2 (Hu and Zhang,
2004).
• A response-adaptive strategy with (2.17) as its target, which is implemented by
means of the efficient randomized adaptive design with α′ = 0.55 (Hu, Zhang and
He, 2009).
The observed allocation proportion {NA(m)/m} for the optimal designs at the mth
stage of a clinical trial converges to its target allocation proportion pi at the rate of
n−1/2. The asymptotic results of the CADBCD and the CAERADE do not depend
on its randomization parameter α and α′ respectively. This is because the first order
approximation of the allocation probability function do not depend on the randomiza-
tion parameter. In practice, one need to choose a suitable value of the randomization
parameter to implement the proposed designs. For the DBCD and the CADBCD de-
signs in Table 2.2 above, it must be noted that following Zhang and Hu (2009), Hu and
Zhang (2004) and Rosenberger and Hu (2004), the trade-off parameter for randomness
is taken to be α = 2. Similarly, Burman (1996) introduced the expected p-value defi-
ciency to evaluate the performance of a particular design. Based on Burman’s studies,
Hu, Zhang and He (2009) recommended that, for appropriate implementation of the
ERADE designs, it is reasonable to choose α′ between 0.4 to 0.7. The parameter α′
controls the degree of randomness of the design. When α′ is smaller, the ERADE is
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more deterministic and has a smaller variability. Here, α′ for CAERADE and ERADE
is chosen to be 0.55.
Similation of 5000 runs were considered for sensitivity analysis of the effect of α′
on the variability of a CAERADE design. It has been seen that α′ is related to the
randomness of the design. When α′ is smaller, the CAERADE is more determined and
could have a smaller variance. Following Hu,Zhang and He (2009) a simulation study
was conducted with α′ = 0.125, α′ = 0.25, α′ = 0.50, α′ = 0.67 and α′ = 0.75. Overall
sample sizes of 50, 100 and 200 were considered. It has been found that the simulated
results of α′ = 0.125 and α′ = 0.25 are very similar to the results of α′ = 0.50 in terms of
obtaining the target allocation proportion and its variability. However, the CAERADE
with α′ = 0.75 has slightly higher variability than others. Therefore, it is reasonable to
choose α′ in between 0.4 to 0.7 which agrees with the findings of Burman (1996) based
on biased coin designs.
A similar simulation study was also conducted to assess the sensitivity of the ran-
domization parameter α on the CADBCD. With α = 0, the CADBCD becomes the
adaptive randomized design proposed by Melfi, Page and Geraldes (2001). One disad-
vantage of the adaptive randomized design is that, for small experiments, the allocation
at times could be far from the target proportion. This was shown by Efron (1971) with
pi = 1/2 . Such designs with α = 0 also has the highest asymptotic variability and thus
low power for treatment comparison. The CADBCD with α > 0 always has smaller
asymptotic variance than the adaptive randomized design. If α = 1, the variance of
CADBCD is half of the variance of the adaptive randomized design. Therefore, one can
force a small-sized experiment to efficiently target a derived allocation proportion by
choosing a value of α for the proposed designs. As α tends to ∞, the CADBCD proce-
dure assigns the incoming patient to treatment A with probability one if NA(m)/m < pi,
and to treatment B with probability 1 if NA(m)/m > pi. This procedure is entirely
deterministic (except when NA(m)/m = pi). It turns out that the deterministic pro-
cedure has the smallest variability that can be attained by any procedure targeting
the optimal allocation proportion. However, one loses the benefit of randomization.
As α becomes smaller, we have more randomization, but also more variability. The
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CADBCD with α = 2 tends to have very good convergence for moderate sample sizes.
Simulation results on the sensitivity analyses on the value of α show that α = 2 is a
good tradeoff that yields almost the same results as α = ∞, but is slightly better than
the adaptive randomized design. Results have also been simulated for α = 5 and it was
nearly identical to α = 2. In every case, the CADBCD with α = 2 works better than
complete randomization, in terms of reducing the number of events in a clinical trial.
2.6.2 Comparing CARA Designs for No Difference Between
the Treatment Effects
To visualize the performances of the various competing designs in Table 2.2 when the
survival response of the patients follows a Weibull distribution, it is always useful to
start with the simplest case, that is, when under the null hypothesis H0 that there is
no difference between the covariate-adjusted treatment effects is true. All simulations
were carried out using the R statistical software. For each experimental procedure, a
trial with n = 400 patients was simulated 5,000 times and the significance level of the
Wald test for testing the difference between the covariate-adjusted treatment effects
has been set to 0.05. Table 2.3 presents operating characteristics of the randomization
designs in Table 2.2 in the case of the neutral model.
Table 2.3 consists of seven columns and it gives the summary results for the 14
different competing designs for the neutral model. The third column gives the observed
allocation proportion of patients assigned to treatment A and its standard error over
5000 simulation runs. The first column represents the two scenarios in which the shape
parameter is less than or greater than 1, whereas the fourth and fifth columns provide
the average numbers of patients categorized by their gender, allocated to each of the
two treatments. The sixth column shows the average total number of events in a trial.
The final column presents the type I error rate of the Wald test, which is used to test for
the covariate-adjusted treatment difference. It is essential that the randomization pro-
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Hazard Design NA
n
(SE) NAM -NBM NAF -NBF Event Type I Error
Decreasing I 0.50 (0.025) 100-100 100-100 325 0.05
II 0.50 (0.003) 100-100 100-100 325 0.05
III 0.50 (0.012) 100-100 100-100 325 0.06
IV 0.50 (0.038) 100-100 100-100 325 0.03
V 0.50 (0.033) 100-100 100-100 325 0.03
VI 0.50 (0.027) 100-100 100-100 325 0.03
VII 0.50 (0.025) 100-100 100-100 325 0.04
VIII 0.50 (0.026) 100-100 100-100 325 0.03
IX 0.50 (0.021) 100-100 100-100 325 0.04
X 0.50 ( 0.016) 100-100 100-100 325 0.04
XI 0.50 (0.006) 100-100 100-100 325 0.04
XII 0.50 (0.037) 100-100 100-100 325 0.05
XIII 0.50 (0.030) 100-100 100-100 325 0.05
XIV 0.40 (0.047) 80-121 80-119 325 0.02
Increasing I 0.50 (0.025) 100-100 100-100 306 0.05
II 0.50 (0.003) 100-100 100-100 306 0.05
III 0.50 (0.012) 100-100 100-100 306 0.06
IV 0.50 (0.038) 100-100 100-100 306 0.04
V 0.50 (0.034) 100-100 100-100 306 0.04
VI 0.50 (0.029) 100-100 100-100 306 0.05
VII 0.50 (0.026) 100-100 100-100 306 0.05
VIII 0.50 (0.033) 100-100 100-100 306 0.05
IX 0.50 (0.028) 100-100 100-100 306 0.05
X 0.50 ( 0.020) 100-100 100-100 306 0.04
XI 0.50 (0.009) 100-100 100-100 306 0.05
XII 0.50 (0.055) 100-100 100-100 306 0.05
XIII 0.50 (0.049) 100-100 100-100 306 0.05
XIV 0.40 (0.047) 80-120 80-120 306 0.03
Table 2.3: Performances of the competing designs in the case of the neutral model
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cedure maintains the nominal type I error rate and has high power to detect treatment
differences.
Table 2.3 shows that under the neutral model, irrespective of the value of the shape
parameter, almost all of the randomization designs result in an equal allocation of pa-
tients to treatments A and B. The CARA design using the glink function on average
allocates significantly more patients to treatment B even though the difference between
the covariate adjusted effects for the two treatments is zero. On the other hand, all
of the CAERADE and the ERADE randomization procedures are less variable than
the corresponding CADBCD and the DBCD procedures. This reflects the theoreti-
cal phenomenon explained earlier that the ERADE being the most efficient adaptive
randomization design makes it the least variable, as the asymptotic variance of the
observed allocation proportion attains the Cramer-Rao lower bound. The column in
Table 2.3 showing the average total number of events in a trial suggests that, even
after a slight under allocation in the CARA design based on the glink function, it does
not result in any ethical gain or loss. This phenomenon of the CARA design with the
glink function may be due to the fact that the cumulative distribution function of a
Gumbel model is not symmetric about zero. All of the other competing designs result
in an equal number of events on an average from 5000 different trials. Therefore when
the difference between the covariate-adjusted effects for the two treatments is zero, the
CARA designs ethically performs as well as the traditional balanced randomization
procedures or the response-adaptive randomization procedures.
While maintaining the type I error rate of the Wald test for testing the covariate-
adjusted treatment difference, it can be seen that Efron’s biased coin design and the
response-adaptive designs perform the best compared to the other traditional balanced
randomization procedures when the value of the shape parameter is less than 1. When
the value of the shape parameter is greater than 1, most of the competing designs have
a type I error rate closer to the nominal value. The Pocock-Simon design, however, in
both the cases gives a slightly inflated error rate. With n = 400 patients, most of the
type I error rates for the designs when the shape parameter is less than 1, are slightly
conservative. This is improved in the case when the shape parameter for the Weibull
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model is greater than 1. This behaviour was further explored by simulation for larger
sample sizes and other values of the shape parameter. The simulated type I error for
adaptive designs continued to be conservative for shape parameter is less than 1. This
may be because of the fact that the density function of the Weibull model is closer to
normality when the hazard function is increasing compared to when the hazard function
is decreasing. The CARA design with the glink function being a non-optimal design
gives a very conservative type I error rate. The standard errors of the type I error rates
are found to be between 0.002 and 0.004. All of the standard errors of the average
number of events in a trial are found to be 8 in the case of an increasing hazard and
9 in the case of a decreasing hazard apart from the CARA design based on the glink
function whose standard error for the events is 8.
2.6.3 Comparing CARA Designs for Differences in Treatment
Effects
The usefulness of a CARA design is appreciated when the covariate-adjusted effects
differ between the two treatment arms. Table 2.4 presents the operating characteristics
of the competing randomization designs in Table 2.2 in the case of the positive model
where the covariate-adjusted treatment effect has a positive impact on the survival
experience of the patients having treatment A. Similar to Table 2.3, this also lists two
scenarios according to the shape parameter of the Weibull model being less than 1 or
greater than 1.
Unlike the neutral model, most of the designs apart from the traditional balanced
randomization designs result in a skewed treatment allocation towards the better-
performing treatment arm, which in this case is A. It can again be seen from column
3 of Table 2.4 that the CAERADE or the ERADE is less variable than the CADBCD
or the DBCD respectively. If the variability of the randomization procedure is the only
criterion for assessing the performance of a design, then the CAERADE proivide the
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Hazard Design NA
n
(SE) NAM -NBM NAF -NBF Event Power
Decreasing I 0.50 (0.025) 100-100 100-100 168 0.98
II 0.50 (0.003) 100-100 100-100 168 0.99
III 0.50 (0.012) 100-100 100-100 168 0.99
IV 0.54 (0.035) 106-94 111-89 166 0.95
V 0.53 (0.031) 104-97 106-93 166 0.94
VI 0.39 (0.028) 77-123 80-120 168 0.97
VII 0.57 (0.027) 113-87 113-87 165 0.96
VIII 0.57 (0.029) 107-93 121-79 166 0.97
IX 0.53 (0.028) 106-94 107-93 165 0.97
X 0.38 (0.025) 74-126 80-120 168 0.98
XI 0.58 (0.020) 116-84 116-84 166 0.98
XII 0.55 (0.034) 110-90 110-90 165 0.96
XIII 0.55 (0.029) 110-90 110-90 166 0.97
XIV 0.68 (0.049) 136-65 135-64 152 0.92
Increasing I 0.50 (0.025) 100-100 100-100 194 0.99
II 0.50 (0.003) 100-100 100-100 194 0.99
III 0.50 (0.012) 100-100 100-100 194 0.99
IV 0.55 (0.027) 111-91 108-90 192 0.96
V 0.54 (0.027) 109-88 111-92 192 0.96
VI 0.44 (0.030) 88-112 90-110 194 0.96
VII 0.55 (0.028) 110-90 110-90 192 0.96
VIII 0.55 (0.024) 110-90 110-90 192 0.99
IX 0.53 (0.023) 105-95 107-93 192 0.98
X 0.44 (0.024) 85-115 91-119 195 0.98
XI 0.56 (0.020) 113-87 113-87 192 0.97
XII 0.54 (0.038) 108-92 108-92 192 0.96
XIII 0.53 (0.029) 105-95 106-94 192 0.97
XIV 0.65 (0.052) 130-70 131-69 183 0.93
Table 2.4: Performances of the competing designs in the case of the positive model
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most suitable design. It can be seen that almost all of the CARA designs result in a
skewed allocation of patients to the better treatment arm, but the degree of skewness
varies between the different designs. With n=400 patients, the powers of the balanced
designs are the highest compared to the other ones. However, they result in more
events, and are therefore ethically not as attractive as the CARA or the response-
adaptive designs. The CARA design with the glink function provides the most skewed
design towards the better treatment arm. This, in turn, results in considerably fewer
events without compromising much on the power of the Wald test for testing the dif-
ference in the covariate-adjusted treatment effects. This design is not based on any
formal optimization procedure, but sequentially takes into account the hazard ratio of
the patients between the two treatment arms and uses it as a scaling factor . It has an
ethical advantage over the other designs because the cumulative distribution function
of a Gumbel model is a steep increasing function and the probability of allocation to A
is being forced towards F[log{µA(m)(z)}− log{µB(m)(z)}], a steep increasing function of
[log{µA(m)(z)} − log{µB(m)(z)}] provided the estimators are consistent. It can be seen
that using the adaptive designs results in slightly fewer events compared to the tradi-
tional balanced randomization designs. The average number of events is quite similar
across the competing designs. The standard error of these for all of the designs is 10
except for the CARA design based on the glink function whose standard error is 9 for
the decreasing hazard scenario.
The final column of Table 2.4 shows the power of the Wald test. It can be seen that,
when treatment A has a more positive effect on the survival experience of the patients,
using a CARA randomization procedure addresses the ethical criterion of a clinical trial
of treating more patients wiith the better treatment without compromising much on
the power of the Wald test, compared to that of the traditional balanced designs. In
case both hazard scenarios, the response-adaptive designs and the CARA design with
the glink function have the most variable power, whereas the balanced randomization
designs have the least variable power. For the case of decreasing hazard, the variability
of the power for design VIII is similar to that of the balanced randomization designs. In
the case of increasing hazard the variability of the power for design V is similar to that
of the response-adaptive procedures. All of the standard errors for the power ranged
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from 0.001 to 0.004.
Unlike the case of the exponential survival responses, when comparing CARA and
response adaptive designs with targets, the CARA designs perform slightly better when
the Weibull distributed responses with an increasing hazard rate are delayed and the
effect of treatment A is better on the survival experience of the patients compared to
that of treatment B. In contrast to the response adaptive designs, the CARA designs
also cater for situations when there exists a need to allocate a treatment based on the
individual’s covariate profile. The CARA designs allocate more patients to the better
treatment arm at each of the patient subgroup levels. It can also be seen that CARA
designs targeting the Neyman allocation proportion results in more events compared
to the other CARA designs. This is mainly because the Neyman allocation proportion
does not account for any ethical criteria, but it minimizes the overall sample size for a
fixed variance of the treatment difference.
Sometimes an experimenter can face situations where treatment B performs better
than treatment A, or, in situations when comparing a new treatment to a control, the
control performs better than the new treatment. The operating characteristics in Table
2.5 show the performance of the competing designs in such a situation.
It can be seen from Table 2.5 that all of the competing designs are fairly powerful in
the case of the negative model. Similar to the Positive model, both the CARA and the
response adaptive designs result in slightly fewer events compared to the traditional
balanced randomization procedures. The average number of events is quite similar
across the competing designs. The standard error of the average number of events
for almost all of the designs for the increasing hazard scenario is 6, apart from that
of design I whose standard error is 7 and that of design XIV whose standard error is
8. For the decreasing hazard scenario, almost all of the designs have a standard error
for the average number of events of 7 apart from those of design III and XI whose
standard error is 6 and that of design XIV whose standard error is 8. The negative
model also shows that, irrespective of the shape of the hazard function, using a CARA
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Hazard Design NA
n
(SE) NAM -NBM NAF -NBF Event Power
Decreasing I 0.50 (0.025) 100-100 100-100 361 0.99
II 0.50 (0.003) 100-100 100-100 361 0.99
III 0.50 (0.012) 100-100 100-100 360 0.99
IV 0.44 (0.034) 88-112 89-111 358 0.93
V 0.46 (0.030) 90-109 93-108 359 0.94
VI 0.47 (0.028) 94-106 95-105 360 0.95
VII 0.49 (0.027) 96-104 97-103 359 0.95
VIII 0.46 (0.025) 90-110 94-106 358 0.95
IX 0.48 (0.018) 92-106 99-103 359 0.96
X 0.48 (0.014) 94-106 99-101 360 0.96
XI 0.49 (0.007) 98-102 98-102 358 0.97
XII 0.45 (0.033) 89-111 89-111 359 0.93
XIII 0.46 (0.024) 92-108 92-108 359 0.94
XIV 0.33 (0.029) 67-135 66-132 328 0.90
Increasing I 0.50 (0.025) 100-100 100-100 351 0.99
II 0.50 (0.003) 100-100 100-100 351 0.99
III 0.50 (0.012) 100-100 100-100 351 0.99
IV 0.44 (0.036) 87-113 88-112 348 0.96
V 0.45 (0.031) 90-111 91-109 348 0.93
VI 0.47 (0.029) 93-117 94-116 348 0.98
VII 0.48 (0.026) 96-107 93-104 348 0.95
VIII 0.46 (0.029) 89-111 94-106 348 0.97
IX 0.47 (0.023) 90-110 96-114 348 0.96
X 0.48 ( 0.016) 93-107 99-101 349 0.99
XI 0.49 (0.009) 98-102 98-102 348 0.96
XII 0.44 (0.034) 89-111 89-111 348 0.94
XIII 0.46 (0.027) 92-108 91-109 348 0.94
XIV 0.33 (0.029) 65-135 65-135 315 0.90
Table 2.5: Performances of the competing designs in the case of the negative model
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randomization procedure results in a skewing of the treatment allocation probabilities
in favour of the better treament arm while maintaining a high statistical power of the
Wald test. This further shows that even when the response of the patients follow a
non-linear Weibull model, using a CARA randomization procedure is ethically more
attractive compared to the traditional balanced randomization designs, while it also
maintains high statistical efficiency in estimating treatment effects in the presence of
covariates. The inverse proportionality between the average power of the Wald test for
the covariate-adjusted treatment difference, and the variance of the CARA designs was
established theoretically in section 2.5 using a Taylor series expansion of the random
non-centrality paramenter of the test. Comparing the CARA designs, it can be seen
that the CAERADE or ERADE designs a much less variable than the CACBCD or
DBCD counterparts respectively. This is also true for the response-adaptive designs.
The variance of the CARA design based on the glink function also depends on the
difference between the two treatment effects. It can be seen in Table 2.5 that this
design has a relatively small variance, and thus a fairly high power of the Wald test
for detecting the difference in the covariate-adjusted treatment effects. Since all of the
CARA designs result in a skewing of the treatment allocation probabilities towards the
better treatment and achieving high statistical efficiency in estimating treatment effects
in the presence of covariates, they can be considered to be suitable alternatives to the
traditional balanced designs. Similar to the positive model, for both increasing and
decreasing hazard scenarios, the response-adaptive designs and the CARA design with
the glink function have the most variable powers whereas the balanced randomization
designs have the least variable power. For the case of decreasing hazard, the variability
of the power for design X is similar to those of the balanced randomization designs. In
the case of the increasing hazard, the variability of the power for design IV is similar
to that of the response-adaptive procedures. All of the standard errors for the powers
ranged from 0.001 to 0.004.
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2.6.4 Distribution of the Allocation Proportions
Apart from observing the performances of the designs on an average level over 5000
simulation runs, it is useful sometimes to learn about the performance of the individual
trials. The overall performance in the individual trials for the competing designs in
Table 2.2 when the shape parameter of the Weibull model is less than 1 is shown in
Figure 2.2.
Figure 2.2: Effect Size usually skews CARA allocation proportions towards better treatment
The boxplots in Figure 2.2 depict the observed allocation proportions of the com-
peting randomization procedures for n = 400 patients sequentially arriving in the trials.
The distributions of the observed allocation proportions appear to be very close to a
symmetric distribution, but with different means and with different variability. With
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the response-adaptive procedures, the adaptive allocation started somewhat earlier in
the trial as compared to the CARA designs, because the former estimate the main
treatment effects only, and the latter involves estimation of the full vector of treatment
effects. It can be seen that, for all three models, Efron’s biased coin design and the
Pocock and Simon covariate adaptive randomization procedure are least variable among
the competing designs. However, they along with the completely randomized design
allocate patients equally between the two treatment arms irrespective of their perfor-
mance based on patient responses. Therefore, these traditional balanced designs suffer
from the disadvantage of allocating more patients to the worse treatment arm during
the course of the trial. On the other hand, the CARA as well as the response-adaptive
designs skew the patient allocation on an average towards the better-performing treat-
ment arm. The boxplots also confirm the finding that the CAERADE and the ERADE
designs are more efficient than the corresponding CADBCD and the DBCD procedures
respectively.
The simulation results in this section clearly suggest that, when the survival response
of the patients to a treatment has a Weibull distribution, using the CARA designs would
significantly skew the allocation probabilities away from balance, but the degree and
the direction of the skewness may vary depending on the target allocation proportions
that the CARA designs converge to. The variabilities of the designs may also vary. It
has been seen that the CAERADE designs are the most efficient and that the CARA
design with the glink function is the most ethical among all the other CARA designs.
Therefore, when balancing the competing goals of statistical efficiency and of treating
more patients with the better performing treatment, the CARA designs outperform the
balanced randomization designs.
It was seen in Sverdlov, Rosenberger and Ryeznik (2013) that building the CARA
designs assuming exponential regression model for the survival responses, the type I
error rates of the Wald test for treatment comparison were slightly inflated. However it
is seen from the simulation results here that using the designs of section 2.4 when the
responses of the patients follow a Weibull regression model, gives slightly conservative
type 1 error rates of the Wald test for treatment difference when the hazard is decreasing
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over times. When the hazard rate is increasing over time the they are closer to the
nominal value of 0.05 for most of the optimal allocation proportions. This may be
because of the fact that when the hazard rate is increasing over time, the density
function for the Weibull model is closer to the shape of normality as compared to the
exponential density function. Therefore using the correct model for Weibull distributed
survival responses helps controlling the type 1 error rate of the Wald test for treatment
comparison which is a primary concern in any clinical trial.
This section dealt with simulation studies to validate the performance of the derived
CARA designs for patients with Weibull distributed survival responses. It is therefore
now worth applying these derived methodologies to a clinical trial in order to observe
their performance in the trial. The next section gives an applied outlook to this detailed
framework by using a real-life clinical trial.
2.7 Real-Life Example of the Proposed Methodol-
ogy
To assess the performance of the derived methodologies in a real-life clinical trial, a
survival trial in pulmonary adenocarcinoma has been re-designed. The study has been
previously explored in Sverdlov, Rosenberger and Ryeznik (2013) in terms of CARA de-
signs based on exponential models. Here, the study is re-designed based on the derived
methodologies for Weibull distributed survival responses. In this phase 3 open-label
study, during a 20-month period, 1217 adult patients from East Asia between the age
18 to 50 were randomly assigned in a 1:1 ratio between gefitinib (treatment A) and pa-
clitaxel (treatment B). The study excluded all patients who were former smokers. The
patients were followed up for a period of 12 months after the treatment phase. The pri-
mary objective of this trial was to test if treating patients with gefitinib would increase
the time to relapse from pulmonary adenocarcinoma, as compared to those patients
who are being treated with paclitaxel . The primary endpoint was progression-free
survival which considered relapse from pulmonary adenocarcinoma to be the event of
interest, whereas patients who do not experience the relapse until the end of the study
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period or if they are lost to follow-up during the study or if they die to to other events
are considered to be censored . Epidermal growth factor receptor (EGFR) gene muta-
tion was considered to be one of the significant factor affecting the patients’ response.
The study showed that there was a significant interaction between the treatments and
EGFR. Treatment A was superior to treatment B in the EGFR+ subgroup (hazard rate
for progression 0.48) and inferior in the EGFR− subgroup (hazard rate for progression
2.85).
Patient survival times for treatment k were simulated from an exponential distribu-
tion with mean exp(βk0 + βk1z), for k = A,B and z = 0,1. Following Sverdlov, Rosen-
berger and Ryeznik (2013), the parameters were chosen as follows: R = 20 months and
D = 26.5 months; z = 0 (EGFR+) with probability 0.6 and z = 1 (EGFR−) with
probability 0.4; βA0 = 1.62, βA1 = 0.98, βB0 = 2.35, and βB1 = 0.80. For appropri-
ate implementation of the derived CARA designs, 315 patients were initially equally
randomized to the two treatment arms using Efron’s biased coin design before the adap-
tive randomization process started. The results for the performances of the designs are
presented in Table 2.6.
Designs NA
n
(SE) NA−-NB− NA+-NB+ Events Power
I 0.50 ( 0.014) 243-243 365-365 1208 0.99
II 0.50 (0.001) 244-244 365-365 1208 0.99
IV 0.46 (0.019) 229-499 333-156 1196 0.98
VIII 0.45 (0.018) 241-489 305-182 1197 0.99
XII 0.46 (0.017) 335-358 229-295 1205 0.97
XIII 0.47 (0.016) 320-356 251-290 1205 0.98
Table 2.6: CARA Designs Outperforms other Designs for treating individual patients
Table 2.6 summarizes the performances of some of the competing designs in Table
2.2. It can be seen that irrespective of the performance of the treatment arms, the com-
pletely randomized design and the Efron’s biased coin design allocte patients equally
between the two treatment arms, resulting in more events. They also do not take into
61
account the difference betweens the covariate-adjusted treatment effects within the lev-
els of EGFR. Thus, they allocate equal numbers of patients within both the EGFR
subgroups. Due to delayed responses, the convergence to the target allocation propor-
tions was dampened. The average allocation proportions for both the CARA and the
response-adaptive designs are similar. This is because of the different direction of the
treatment effect in the EGFR+ and EGFR− subgroups. The overall allocation pro-
portion is therefore close to 0.5 for both the CARA and the response-adaptive designs.
However the CARA designs IV and VIII, unlike the response-adaptive designs XII and
XIII, account for the difference in the direction of the treatment effect in the EGFR
subgroups.
One of the primary reasons for developing CARA designs is that, in some clinical
trials, the degree and direction of the treatment effect differ for patient subgroups
within a treatment arm and the research design should account for such covariate-
specific treatment effects. Therefore, within each of the EGFR subgroups, the CARA
procedure allocates more patients to the better treatment arm and has, on average,
fewer events than each of the response-adaptive randomization procedures and the two
balanced designs. The response-adaptive designs also result in a skewed allocation
towards treatment B, but the degree of skewing is similar across the EGFR subgroups.
It can be seen that design VIII is less variable than design IV. Thus, if the sole criterion
is to have an ethical design with minimum variability, the CAERADE design is the
preferable one. The simulated type I error rates for the designs were between 0.03 and
0.05. All the randomization procedures have similar powers and the standard errors of
the averge number of events were no more than 10.
2.8 Critical Evaluation
The main objective of the present thesis has been to explore the likely ways of widening
the scope of applicability of CARA designs. The procedure of Bandyopadhyay and
Biswas (2001) used probit link function for normally distributed responses to relate
the past allocation, and covariate and response histories of the patients to the present
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allocation. Here, the design was scaled by using an arbitrary tuning parameter to
control the variability. This design has all of the major features of CARA randomization
designs, except for the fact that, unlike the optimal allocation designs, it does not
involve any adjustment for the covariates of the incoming patients. The concomitant
information of the incoming patients can be crucial in many cases. For instance, if
it relates to the gender of the patients and the patients are being treated with two
competing treatments, if males and females react very differently to treatments A and
B, whether the next patient is male or female is an important element in making the
treatment assignment to the incoming patient. It is because of this that the probit link
based design cannot be categorized as a CARA design.
The design based on the glink function, however, is a CARA design, as its treat-
ment allocation probabilities are sequentially modified based on the history of previous
patients’ treatment assignments, responses and covariates, and the covariates of the
incoming patient. The scale parameter of the cumulative distribution function of the
Gumbel model here is the reciprocal of the Weibull shape parameter obtained from
the information about the previous allocation, covariate and response histories of the
patients. On the other hand, the location parameter of this cumulative distribution
function is the reciprocal of the covariate-adjusted scale parameter obtained from the
Weibull regression accelerated life model based on the covariates of the incoming patient.
Another important feature of the present CARA design based on the glink function is
that, unlike the probit link based design of Bandyopadhyay and Biswas (2001), it does
not rely on an arbitrary tuning parameter T as a scaling factor.
The rationale behind the inclusion of the glink based CARA design has been its
close affinity to the other CARA designs in one very significant respect, namely that
they are all ethically oriented and are aimed at skewing the patient allocation in favour
of the better of the two competing treatments. Although the concept of skewing the
treatment allocation arose from ethical considerations such designs are also conducive
to minimization of outlay of resources in clinical trials. However, some care is needed
from the experimenter before using the CARA design based on the glink function. Since
the design is based on the cumulative distribution function of a Gumbel model which
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is a light tailed, steeply increasing function, it is ethically very attractive in terms of
treating a greater number of patients with the better treatment and achieving fewer
events in the trial. Moreover, it gives more weight to the available data than the designs
based on the probit link function or the Cauchy distribution function.
Figure 2.3 shows the probabilities of allocation to the better treatment arm for
different estimates of the covariate adjusted treatment difference when treatment A
performs better treatment B and the survival response follows a Weibull distribution.
Here, 110 patients were initially equally randomized between the two treatment arms
using Efron’s biased coin design, and then adaptive allocation was used separately with
each of the four link functions in Table 2.7. The scale parameter for each of these link
functions is σˆm = 1/γˆm and the location parameter is µ = 1/µˆ(zm+1), where γˆm is
the estimate of the Weibull model shape parameter from the previous m allocations
and µˆ(zm+1) is the estimate of the Weibull model scale parameter as a function of the
concomitant information of the incoming patient. The covariates considered are the
same as those in section 2.6 .
It can be seen from Figure 2.3 that using a light-tailed cumulative distribution func-
tion such as the glink leads to a faster increase in the allocation proportions with the
covariate-adjusted treatment difference compared to a heavy-tailed counterpart such
as the Cauchy distribution. An abrupt-tailed one like the uniform distribution would
give over-optimistic skewed allocation because of its abrupt increase in the allocation
proportion for every increase in the treatment difference. It can also be seen that the in-
crease in the observed allocation proportions for the design based on the glink is slightly
steeper than that for the probit link function and that the cumulative distribution func-
tion of the Gumbel model tends to assign slightly more patients to the better-performing
treatment arm. The estimated rate of change of the allocation proportions with the
covariate-adjusted treatment difference and the proportion of explained variability is
summarized in Table 2.7:
The residual degrees of freedom when regressing the allocation proportions against
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Figure 2.3: Rate of change of the Observed Allocation Proportions
Link F(x) Estimated Slope Residual SE R2
Cauchy 1
pi
arctan
(
x−µ
σ
)
+ 1
2
0.41 0.025 0.61
Gumbel exp{−e(x−µ)/σ} 0.57 0.029 0.68
Probit 1
2
{
1 + erf
(
x−µ
σ
√
2
)}
0.55 0.027 0.73
Uniform x−σ
µ−σ 1.05 0.048 0.71
Table 2.7: Behaviour of the different link function-based designs
the covariate-adjusted treatment difference for each of the designs based on the link
functions in Table 2.7 is 4998. Although the design based on the glink function tends
to allocate more patients to the better treatment arm than those based on the other link
functions, it has a serious drawback. In the initial stages, one should not rely heavily
on the available data. If the first few observations happen to be outliers, more patients
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might be allocated to the worse treatment arm than is desirable. It is therefore advisable
that, to use the CARA design based on the glink function, the experimenter needs to
choose a sufficiently large sample size for the interim stage of the trial during which
the patients are balanced across the treatment arms using restricted randomization in
order to calculate the maximum likelihood estimates to initiate the adaptation. As
suggested by Bandyopadhyay and Biswas (2001), in practice, one may also decide to
choose a design based on a heavy-tailed distribution in the initial stages and then switch
to a light-tailed one. This is technically a good suggestion, but switching between two
different designs for the same trial is less likely to be acceptable. Therefore, it is
suggested that, if an experimenter wishes to conduct a clinical trial which is ethically
very attractive, he might want to choose a sufficiently large sample size for the interim
stage of the trial during which the patients are balanced across the treatment arms with
the help of some balanced randomization procedure.
2.9 Discussion
The CARA designs here are based on two distinct approaches, the covariate-adjusted
doubly adaptive biased coin design (Zhang and Hu 2009) and the covariate-adjusted
version of the efficient randomized adaptive design (Hu, Zhang and He 2009) on the
one hand, and the glink function. The approach based on the glink function bridges the
past allocation and response histories and the present allocation pattern after allowing
for the incorporation of prognostic factors. The glink is developed using the cumulative
distribution function of a Gumbel model whose location parameter is the reciprocal of
the scale parameter of the Weibull accelerated life model calculated from the covari-
ate information of the incoming patient and its scale parameter is the reciprocal of
the shape parameter calculated from the Weibull accelerated life model based on the
information about the previous patients. The Gumbel model being asymmetric and
light-tailed, gives more weight to the available data and tends to allocate more patients
to the better treatment. Moreover, when the responses of the patients follow a Weibull
distribution, the design based on the Gumbel model is more appropriate compared to
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other continuous models because the theoretical errors in the Weibull accelerated life
regression model follow a Gumbel distribution. The arbitrariness of choosing a value
for the tuning parameter T present in the design based on the probit link function of
Bandyopadhyay and Biswas (2001) is not present in the one based on the glink function.
Scaling the estimated covariate-adjusted treatment difference by its standard error plus
the estimated hazard ratio makes this design more applicable.
The operating characteristics of the proposed adaptive designs as well as the bal-
anced randomization designs have been compared through simulation for a two-arm
survival trial with three predictive covariates and right-censored data. It has been
found that almost all of the proposed CARA designs generate skewed allocations to-
wards the better treatment according to covariate-specific treatment effects, and thus
result in fewer events in the trial, without compromising much on the statistical effi-
ciency compared to the balanced randomization designs. The only exceptions to this
are the CARA designs targeting the Neyman allocation proportion. This is because
the objective function for the Neyman allocation does not address any ethical criteria.
Its objective is to minimize the trial size. The degree of skewness also varies according
to the background model that the design is based on. A slight delay in the response
does affect the convergence of the CARA designs to their target allocation proportions.
The skewness in the treatment allocation proportions in favour of the better treatment
establishes the ethical gain of using the CARA designs compared to the traditional
balanced randomization procedures. It has been established by simulation that such
ethical gain is achieved most with the CARA design based on the glink function without
compromising much on the power of the Wald test for the covariate-adjusted treatment
difference. Using the correct model for adaptation when the responses of the patients
follow a Weibull model helps to control the type 1 error rate which was slightly inflated
while using the designs based on exponential accelerated life model.
A family of CARA designs has also been proposed here that are fully randomized
and asymptotically efficient of the first order. The CAERADE can be regarded as a
generalization of the Efron’s biased coin design for any desired allocation proportion,
which may depend on the unknown parameters. Delayed responses, which are very
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common in the case of survival trials, present no logistical difficulty in their incorpo-
ration in the CAERADE. It has been established that, when the new treatment has a
better effect on the survival experience of the patients than the existing control or when
treatment A performs better than treatment B, the CARA designs based on the Ney-
man allocation proportion assignsmore patients to the worse treatment and therefore
are not ethically attactive compared to the other competing designs.
A relationship between the non-centrality parameter and the variance of the CARA
designs has been arrived at using a Taylor series expansion of the non-centrality param-
eter of the Wald test for the difference between the covariate-adjusted treatment effects.
It is known that the power is an increasing function of the non-centrality parameter of
the Wald test and therefore it has been shown that the variance of the CARA designs is
inversely proportional to the power of the Wald test for the difference between the treat-
ment effects in the presence of covariates. The CAERADE being the asymptotically
most efficient CARA design increases the power compared to the corresponding CAD-
BCD. In the situation where efficiency is critically important, in theory, the CAERADE
should be the best choice among all of the CARA randomization procedures. However,
sometimes the CAERADE does not converge to the target allocation proportion as
fast as the CADBCD does, although its finite-sample variances are always small. This
is mainly because the allocation probabilities for the CAERADE are not stable. The
allocation function being discrete, they always jump from one value to another. A
continuous allocation function like the CADBCD can make the allocation probabilities
stable and speed up the convergence of the sample allocation proportions. Since in a
clinical trial the subjects are human beings, it would be insensitive for a statistician
not to take into serious consideration the need for minimization as far as possible of the
proportion of patients receiving the inferior treatment. Ethical considerations would
therefore appear to be quite unavoidable. Despite the marginal loss of statistical power
of the Wald test, a CARA design would irrefutably outperform any traditional balanced
randomization design in terms of ethical considerations, while achieving reasonably high
efficiency in estimating covariate adjusted treatment differences.
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Chapter 3
Covariate-Adjusted
Response-Adaptive Designs for
Semi-Parametric Survival Models
3.1 Introduction
Clinical trials are designed to answer specific questions about biomedical interven-
tions, including new treatments and known interventions that justify further study and
comparison. Treatment comparisons for a particular disease are often performed in
a clinical trial to obtain information about the efficacy of the competing treatments.
However, the involvement of human patients gives rise to an ethical concern of treat-
ing as many as possible with the best treatment found so far during the course of
the experiment. Patients arrive sequentially and are assigned to one of the competing
treatments. In order to make use of this sequential arrival of patients, designs are de-
veloped in stages, after each of which a decision is made. Adaptive allocation schemes
are sequential designs in which the method of allocation of treatments to patients is
modified based on the results obtained in the previous stage until a particular treatment
is declared to be a clear winner over the others. There has long been an interest in
developing methods that use the accrued information in the course of a clinical trial.
69
Quite often there exists a trial protocol and a statistical analysis plan (SAP) which is set
before the clinical trial begins. The protocol as well as the SAP pre-specifies the adap-
tation schedule and procedure. The adaptation process generally continues throughout
the trial as prescribed in the trial protocol and the SAP. The aim of an adaptive trial
is to more quickly and cost-effectively identify drugs or devices that have a therapeutic
effect, and to zero in on patient populations for whom the drug is appropriate.
Over the past several decades, there has been an enormous amount of work on devel-
oping adaptive designs in clinical trials. Traditionally, interest mainly lay in balancing
the patient allocation between the treatment arms while incorporating randomization
in the method of allocation. The motivation behind this was to develop a method of
experimentation which would retain the maximum power for testing the difference be-
tween the treatment effects. However, forcing a sequential experiment to be balanced
leads to the problem of its results incurring several forms of bias. These includes selec-
tion and accidental bias. Kalish and Harrington (1988) found optimal designs for the
special case when two treatments are available. They investigate empirically the loss
of efficiency when equal numbers of patients are allocated to each treatment. Efron
(1971), as a remedy to this problem, introduced biased coin designs for comparing two
treatments in which allocation of the treatment is determined probabilistically, but
with a bias towards the underrepresented treatment. Such a method of experimenta-
tion which decides on the next treatment allocation based on the information about
the allocation history only is widely classified as restricted randomization.
One property of human patients not shared by inbred laboratory animals is that they
are heterogeneous, that is, they can differ greatly in their responses to treatment. Such
heterogeneity can be accounted for during the course of the clinical trial by considering
the covariate information of the incoming patients. One of the disadvantages of Efron’s
scheme is that it does not include balance over covariates or prognostic factors which
may affect the response of the patient to the treatment. This has led to the development
of a method called the covariate-adaptive randomization where the current patient is
randomized to a treatment arm based on the history of previous treatment assignments,
the covariate vectors of past patients and the current patient’s covariate vector. The
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goal of covariate-adaptive randomization is to adaptively balance the covariate profiles
of patients randomized to each of the competing treatments.
Clinical trials involve experimentation on human patients, there is a large regula-
tory presence in the running of trials. Therefore, it is quite often that, from ethical
considerations, the goal of an adaptive design may be to allocate a large number of
patients to the treatment performing better thus far in the trial. Designs that adapt
to the responses of the previous allocated patients as well as the previous allocation
history are termed to be response-adaptive designs.
In contrast, for CARA designs, the treatment allocation probabilities are sequen-
tially modified based on the history of previous patients’ treatment assignments, re-
sponses and covariates, and the covariates of the incoming patient. Information related
to the covariate of the incoming patient is crucial in many cases when deciding on the
treatment allocation for this patient. For instance, if males and females react very dif-
ferently to the two treatment arms, then the information about the incoming patient
being a male or a female is an important element in the assignment of a treatment to
that patient.
Most of the CARA designs developed so far have dealt with clinical trials where the
response of the patients to a particular treatment is considered to be a binary random
variable. Hu, Zu and Hu (2015) developed unified family of CARA designs that balances
the efficiency and ethical criterias of a clinical trial, using a tuning parameter as the
power of the D-optimality criterion. Thier proposed family unifies several well-known
randomization methods such as the covariate-adjusted doubly-adaptive biased coin de-
sign as given in (2.26) and the optimal biased coin design of Atkinson (1982). There has
also been some work carried out with survival outcomes following a certain paramet-
ric model. Sverdlov, Rosenberger and Ryeznik (2013) used the exponential parametric
model to develop CARA designs for survival trials with administrative right censoring
for patients who are sequentially arriving in the trial. Biswas, Bhattacharya and Park
(2016) introduced a class of covariate-adjusted response-adaptive designs for phase III
clinical trials when the treatment response follows a parametric survival model and
there is random censoring. They developed optimal allocation designs for parametric
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survival responses based on the Koziol-Green (1976) model of random censoring, where
the survivor function of the censoring variable is a positive power of that of the lifetime
variable, and hence allows for the risk of experiencing the event of interest to depend on
the censoring mechanism. Such a kind of random censoring is referred to as informative
censoring.
While using a parametric form for the survival responses results in robust parame-
ter estimates from the fitted statistical models, it is rare in real-life clinical trials that
the survival responses conform closely to a certain parametric model. Therefore, an
attempt is made in this chapter to develop a CARA design whch is more applicable in
real-life situations, and, at the same time, is based on methods which yield sufficiently
robust parameter estimates from the fitted statistical model. The CARA designs de-
veloped are based on the lighter assumption that the hazard functions of the patients
at any given time point are proportional and time independent. It is because of this
reason that the approach is termed semi-parametric. To handle such situations, Fidalgo
and Lopez (2014) developed a partial information matrix and compared their derived
optimal designs with the optimal designs based on the full likelihood information, and
Konstantinou, Biedermann and Kimber (2015) obtained optimal designs by finding a
closed-form expression for the asymptotic covariance matrix for the Cox model. These
do not fit the definition of a CARA design which incorporates the covariate informa-
tion of the incoming patient. In this chapter, various CARA designs are developed
based on a semi-paramtric approach and the performance of the designs is validated by
simulation.
The outline of this chapter is as follows. Section 3.2 explains the background mate-
rial relating to the Cox proportional hazards model. The method of obtaining parameter
estimates for the model is discussed in Section 3.3. This is followed by Section 3.4 that
proposes the various CARA randomization procedures for a survival trial without any
parametric assumptions on the survival responses, which are then validated in Sec-
tion 3.5 using extensive simulation. The results obtained from applying the proposed
CARA designs to re-design a real-life clinical trial are detailed in Section 3.6. Section
3.7 concludes with a discussion and an outline of some future research in this direction.
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3.2 Background on Proportional Hazards
As mentioned earlier, Sverdlov, Rosenberger and Ryeznik (2013) used the exponen-
tial parametric model to develop CARA randomization procedures for survival trials.
These have been generalized in Chapter 2 to the Weibull case citing the limitations
of the applicability of the exponential model in real-life clinical trials. The methods
discussed in this chapter extend the applicability of CARA designs even further by en-
compassing situations where the designs are suitable for survival responses conforming
to any distribution, provided that the hazards of the event considered at any given time
point are proportional and time-independent for any two patients in the trial.
In a medical context, the hazard rate is also known as the force of mortality and it
represents a continuous version of a death rate per unit time. It is always convenient
in survival analysis to describe the distribution of the survival responses in various
different but inter-related ways. For a continuously distributed survival time T , let f(t)
be the density function and F (t) be the distribution function. In addition, let:
• the survivor function be S(t) = P(T ≥t), where S(t) gives the probability for a
patient to survive beyond a given time point t;
• the hazard function be h(t) = f(t)
S(t)
, where h(t) can be interpreted as the instan-
taneous failure rate;
• the risk function be h(t)δt, which gives the risk of an event in the time interval
[t, t+δt), given survival up to time t.
The survivor function can also be written as
S(t) = e−
∫ t
0 h(u)du = e−H(t), (3.1)
where H(t) is known as the integrated hazard or the cumulative hazard. It can therefore
be seen that, for the distribution of T to be proper, that is, for its density to integrate
to one, H(t)→∞ as t→∞. If this is not true, the implication is that the individual
may never die, though in some contexts this may not be an unreasonable approximating
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assumption. For example, when measuring progression-free survival, children may be
cured of a childhood tumour and live indefinitely in relation to the time scale of the
study. Normally, statisticians would want to insist on the distribution of T being
proper.
The hazard function gives the event rate at a given time t, conditional on having
survived to time t. The actual value of the hazard function is not usually of any
practical importance. It is mainly used to calculate risk ratios or to compare the risks
at different time points in a clinical trial. It is also useful for comparing death or
failure rates over time. The hazard function can be used as a means of identifying an
appropriate parametric model for the data or ruling out models that are not appropriate.
For example, the exponential distribution has a constant hazard function. Therefore,
if there is knowledge about the systems that they do not age with time, then the
exponential distribution can be used to model the survival times. If the hazard rate
is increasing, the risk of death or failure is also increasing with time because the ratio
of the hazard rates will be the same as the ratio of the risk functions. This ratio is
known as the risk ratio because over a small interval around time t when comparing
two treatments A and B, we have
hA(t)
hB(t)
=
hA(t)δt
hB(t)δt
. (3.2)
The concept of a risk ratio is used extensively in survival modelling when emphasis lies
in comparing different groups. This gives rise to the Lehmann family.
This family, also known as the proportional hazards family, is an important family
of distributions in modelling survival times. If ψk is an arbitrary constant with respect
to time at treatment k, the form of the Lehmann-family can be generated by;
Sk(t;ψk) = {S(t)}ψk , fk(t;ψk) = ψk{S(t)}ψk−1f(t), hk(t;ψk) = ψkh(t) (3.3)
for k = A,B. It can be used to model the log hazard and is the basis for the important
proportional hazards model, where the covariates act additively on the logarithm of the
hazard function. In such cases, ψk is a function of the model covariates. The exponential
distribution and the Weibull distribution with constant shape parameter belong to the
Lehmann family. From (2.3) it can be seen that, for the exponential model, the hazard
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ratio ψk can be obtained by taking the ratio of the covariate-adjusted means for the
two treatment arms. For Weibull distributed survival responses with constant shape
parameter γ, the value of ψk is estimated as in (2.3). In both these cases, ψk is time
independent and is just a function of the model covariates.
Cox (1972) had used this concept to provide a semi-parametric approach to model
time to event data where the survival experiences of patients in different groups can
be compared after adjusting for the effects of other variables which have an effect on
the patients’ responses. Unlike the accelerated life models which assume a particular
parametric distribution for the survival time of the patients, the Cox proportional
hazards model does not make any strong assumption about the functional form of the
survival times but a lighter assumption about the hazard ratio between two individuals
at a particular time point being constant. Since the model makes no assumption about
the functional form of the survival time distribution, the parameter estimates are not
based on the probability of the observed outcomes given the parameter values. Instead
of attempting to construct a full likelihood, Cox (1972) considered the conditional
probability that, given that exactly one individual in the risk set Ri with covariate
vector zm dies at time ti, it is the m
th individual that does so. Associated with patient
m = 1, 2, ...., n is a vector of baseline covariates zm = (z1m, ........, zpm)
T , the vector of
unknown model parameters βk = (βk1, ...., βkp)
T for treatment k = A,B, and a risk set
Ri, which is defined as the set of individuals still at risk at time ti, where ti is the i
th
ordered event time.
Let the hazard for the mth individual in the trial with treatment k and covariate
vector zm be hk(t|zm) = h(t|z = 0) eβTk zm , where h(t|z = 0) denotes the baseline hazard
function. Throughout this chapter, it is assumed that the survival responses follow a
continuous time model, so that only one event occurs at any one time. Therefore, the
conditional probability is given by
P ( individual m dies in[ti, ti + δt]|one death at ti) = hk(ti|zm)δt∑
l∈Ri hk(ti|zl)δt
or, P ( individual m dies in[ti, ti + δt]|one death at ti) = h(ti|z = 0)e
βTk zm∑
l∈Ri h(ti|z = 0)eβ
T
k zl
,
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which yields
P ( individual m dies in[ti, ti + δt]|one death at ti) = e
βTk zm∑
l∈Ri e
βTk zl
.
Thus, the baseline hazard cancels out from the expression. This is the essence of the
analysis to evaluate the conditional probability, the hazard at the event times ti only
needs to be considered. The product of these conditional probabilities over all of the
ordered event times ti is termed the partial likelihood, and is given by
PL =
B∏
k=A
nk∏
i=1
eβ
T
k zm(i)∑
l∈Ri e
βTk zl
. (3.4)
It can be seen from (3.4) that the individual times ti do not appear in the expression
for the partial likelihood. This can be justified by the argument that, in the absence
of a parametric form for the hazard, there is no information about its value between
successive ti: it could quite possibly be zero. It follows that the partial likelihood is a
function of only the ranks of the times and it would be unchanged if the time scale were
transformed by any monotonic transformation. The partial likelihood can be thought
of as the joint density function of the subjects’ ranks in terms of event order if there
were no censoring and no tied event times. This means that the functional form of
the baseline hazard function is not required. The censoring times do not enter the
expression for PL except to the extent that they help to determine the risk set. This
is also reasonable: knowing where in an interval an individual was censored conveys no
information about the hazard, provided that there exists independent censoring.
This intuitive justification, first proposed by Cox (1972) disguises the fact that PL is
not actually a likelihood. Indeed he originally described PL as a conditional likelihood.
Subsequent discussion led to a changed perception of the nature of the expression, which
is closer to being a marginal likelihood. Cox (1975) was able to recast his method of
estimation through what he called partial likelihood.
Ignoring the times at which the events occur leads to a loss of information. There-
fore, using partial likelihood for estimation of parameters leads to a little loss of in-
formation because it suppresses the actual event times, even though they are known.
Cox (1975) studied the properties of partial likelihood and showed that it does indeed
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have asymptotic properties that justify treating it as if it were a likelihood. He showed
that, even with the loss of information compared with a fully parametric analysis, the
partial likelihood acts in a similar manner to the likelihood and has all of the usual
properties.This approach is based on sound inferential principles and rigorous proofs
showing the consistency and asymptotic normality of the partial likelihood estimator.
Tsiatis (1981) demonstrated these large-sample properties. Anderson and Gill (1982)
simplified and generalized these results through the use of counting processes. The
amount of information lost by ignoring the actual event times is less than what one
might expect if the Cox proportional hazards model fits the data well.
Another useful distinction between the accelerated life model and the Cox propor-
tional hazards model is that the intercept is non-identifiable in the latter. The effect
of the covariates in a proportional hazards model is to increase or decrease the hazard
function by a constant proportion relative to the baseline hazard function. If two treat-
ments are being compared, from (3.3), putting log(ψk) =β
T
k zm, hk(t;ψk) = hk(t|zm)
and h(t) = h(t|z = 0) the logarithm of the hazard function for treatment k at any time
can be modelled as
log{hk(t|zm)} = log{h(t|z = 0)}+ βTk zm, hk(t|zm) = eβ
T
k zmh(t|z = 0). (3.5)
Therefore, using this model leads to the estimation of the relative risk between subjects
and not the absolute risk when the model parameters are estimated.
Although the values of the partial likelihood parameter estimates are interpretable
by themselves, the overall survival behaviour of the model cannot be understood without
knowing the baseline hazard function. One way to understand the baseline hazard
function is to specify it. However, in practice clinicians seldom specify a parametric
form for the baseline hazard function, because they seldom have even the faintest idea
as to what it might look like. The Cox proportional hazards model offers a neat way to
overcome this problem. When calculating the survival probabilities, one would estimate
the cumulative baseline hazard using an adaptation of the Nelson estimator attributed
to Breslow(1972).
Hˆk(t|z = 0) =
∑
ti≤t
dik∑
l∈Ri e
βTk zl
, (3.6)
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where dik represents the total number of events on treatment k at time ti, for k =
A,B. This is precisely what is expected from a discrete distribution with hˆk(t|z =
0) =
∑
ti≤t
1∑
l∈Ri e
βT
k
zl
. From this, the baseline survivor function can be estimated by
Sˆk(t|z = 0) = e−Hˆk(t|z=0).
Once the baseline survivor function is estimated, a survival curve can be constructed
as follows with covariates z:
Sˆk(t|z) = Sˆk(t|z = 0)exp(βTk z). (3.7)
In some sense, the discrete estimates hˆk(t|z = 0) can be thought of as similar to the
maximum likelihood estimate from the full likelihood, provided that it is assumed that
the hazard distribution is discrete. To estimate the average survival for a group of
subjects, either the individual survival estimates can be averaged or the survival for a
subject can be calculated using (3.7) with average covariates.
In this chapter, a survival trial is considered where patients enter the trial sequen-
tially and must be immediately randomized to either of the treatment arms. In survival
trials, it is not always possible to observe a random sample of completed observations.
This is because the observations are often censored in real-life clinical trials. It is as-
sumed that the survival time Tik is subject to an independent censoring time Cik , and
that the observed response on treatment k is a bivariate random vector (Tik, δik ), where
Tik = min(Tik, Cik) and
δik =
0 if Tik is a right-censored time,1 if an event occured at time Tik. (3.8)
With such a model, the ith patient’s observed response with treatment k = A,B is
represented by (tiA, δiA ) when xi = 1 and (tiB, δiB ) when xi = 0. Throughout this
chapter, the censoring scheme is assumed to be generalized type I right ceonsoring.
The trial has a limited recruitment period of length R > 0 and the trial duration
is fixed at D >R. At time D, patients who have not died or have not already been
censored are considered to be generalized type I right censored. It is possible to facilitate
CARA randomization only if the recruitment phase is relatively long and the number
of accumulating survival responses during the recruitment phase is substantial. The
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derivation of the parameter estimates using the partial likelihood function is considered
in the next section.
3.3 Deriving the Parameter Estimates from Partial
Likelihood
The partial likelihood function is a joint density function for the ranks of the patients in
terms of the event order. It is formed by taking a product of the conditional probabilities
that the mth patient, experiences the event in the interval [ti, ti + δt), given that there
is only one event at time ti, over all of the event times. Note that the censoring times
do not contribute towards the partial likelihood, as the values of probabilities are 1.
Therefore, the partial likelihood for treatment k expression can be written as
PLk =
nk∏
i=1
{
eβ
T
k zm(i)∑
l∈Ri e
βTk zl
}δik
. (3.9)
The essence of using the partial likelihood is that this function depends only on βk,
and is free of the baseline hazard function h(t|z = 0). Cox (1975) suggested treating
PLk as a regular likelihood function and making inferences about βk accordingly. This
means that the partial likelihood function can be maximized to obtain maximum partial
likelihood estimate (MPLE) of βk, and also the negative partial second derivative of
the log partial likelihood function can be used as the observed information matrix for
calculating the variance of the MPLE.
Survival trials are likely to involve censored observations. A critical assumption
made here is that the survival times and the censoring times are independent. The
generalized type I right censoring is considered here because the patients arrive sequen-
tially in the clinical trial and are observed until the end of the study. When subjects
join a study at different times and are all observed until a fixed time, generalized type
I right censoring. Here, time is measured from a different origin for each subject. This
is shown in Figure 2.1.
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Taking the logarithm of both sides of (3.9) yields
lk(βk) = log(PLk) =
nk∑
i=1
δik{βTk zm(i) − log(
∑
l∈Ri
eβ
T
k zl)}. (3.10)
This function can be maximized over βk to produce the maximum partial likelihood
estimates of the model parameters. Therefore, the partial score function is;
∇lk(βk) =
nk∑
i=1
δik
{
zm(i) −
∑
l∈Ri zle
βTk zl
(
∑
l∈Ri e
βTk zl)
}
. (3.11)
The Hessian matrix of the partial log-likelihood is given by
∇2lk(βk) = −
nk∑
i=1
δik
{∑
l∈Ri zlz
T
l e
βTk zl∑
l∈Ri e
βTk zl
− (
∑
l∈Ri zle
βTk zl)(
∑
l∈Ri zle
βTk zl)T
(
∑
l∈Ri e
βTk zl)2
}
. (3.12)
Using the score function and the Hessian matrix, the partial likelihood function can be
maximized with the help of the Newton-Raphson algorithm. The negative inverse of the
Hessian matrix, evaluated at βˆk, the partial likelihood estimate of βk, can be used as
an approximate covariance matrix for the estimate, and used to produce approximate
standard errors for the estimated regression coefficients in the Cox proportional hazards
model.
Let
z¯(ti,βk) =
∑
l∈Ri zle
βTk zl∑
l∈Ri e
βTk zl
=
∑
l∈Ri
zlwl,
where wl = e
βTk zl/
∑
l∈Ri e
βTk zl is the weight that is proportional to the hazard of the
patient experiencing the event. Therefore, z¯(t,βk) can be interpreted as the weighted
average of the covariate vectors among those individuals still at risk at time t with
weights wl. Thus (3.12) can be written as
∇2lk(βk) = −
nk∑
i=1
δik[
∑
k∈Ri
zlz
T
l wl − z¯(ti,βk){(z¯(ti,βk)}T ], (3.13)
which can also be written as
∇2lk(βk) = −
nk∑
i=1
δik[
∑
l∈Ri
{zl − z¯(ti,βk)}{zl − z¯(ti,βk)}Twl]. (3.14)
The quantity V (ti,βk) =
∑
l∈Ri{zl− z¯(ti,βk)}{zl− z¯(ti,βk)}Twl can be interpreted
as the weighted covariance matrix of the covariates among those individuals still at risk
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at time t. If {Vss(ti,βk)}ps=1 are the diagonal entries of this covariance matrix then
Vss(ti,βk) ≥ 0 and ∂2lk∂β2ks ≤ 0. Therefore, the log partial likelihood function has a unique
maximizer which can be obtained by equating the score function to zero and solving
for βk.
Moreover,
Vst(ti,βk) =
[∑
l∈Ri zslztle
βTk zl∑
l∈Ri e
βTk zl
−
{
(
∑
l∈Ri zsle
βTk zl)(
∑
l∈Ri ztle
βTk zl)
(
∑
l∈Ri e
βTk zl)2
}]
can be interpreted as the weighted sample covariance between the sth and the tth ele-
ments of the covariate vector among those individuals at risk at time ti. So the weighted
covariance matrix of the covariates among those individuals at risk at time ti, which con-
sists of {Vss(ti,βk)}ps=1 as its diagonal entries and {Vst(ti,βk)}ps,p=1 as its off-diagonal
entries, is positive definite. Hence the observed information matrix for βk, given by
Jk(βk) =
∑nk
i=1 δikV (t(i), βk), is also positive definite. The Hessian matrix - Jk(βk) is
negative definite, which implies that the log partial likelihood is a concave function of
βk and hence has a unique maximum which can be obtained by setting ∇lk = 0 . The
maximizing estimate βˆk defines the MPLE of βk.
Using the martingale central limit theorem, Cox (1975) showed that
(βˆk − βk) d−→ Np{0, J−1k (βk)}.
In practice, since βk is unknown, βˆk is substituted for βk in J
−1(βk) and J−1(βˆk) is used
as the estimated covariance matrix of βˆk. Since J(βk) is positive definite, its unique
inverse exists and is also positive definite.
To test the difference between the covariate-adjusted treatment effects, the Cox
proportional hazard model uses the score function in (3.11). Let uk(βks) =
∂lk
∂βks
and
let Uk(βk) = ∇lk be the score function for the kth treatment arm. If βks measures
the difference between the covariate adjusted treatment effects, then, under the null
hypothesis H0: βks = 0, we have uk(0)
d−→ N{0, Jkss(0)}. Equivalently,{
uk(0)√
Jkss(0)
}2
d−→ χ21.
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Under the global null hypothesis H0 : βk = 0, the score function Uk(0) converges to a
multivariate normality and Uk(0)
d−→ Np(0, Jk(0)). Equivalently,
[{Uk(0)}J−1k (0){Uk(0)}T ] d−→ χ2p.
Here, uk(0) can be regarded as the difference between the sum over the survival times
of the observed number of events from treatment k and the expected number of events
under the null hypothesis, which is also the numerator of the log-rank test. However,
unlike the score function, the log rank test does not adjust for the effects of other
variables having an effect on the survival experience of the patients.
The partial likelihood ratio test can also be performed to test for the difference
between the covariate adjusted treatment effects. As in the ordinary likelihood theory,
the null hypothesis can be regarded as H0: βk = ξk, where ξk is an arbitrary known
constant vector of dimension p for treatment k. If H0 is true, then βˆk, should be close to
ξk. Hence, lk(βˆk) should be close to lk(ξk) . Since lk(βˆk) - lk(ξk) is always non-negative,
H0 should be rejected if this difference is large. The partial likelihood ratio test uses
the fact that, under H0,
2{lk(βˆk)− lk(ξk)} d−→ χ2p.
Therefore, for a given level of significance α, H0: βk = ξk is rejected if 2 {lk(βˆk) -
lk(ξk)} ≥ χ2p,α, where χ2p,α is the value of χ2p distribution such that P(χ2p > χ2p,α) = α.
Taylor expanding lk(ξk) about βˆk gives
lk(ξk) ≈ lk(βˆk) +∇lk(βˆk)(ξk − βˆk) + 12!(ξk − βˆk)T∇2lk(βˆk)(ξk − βˆk)
Since βˆk maximizes lk(βk) Uk(βˆk) = ∇lk(βˆk) = 0 and ∇2lk(βˆk) = - Jk(βˆk) we have,
2{lk(βˆk)− l(ξk)} ≈ (ξk − βˆk)TJk(βˆk)(ξk − βˆk).
Moreover, using the martingale central limit theorem, it can be shown that
(βˆk − ξk) d−→ Np{0, J−1k (βˆk)}.
Therefore under H0 : βk = ξk,
2{lk(βˆk)− lk(ξk)} = (βˆk − ξk)TJk(βˆk)(βˆk − ξk) d−→ χ2p.
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The score test is the most powerful test when the true value of βk is close to ξk.
The main advantage of the score test is that it does not require an estimate of the
information matrix under the alternative hypothesis or unconstrained maximum partial
likelihood. This constitutes a potential advantage in comparison to other tests, such as
the Wald test and the partial likelihood ratio test, and makes testing feasible when the
unconstrained MPLE is a boundary point in the parameter space. The score test based
on the partial likhelihood function and the Wald test are used in the following section
to develop CARA designs based on Cox propotional hazard model for comparing two
treatment arms.
3.4 The Proposed Semi-Parametric CARA Designs
Clinical trials are complex experiments on humans with multiple and often competing
expetimental objectives. Some of these objectives include maximizing the power to
detect clinically relevent differences in treatment outcomes, maximizing the patient’s
personal experience while being treated in the trial and making the trial economically
more effective. An optimal solution for allocating patients to the competing treatment
arms is a function of the unknown parameters. Unlike inbred laboratory animals,
the humans involved in clinical trials are heterogeneous. Therefore, the objective of
maximizing the patient’s personal experience while being treated in the trial needs to
be satisfied after taking such heterogeneity into account. A CARA design achieves most
of these objectives in a clinical trial after taking the between-patient heterogeneity into
account.
CARA randomization is applicable when the responses of the patients to the treat-
ments follow a non-linear and heteroscedastic model, and when multiple experimental
objectives are being pursued in the clinical trial. In this chapter, it is assumed that
the survival responses of the patients follow a semi-parametric survival model which in
this case is a Cox proportional hazard model. This means that there is no assumption
made about the underlying theoretical distribution of the responses. However it is as-
83
sumed that the hazard of an event at any time in the clinical trial for a patient in one
treatment group is proportional to the hazard of the event at that particular point of
time in the trial for another patient in the opposite treatment group. Proportionality
here means that the ratio of the hazard functions for patients on the two treatment
arms at a given point of time in the trial is not dependent on time. The censoring
scheme assumed throughout is a generalized type I right censoring scheme, where the
recruitment period is of length R > 0 and D is the overall duration of the clinical trial.
At time D, the subjects who have not experienced the event or have not already been
right censored are considered to be generalized right censored of type I. When the re-
cruitment phase of the survival trial is long enough to accumulate a substantial number
of responses, CARA randomization is applicable. To allocate an incoming patient to a
particular treatment arm, apart from the covariate profile of this patient, this type of
randomization relies heavily on the response history, treatment allocation history and
the history of the covariate profiles of the patients.
When comparing two treatments, let βA and βB be the covariate-adjusted treatment
effects of treatments A and B, respectively. During the initial phase of the trial, some
restricted randomization procedure is used to randomize the initial 2m0 patients equally
among the two treatment arms, where m0 is a positive integer. This ensures that at least
m0 patients are allocated to each treatment arm, and that estimates of the parameters
(βA, βB) can be obtained from the observed responses of this initial sample. At a
general stage, one computes the partial likelihood estimates (βˆA,m, βˆB,m) of the model
parameters (βA , βB). When the (m+1)
th patient enters the trial with covariate vector
zm+1, this patient is randomized to treatment A with probability c(βˆA,m, βˆB,m,zm+1),
where 0 ≤ c(.) ≤ 1 is an allocation function which bridges the past allocation pattern,
response histories and covariate vectors of the m patients to the (m + 1)th allocation
with the covariate vector zm+1. This allocation function skews the treatment allocation
probability in favour of the better treatment arm found thus far in the course of the
clinical trial, without compromising much on the power of the statistical test to detect
any covariate adjusted treatment differences.
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3.4.1 Deriving a Suitable Semi-Parametric Target Allocation
Proportion
Treating the baseline hazard as arbitrary makes the design more dependent on the
observed data compared to the designs based on parametric models. Such a design
therefore increases its applicability in real-life clinical trials. Let k(z;βk) be the prob-
ability of an event before censoring for a patient on treatment k and with covariate
vector z. Then, k(z;βk) = P(Tk ≤ Ci |z; βk). This probability can be estimated by
the proportion of patients facing events on each treatment.
One way to meet most of the multiple experimental objectives in a clinical trial
is to minimize the overall hazard for a patient with a given covariate subject to the
constraint of keeping the asymptotic variance of the difference between the estimated
hazard functions for the two treatment groups, constant. This is achieved by minimizing
nAhA(t|z) + nBhB(t|z),
subject to zT{zTJ−1A (βA)z}ze2β
T
Az + zT{zTJ−1B (βB)z}ze2β
T
Bz = k > 0,
where k>0 is a constant and Jk(βk) is the observed information matrix of the Cox
regression coefficients βk for treatment k. If V ak{ĥk(t|z)} = zT{zT V¯ −1(t,βk)z}ze2βTk z
, the optimal allocation proportion for treatment A is given by
piSA1(βA,βB, z) =
√
B(z;βB)hB(t|z)V aA{ĥA(t|z)}√
B(z;βB)hB(t|z)V aA{ĥA(t|z)}+
√
A(z;βA)hA(t|z)V aB{ĥB(t|z)}
.
(3.15)
One can use other metrics of treatment difference and obtain different optimal allo-
cations. For instance, minimizing the overall sample size subject to the constraint of
keeping the asymptotic variance of the difference between the estimated hazard func-
tions for the two treatment groups, constant, leads to the Neymann allocation given
by
piSA2(βA,βB, z) =
√
B(z;βB)V aA{ĥA(t|z)}√
B(z;βB)V aA{ĥA(t|z)}+
√
A(z;βA)V aB{ĥB(t|z)}
. (3.16)
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The derivation of the allocation proportion in (3.16) is provided in Appendix E. The
variance of the estimated hazard for a particular treatment arm has been derived by
applying the delta method. This derivation is given in Appendix C.
Apart from using the formal optimization procedure, one can make use of the cu-
mulative distribution function of a normal model to obtain an allocation proportion.
This idea was first introduced by Bandyopadhayay and Biswas (2001), where they used
a probit model as a link function to bridge the past history to the present allocation
pattern for patients whose responses follow a normal linear model. However, that de-
sign did not fit the definition of a CARA design, as it did not take into account the
covariate information of the incoming patient. Moreover, the main criticism which
the design faced was of the arbitrariness of the user defined tuning parameter used to
control the variability of the design. In the results obtained in the previous chapter
it was seen that the increase in the allocation proportions with every increase in the
treatment difference did not significantly differ between the probit link function and
the glink function. Moreover unlike the Weibull accelerated failure time model whose
theoretical errors follow a Gumbel distribution, the baseline hazard function for the
Cox proportional hazard model is a nuisance parameter whose paramteric distribution
is not estimable. A similar design to Bandyopadhayay and Biswas (2001) is therefore
now developed for patients whose survival responses follow a semi-parametric model
and uses the partial likelihood estimators instead of the least squares estimators.
Let Φ(.) be the probit link function, which is the cumulative distribution function
of a normal model with mean zero and standard deviation determined by the covariates
of the incoming patient. Let βˆA(m) and βˆB(m) be the partial likelihood estimators of the
effects of the two treatments upto the mth stage of the clinical trial. Using Φ(.) it is
intended to seek for a suitable cumulative distribution function F (.) which can be used
as a link function such that after m allocations, the (m + 1)th patient is allocated to
treatment A with probability F [log{hA(t|zm)}−log{hB(t|zm)}] and to treatmentB with
probability 1- F [log{hA(t|zm)} − log{hB(t|zm)}] = Φ[log{hB(t|zm)} − log{hA(t|zm)}].
The probit link function being an increasing function of the treatment effect difference
make this allocation procedure favour the treatment performing better at each stage of
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the clinical trial. Let ĤR(zm) represent the estimated hazard ratio of the two treaments
at the mth stage of the clinical trial. The allocation function for treatment A for the
(m+ 1)th patient can therefore be written as :
piSA3(βˆA(m) , βˆB(m) , z) = Φ
{
log{hˆA(t|zm)} − log{hˆB(t|zm)}
SE[log{hˆA(t|zm)} − log{hˆB(t|zm)}] + ĤR(zm)
}
. (3.17)
This design scales the covariate adjusted treatment difference by the hazard ratio be-
tween the two treatment arms. This means that, if the hazard of an event for a par-
ticular treatment group is greater than that for the other, there would be less chance
of allocating the next patient to that particular treatment arm. Let β−k be the model
parameters ignoring the treatment effect. The probit link function in (3.17) has mean
zero and the standard deviation as h(t|zm+1) = exp(βT−kzm+1).
Let Xm, Ym,Zm and zm+1 denote, respectively, the past allocation history, responses
history, the prognostic factors for the first m patients and the covariates of the incoming
patient. Based on the probit link, the conditional probability that the (m+1)th patient
with covariate vector zm+1, will be assigned to treatment A is given by
P (X(m+1) = 1|Xm,Ym,Zm, zm+1) = Φ
{
log{hˆA(t|zm)} − log{hˆB(t|zm)}
SE[log{hˆA(t|zm)} − log{hˆB(t|zm)}] + ĤR(zm)
}
,
(3.18)
where, conditional on χm,
[log{hˆA(t|zm)} − log{hˆB(t|zm)}] d−→ N([log{hA(t|zm)} − log{hB(t|zm)}], σ2).
as m → ∞. The variance σ2 is calculated from inverting the observed information
matrix given by (3.14). Let ζ(m) = P (Xm+1= 1). Then the sequence {ζ(m) : m ≥
(2m0 + 1)} converges to Φ
[
log{hA(t|zm)}−log{hB(t|zm)}
HR(zm)
]
. The limiting proportion of the
allocation of patients on treatment A is also Φ
[
log{hA(t|zm)}−log{hB(t|zm)}
HR(zm)
]
.
Most phase III clinical trials of two treatments employ an equal allocation scheme.
Such schemes are often unattractive to clinicians and volunteers, as they assign almost
half of the patients to the less effective treatment even if a treatment effect exists. For
many years, adaptive designs have been proposed as a compromise. Apart from using a
link function or a formal optimization procedure, CARA designs for such scenario can
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also be developed by the method of treatment effect mappings similar to Rosenberger
and Sheshaiyer (1997). The score function uk(0) can be used to map the past histories
to the present allocation pattern. When a patient is ready for randomization, a function
of the current value of the score function from the fitted Cox regression model is used to
bias a coin, which is then used for randomization. As mentioned earlier, uA(0) measures
the difference between the sum over the survival times of the observed number of events
from treatment A and the expected number of events under the null hypothesis. In
general, the score function can be used to develop a mapping onto [0,1] that exceeds
0.5 if treatment A has been performing better thus far, and is less than 0.5 if treatment
B has been performing better. Let NA(m) and NB(m) be the numbers of patients
allocated to treatments A and B, respectively, up to stage m. Define
Qk =
uk(0)
{max(NA(m), NB(m)}hA(t|zm)hB(t|zm)
∑dm
i=1(
1
N−i) + h(t|zm+1)
as the treatment effect mapping factor . Then the allocation function to treatment A
can be suggested with the following mapping :
P [X(m+1) = 1|Xm,Ym,Zm, zm+1] = 1
2
(1−QA) . (3.19)
It can be seen from (3.19) above that if the null hypothesis of the equality in the
covariate adjusted treatment effects is true, the treatment effect mapping factor Qk
is zero and therefore the probability of allocating the next patient to one of the two
treatment arms would be 0.5. If the null hypothesis is false, the allocation proportion to
treatment A drifts away from 0.5 according to the magnitude of Qk. This idea is similar
to that of Rosenberger (1993) in dealing with immediate continuous outcomes using a
nonparametric rank test. Most clinical trials in the United States use a fixed sample
design and interim monitoring. The design in (3.19) assumes a fixed sample size and
also skews the allocatio proportions according to the covariate-adjusted relative efficacy
of the treatments, making it fully randomized.
The allocation proportions obtained by using the formal optimization procedure can
be targeted using the covariate-adjusted doubly-adaptive biased coin design (CADBCD)
or the covariate-adjusted efficient-randomized adaptive design (CAERADE). The CAD-
BCD is a randomization procedure which is used to target the allocation proportions
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{piSAi(βA,βB, z)}2i=1 and applies to the cases where the desired allocation proportions
are unknown, but estimated sequentially. When the (m+1)th patient enters the clinical
trial with covariate vector zm+1, let pˆim = pi
S
A(βˆA,m, βˆB,m, zm+1) represent the estimate
of piSA(βA,βB, z) based on the responses observed from the m patients, adjusted for the
covariate zm+1 of the incoming patient. Let ρˆAm = {
∑m
i=1 pi
S
A(βˆA,m, βˆB,m, zi)/m} be an
estimate of the average target allocations for treatment A based on the data for the
first m patients. Using the CADBCD procedure, the (m+ 1)th patient can be assigned
to treatment A with probability jm+1[{NA(m)/m}, pˆim, ρˆAm], where {NA(m)/m} is the
observed proportion of patients who have been assigned to treatment A after m alloca-
tions. Therefore, the mathematical form of the allocation rule for the (m+ 1)th patient
entering the clinical trial with covariate vector zm+1,to be assigned to treatment A is
jm+1
{
NA(m)
m
, pˆim, ρˆAm
}
=

pˆim{ρˆAm/NA(m)m }α
pˆim{ρˆAm/NA(m)m }α+(1−pˆim){{1−ρˆAm)/(1−
NA(m)
m
)}α , if 0 <
NA(m)
m
< 1,
1− NA(m)
m
, if NA(m)
m
= 0 or NA(m)
m
= 1.
(3.20)
Here α is a non-negative parameter controlling the degree of randomness of the CAD-
BCD procedure. A value of α = 0 corresponds to the procedure being most random and
a value of α = ∞ corresponds to it being most deterministic. The allocation function
jm+1[{NA(m)/m}, pˆim, ρˆm] is strictly decreasing in {NA(m)/m} and strictly increasing
in (pˆim, ρˆm) on [0,1]×[0,1].
On the other hand the allocation function for the CAERADE is discrete. When
efficiency is the sole criterion for developing a CARA design, the CAERADE performs
the best compared to CADBCD. Let pˆim = pi
S
A(βˆA,m, βˆB,m, zm+1) denote an estimate
of the target allocation proportion piA(βA,βB, z) based on the data from m patients,
adjusted for the covariate zm+1. Then, according to the CAERADE allocation rule,
the probability of the (m + 1)th patient with covariate vector zm+1 being assigned to
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treatment A is given by
jm+1
{
NA(m)
m
, pˆim, ρˆAm
}
=

α′pˆim if
NA(m)
m
> ρˆAm,
pˆim if
NA(m)
m
= ρˆAm,
1− α′(1− pˆim) if NA(m)m < ρˆAm,
(3.21)
where 0 ≤ α′ < 1 is a constant that reflects the degree of randomization. Hu,Zhang and
He (2009), following Burman (1996), recommended the value of α′ between 0.4 and 0.7.
This gives a family of CARA designs that are fully randomized and also asymptotically
efficient. The CAERADE with covariates ignored can be viewed as a generalization of
the Efron’s biased coin design for any desired allocation function, which may depend
on the unknown parameters. If the response distribution belong to the exponential
family, the CAERADE for any α ∈ [0,1) is fully efficient. However, this can also be
used to target the optimal allocation proportions when the survival responses follow a
semi-parametric survival model. Though there is hadrly a reference for the theoretical
asymptotic properties of the ERADE or the CAERADE for response distribution which
do not follow a parametric model, the performance of these randomization procedures
can be viewed using simulations.
Atkinson and Biswas (2005) proposed a class of CARA designs for which the ran-
domization probabilities are sequentially determined by maximizing a utility func-
tion that combines inferential and ethical criteria. The authors concentrated on nor-
mally distributed responses. However, their approach can be applied in the context
of a survival responses of a patient following a semi-parametric model between the
treatment arms. If m patients have been enrolled in the trial and NA(m) patients
have been assigned to treatment A and NB(m) = m - NA(m) have been allocated
to treatment B, a randomization probability for the (m + 1)th patient is determined
by optimizing a utility function that combines the inferential and ethical criteria of
a CARA design. The inferential criteria can be addressed by taking a convex crite-
rion based on the observed information matrix J(β) = diag{JA(βA), JB(βB)}, where
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Jk(βk) =
∑nk
i=1 δikV (ti,βk) for k = A,B. Since the main interest lies in maximizing the
information about the model parameters, let νk = log{1+d(k,βk, zm+1)}+ΣBk=AJk(βk)
be some measure of information from applying treatment k to the (m + 1)th patient,
where d(k,βk, zm+1) is the directional derivative of the D-optimal criterion given by
d(k,βk, zm+1) = k(z;βk)z
T
m+1J
−1
k (βk)zm+1. The (m + 1)
th patient is assigned to
the treatment for which d(k,βk, zm+1) is the maximum. For an ethical criterion,
pA(βA,βB, zm+1) = hB(t|zm+1)/{hA(t|zm+1)+hB(t|zm+1)} can be considered as a map-
ping of the treatment effect, adjusted for the covariates of the new patient. The treat-
ment allocation probabilities, piSA and pi
S
B = 1 − piSA, for the (m + 1)th patient are de-
termined by maximizing the utility function U =
∑B
k=A pi
S
k νk − η
∑B
k=A pi
S
k log(pi
S
k /pk).
Using Lagrange multiplier optimization, the optimal solution is obtained as
piSA =
pA{1 + d(A,βA, zm+1)}1/η
pA{1 + d(A,βA, zm+1)}1/η + pB{1 + d(B,βB, zm+1)}1/η . (3.22)
The optimal allocation probabilities in (3.22) depend on the model parameters,
which must be replaced by their partial likelihood estimates. When η → 0, the alloca-
tion function maximizes the efficiency of the study design, whereas, when η → ∞, it
satisfies the ethical standpoint of the trial.
3.5 Simulation Results
In order to compare the performances of the different derived CARA randomization
procedures, a two-arm survival trial with 800 patients has been considered. A patient’s
arrival time here is simulated from a uniform (0,365) distribution, whereas the response
time of a patient is added to the recruitment time of the patient and patients whose
outcomes have not been observed by the pre-specified study time, are said to be gen-
eralized type I right censored. The recruitment period has been considered to be 365
days, and the overall trial duration is taken to be 581.66 days.
Following Rosenberger, Vidyashankar and Agarwal (2001), a covariate structure of
three independent covariates has been generated. These are gender (Bernoulli, p =
0.5), age {Uniform(30,75)} and cholesterol level {Normal (200,400)}. The censoring
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time of the patients is simulated from a uniform (0,581.66) distribution. The survival
time of a patient with covariate vector z = (1, z1, z2, z3)
T in treatment group k is
simulated from the Weibull distribution with scale parameter µk(z) =exp(β
T
k z) and
shape parameter γk = 2.07527. Three choices of the treatment effects vector have
been considered in this case, which are neutral effect of either treatment, positive effect
of treatment A and negative effect of treatment A. The effects of the corresponding
covariates for the simulation model µk(z) =exp(β
T
k z) are the same as summarized in
Table 2.1. The procedure used here is a fully sequential one that recalculates the
randomization probabilities over 5000 simulation runs. The competing randomization
procedures and the corresponding design numbers are listed in Table 3.1.
Design Competing Randomization Procedures
I Completely randomized design
II Efron’s biased coin design with p = 2/3
III Pocock and Simon design with p = 3/4
IV Taves minimization procedure with p = 1
V CARA CADBCD with(3.15) as the target
VI CARA CADBCD with(3.16) as the target
VII CARA CAERADE with(3.15) as the target
VIII CARA CAERADE with(3.16) as the target
IX CARA design based on the probit link function
X CARA design based on (3.19)
XI CARA design based on (3.22) with η = 1
XII CARA design based on (3.22) with η = ∞
Table 3.1: List of the competing designs
In survival trials, the delay time for a patient is the patient’s survival or censoring
time. To facilitate CARA designs with delayed responses, it is required that, at the ith
patient′s randomization time, only data from those patients who have responded before
the ith patient’s arrival are used in computing the randomization probability for the ith
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patient. For the implementation of the derived CARA designs, initially 2m0 patients
have been equally allocated to the two treatment arms using Efron’s biased coin design.
Here, m0 is a positive number and 2m0 is chosen to be 160. After the model parameters
are estimated from the initial stage of the design, new patients arrive sequentially
into the trial and the Cox proportional hazards model (3.5) is fitted to the available
responses and covariate information of the patients. Next, an allocation proportion is
calculated which is a functions of the partial likelihood estimates obtained from the
fitted Cox model. A randomization rule is then used to allocate the new patients to
a treatment arm. This randomization rule can be based on any one of the derived
allocation functions which target a specific allocation proportion. A pseudo-random
number generator is then used to draw a uniform random number between 0 and 1.
If the derived probability from the randomization rule is greater than or equal to this
random number, the patient is assigned to treatment A or else the patient is assigned
to treatment B. The procedure described is repeated for the subjects entering the trial
in the future.
For the CADBCD designs in Table 3.1 above, following Hu and Zhang (2004),
Zhang and Hu (2009), and Rosenberger and Hu (2004), the trade-off parameter for
randomness is taken to be α = 2. Based on Burman’s (1996) studies on the expected
p-value deficiency to evaluate the performance of a particular design, Hu, Zhang and
He (2009) recomended that for the appropriate implementation of the ERADE designs,
it is reasonable to choose α′ between 0.4 to 0.7. The parameter α′ controls the degree of
randomness of the design. When α′ is smaller, the CAERADE is more deterministic and
has a smaller variability. Here, for the appropriate implementation of the CAERADE
designs, α′ is chosen to be 0.55.
Among the balanced randomization procedures, apart from the completely random-
ized design, Efron’s biased coin design is a restricted randomization procedure, whereas
Pocock and Simon’s (1975) design and Taves’ (1974) design are covariate adaptive
randomization procedures. These covariate-adaptive randomization procedures are is
called minimization procedures, as they minimize treatment imbalances marginally on
important covariates. For their implementation, all covariates must be categorical. The
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covariate age has been dichotomized according to age < 53 and age≥ 53, whereas the
covariate cholesterol level has been dichotomized according to cholestrol level<200 and
cholestrol level ≥ 200. According to Pocock and Simon (1975), for an incoming pa-
tient, one computes the treatment imbalance at each observed levels of the patients
covariates, and with probability 3/4 the patient is assigned to the treatment arm that
reduces the overall covariate imbalance. If the imbalance is zero, the patient is ran-
domized to any competing treatment arms with equal probability. Taves (1974), on
the other hand, proposed a deterministic method to allocate treatments designed to
minimize the overall covariate imbalance marginally on important covariates.
The performances of the competing randomization procedures in Table 3.1 for semi-
parametric survival models, can be analysed from their operating characteristics in
Table 3.2 and Table 3.3. All simulations were carried out using the R statistical software.
For each experimental design, the significance level of the Wald test for testing the
treatment difference has been set to 0.05.
Design NA
n
(SE) NAM -NBM NAF -NBF Event Type I Error
I 0.50 (0.018) 200-200 200-200 650 0.05
II 0.50 (0.001) 200-200 200-200 650 0.04
III 0.50 (0.015) 200-200 200-200 649 0.05
IV 0.50 (0.004) 200-200 200-200 650 0.05
V 0.50 (0.014) 200-200 200-200 649 0.05
VI 0.51 (0.020) 202-198 204-196 650 0.05
VII 0.51 (0.015) 203-197 203-197 650 0.04
VIII 0.51 (0.019) 202-198 204-196 650 0.04
IX 0.50 (0.075) 200-200 200-200 650 0.07
X 0.49 (0.022) 196-204 196-204 650 0.05
XI 0.50 (0.026) 200-200 200-200 650 0.04
XII 0.50 (0.026) 200-200 200-200 650 0.04
Table 3.2: Simulation Results of the competing designs for neutral model
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Table 3.2 presents the operating characteristics of the various competing designs
when there is no difference in the effects of the two treatment arms. It compares the
derived semi-parametric CARA designs with the traditional balanced randomization
procedures, under the null model. It can be seen that, almost all designs result in
an equal allocation of patients to the two treatment arms. Efron’s biased coin design
achieves the lowest variability for the allocation proportions. This is because the asymp-
totic distribution of the allocation proportion for this design converges to a single point.
However, all of the derived allocation proportions for the CARA randomization proce-
dures, apart from designs IV and IX, are similarly variable compared to the completely
randomized design. It has been shown by Cox (1972) that the asymptotic behaviour of
the partial likelihood estimator is similar to the maximum likelihood estimator. There-
fore, the Wald test can be used to compare the covariate-adjusted treatment effects
from the fitted Cox regression model after the patients arrive sequentially. With 800
patients, the type I error rates obtained from the Wald test for almost all of the com-
peting randomization procedures are close to the nominal significance level of 0.05,
whereas that of design IX is inflated. The diference in the standard errors for of the
type I error rates range from 0.001 to 0.004. The variabilities of the type I error rates
for the balanced randomization designs are the lowest and that for design IX is the
highest . This phenomenon was further explored by simulation for a range of sample
sizes and the simulated type I error rates revealed similar results. The average numbers
of events are almost the same for all the designs and their standard errors were no more
than 11.
Table 3.3 presents the operating characteristics of the various competing random-
ization procedures when the covariate adjusted effects of the two treatment arms differ.
From the negative model, it can be seen that all of the derived CARA designs result
in skewed allocation towards the better treatment arm, but the degree of skewness is
different. In this case, it is treatment B which is superior. Design IX is most skewed
towards the better treatment arm and thus result in the least number of events on
average. On the other hand, designs VII and X least skewed compared to the other
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Model Design NA
n
(SE) NAM -NBM NAF -NBF Event Power
Negative I 0.50 (0.018) 200-200 200-200 334 0.99
II 0.50 (0.001) 200-200 200-200 334 0.99
III 0.50 (0.016) 200-200 200-200 334 0.99
IV 0.50 (0.005) 200-200 200-200 334 0.99
V 0.45 (0.015) 180-220 181-219 332 0.99
VI 0.39 (0.020) 157-243 158-242 332 0.98
VII 0.48 (0.016) 192-208 197-203 332 0.99
VIII 0.38 (0.019) 150-250 152-248 332 0.98
IX 0.30 (0.070) 120-280 120-280 322 0.90
X 0.47 (0.080) 188-212 190-210 332 0.87
XI 0.43 (0.026) 172-228 172-228 329 0.97
XII 0.40 (0.028) 160-240 161-239 328 0.96
Positive I 0.50 (0.018) 200-200 200-200 726 0.99
II 0.50 (0.001) 200-200 200-200 726 0.99
III 0.50 (0.016) 200-200 200-200 725 0.99
IV 0.50 (0.005) 200-200 200-200 725 0.99
V 0.56 (0.014) 223-177 226-174 723 0.99
VI 0.62 (0.020) 248-152 249-151 720 0.98
VII 0.52 (0.015) 208-192 209-191 723 0.99
VIII 0.62 (0.019) 248-150 248-154 723 0.98
IX 0.71 (0.074) 299-101 272-128 710 0.89
X 0.52 (0.083) 122-118 122-118 725 0.84
XI 0.57 (0.025) 227-173 227-173 722 0.98
XII 0.60 (0.025) 228-172 228-172 721 0.97
Table 3.3: Performance of the competing designs when Treatment effects differ
competing CARA randomization procedures. All of the competing designs, apart from
IX and X, have similar powers for the Wald test, whereas skewing the patient allocation
towards the better treatment arm results in fewer of events on average during the trial.
The standard errors of the latter are no more than 14. Therefore, using the CARA
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designs instead of the balanced randomization procedures can result in more patients
being treated with the better-performing treatment arm. Apart from designs IX and
X, this ethical benefit is achieved without compromising much on the power of the test
for the covariate-adjusted treatment differences.
Similar results can be seen for the positive model in Table 3.3. All of the derived
CARA randomization procedures significantly skew the patient allocation towards the
better treatment arm, with the design based on the probit link function achieving
the highest skewness. Apart from designs IX and X, they have similar powers and the
skewness of the CARA designs towards the better treatment arm results in fewer events
compared to the balanced randomization procedures. This time, the average number
of events have standard errors no more than 10. Therefore, the optimal CARA designs
can be considered as suitable alternatives to the traditional balanced randomization
procedures.
The observed allocation proportions in Figure 3.1 depict the performances of the
derived CARA procedures compared to the traditional balanced designs. The distribu-
tions of the observed allocation proportions for the various designs appear to be very
close to a symmetric distribution, but with different means and with different variabil-
ity. It can be seen that the CARA designs allocate more patients in the trial to the
better performing treatment arm.
The impact of sample size on the type I error rates and powers for different designs
has been explored. Figure 3.2 shows the type I error rates and powers for sample sizes
between 200 to 800.
It can be seen from Figure 3.2 that the type I error rates are in the range 0.05 to
0.07 and that the power are very similar for a sample size of around 800 patients. This
means that, for the statistical power of the Wald test to be greater than 0.9, most of
the competing designs are equally efficient. However, if the the power for treatment
difference is relaxed slightly by the clinicians to greater than 0.8, which is often the
case in late phase clinical trials due to patient recruitment problems, then it can be
seen that most of the proposed CARA designs are more powerful than the traditional
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Figure 3.1: Effect Size for Semi-parametric models skews CARA allocation proportions
balanced designs. It must be noted that the simulations here considered a phase 3 trial
with n = 800 patients instead of n = 400 patients as in chapter 3. This is because such
a sample size is large enough to enable asymptotic properties of CARA procedures to
hold with power less than 1. This is reflected in Figure 3.2 above. More patients are
needed to achieve equivalent level of power in this scenario because chapter 3 assumed a
parametric model for the survival responses and therefore needed less number of patients
to achieve the desired power than the designs based on a semi-parametric model which
is more dependent on the observed data. For the Wald test, the significance level is set
to 0.05.
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Figure 3.2: Type I error rates and Powers for the semi-parametric Competing Designs
3.6 Re-designing a Real-Life Clinical Trial
In order to apply the derived methodologies to re-design a clinical trial, a randomized
trial in advanced colorectal cancer has been considered. The study was previously
explored by Sverdlov, Rosenberger and Ryeznik (2013), where they re-designed the
trial to establish the usefulness of CARA designs for exponentially distributed survival
responses. In this chapter, the trial is re-designed using the derived semi-parametric
CARA designs for survival responses. For a period of 21 months, 572 eligible patients
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were randomized in a 1:1 ratio cetuximab plus best supportive care (treatment A)
and best supportive care alone (treatment B). The primary endpoint of this study
was overall survival, defined as the time to death from any cause. The model-adjusted
median overall survival was 6.1 months for treatment A versus 4.6 months for treatment
B. However, the degree and the direction of the effect of cetuximab differed between
the levels of K−ras mutation status. Patients with wild-type K-ras tumours benefited
from cetuximab (median overall survival 9.5 versus. 4.8 months; hazard ratio for death
0.55), whereas patients with a colorectal tumour bearing mutated K-ras did not benefit
from cetuximab (median overall survival 4.6 versus. 4.5 months; hazard ratio for death
0.98).
A simulation study with 5,000 replications was conducted to compare the CARA
designs with the traditional balanced randomization procedures. The CARA designs
considered here are the ones derived by using an optimality criterion. For appropriate
implementation of the derived CARA designs, 110 patients were initially equally ran-
domized to the two treatment arms using Efron’s biased coin design before the adaptive
randomization process started. Following Karapetis etal. (2008), the parameters were
chosen as follows: R = 21 months; trial duration D = 27 months; : z = 0 (wild-type
K − ras tumour) with probability 0.59 and z = 1 (mutated K − ras tumour) with
probability 0.41. Patient survival times were simulated from an exponential distribu-
tion with mean exp(βk0 + βk1z), k = A,B and z = 0, 1. The model parameters were
set to βA0 = 2.62, βA1 = -0.68, βB0 = 1.87, and βB1 = 0.02.
Designs I II VI VIII XI XII
NA/n (SE) 0.50(0.02) 0.50(0.002) 0.65(0.02) 0.65(0.02) 0.62(0.02) 0.68(0.03)
NA−—NB− 171—171 146—146 248—102 242—104 233—110 257—102
NA+—NB+ 115—115 140—140 124—98 130—96 122—107 132—81
Events 377 377 357 356 361 355
Power 0.99 0.99 0.96 0.97 0.95 0.94
Table 3.4: Re-design of a survival trial in colorectal cancer
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Table 3.4 presents the simulation summary for six different designs in Table 3.1.
It can be seen that using the CARA designs instead of the traditional balanced de-
signs results in more patients being treated with the better treatment during the trial.
This is achieved without compromising much on the power of the Wald test for the of
treatment-biomarker interaction in the Cox regression model, which is fitted after pa-
tients arrive squentially in the trial. It can also be seen that the CARA designs account
the treatment-covariate interaction, whereas the balanced designs do not. The CARA
designs result in greater skewing to treatment A in the wild-type K−ras subgroup than
in the mutated K−ras subgroup. On the other hand, the balanced randomization pro-
cedures balances the treatment allocations in both the K − ras subgroups. Therefore,
the CARA designs on average result in many fewer events during the trial compared
to the balanced randomization procedures, the standard errors being no more than 3.
Since there is a significant interaction between the treatment effects and the K − ras
biomarker subgroup effects, the Wald test is testing the hypothesis of equality in the
treatment effects within each biomarker stratum. Unlike the exponential regression
model, the Cox regression model treats the baseline hazard as a nuisance parameter.
So it does not provide an estimate of the intercept. Simulations were also run for 572
patients assuming no differences between the covariate adjusted treatment effects for A
and B. The simulated type I error rates for the designs were between 0.04 and 0.05.
3.7 Discussion
A new CARA randomization procedure has been introduced in this chapter for two-
arm right censored survival trials. This is done to enhance the applicability of CARA
designs for treatment comparisons in real life clinical trials. The procedures in this
chapter obviate any parametric assumptions about the underlying distribution of the
survival responses of the patients. However, in order to preserve the robustness of
parameter estimation, a lighter assumption has been made about the hazard rate at
any given time-point for an individual in one treatment group being proportional to
the hazard rate at the same time-point for an individual in the other treatment group.
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The designs developed here are based on both formal optimization procedures as well
as non-optimal procedures. The approaches to optimality includes a covariate adjusted
optimal target approach (Zhang and Hu, 2009) and a weighted optimality approach
(Atkinson and Biswas, 2005). The non-optimal procedures such as the probit link
design and the score design are developed with the intention of addressing the ethical
issue of treating more patients with the better treatment during the trial. The operating
characteristics of the proposed CARA designs have been compared with the balanced
randomization designs through extensive simulation for a two-arm survival trial with
three predictive covariates, right-censored data and staggered entry. It has been found
that many of the proposed CARA randomization designs generate skewed allocations
according to covariate-specific treatment differences and result in fewer events in the
trial, while having similar powers for the Wald test for treatment differences compared
to the balanced randomization designs. An application of the proposed methodology
has been illustrated by redesigning a two-arm survival trial from the literature.
When comparing CARA designs based on covariate adjusted optimal targets, two
distinct approaches have been used: the covariate-adjusted doubly adaptive biased coin
design (Hu and Zhang, 2004) and the covariate-adjusted efficient randomized adaptive
design (CAERADE) which is motivated from Hu, Zhang and He (2009). The work of
Hu, Zhang and He (2009) can be regarded as a generalization of Efron’s biased coin
design for any desired allocation proportion, which may depend on the unknown param-
eters. Through simulations it is seen that the CAERADE has got lower variability as
compared to the corresponding covariate-adjusted doubly adaptive biased coin design
(CADBCD). Hu and Rosenberger (2003) established that optimality, variability and
power can be considered as the essential components for selecting a suitable adaptive
randomization procedure. In the situation where efficiency is critically important, the
CAERADE should be the best choice among all of the CARA randomization proce-
dures. However, sometimes the CAERADE does not converge to the target allocation
proportion as fast as the CADBCD does, although its finite-sample variances are al-
ways small. This is mainly because the allocation probabilities in the CAERADE are
not stable. The allocation function being discrete, they always jump from one value
to another. A continuous allocation function like the DBCD can make the allocation
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probabilities stable and speed up the convergence of the sample allocation proportions.
When comparing each class of CARA designs, it has been seen that the designs in
each class have their merits. CARA designs with targets have established asymptotic
properties. By appropriately choosing the trade-off parameter η, the weighted optimal-
ity CARA designs also give skewed allocations towards the better treatment arm and
balance the objectives of statistical efficiency and ethics. However, selecting the value
of the parameter η depends on the experimental criteria. The non-optimal designs also
work well compared to the balanced randomization procedures. If the sole criterion is
to treat more patients with the better performing treatment during the trial, the design
based on the probit link function works the best and also achieves the least number of
events on average. When there is no difference between the effects of the two treat-
ments, the design based on the score function achieves the nominal type I error rate.
On the other hand, when one of the treatment arms performs better than the other, this
design happens to be the least powerful. The merits of the developed methodologies
have also been elucidated by applying them to redesign an existing clinical trial.
The methodology described here is free from any distributional assumption on the
survival responses, but relies on a lighter assumption of the hazard rate at any given
time-point for an individual in one treatment group being proportional to the hazard
rate at the same time-point for an individual in the other treatment group. Conceptu-
ally, instead of considering the proportionality of the hazard rates of individuals from
the two treatment groups, one can also use the proportionality of the odds of survival
of patients from the two treatment groups as the basis for the development of CARA
randomization procedures. Another important area of potential application of CARA
randomization procedures is time-to-event trials with more than two treatment arms.
All of the CARA designs for survival trials developed so far in the literature concen-
trated on trials with events due to a single cause. However, in many real-life trials,
patients experience events due to multiple causes. Therefore, the information related
to the cause of the events is very important when developing a CARA design, which
would make such designs more applicable in real-life survival trials.
It should be acknowledged that the proposed methodology is only suitable for sur-
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vival trials with long recruitment periods. The amount of concomitant information
in the model impacts sequential estimation at the design stage. One should consider
implementing the proposed CARA designs only with a limited number of the most
predictive baseline covariates.
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Chapter 4
Covariate-Adjusted
Response-Adaptive Designs for
Competing Risk Survival Models
4.1 Introduction
A branch of healthcare science that determines the safety and efficacy of treatment
regimens is called clinical research. It involves any test article from its inception in the
laboratory to its introduction to the consumer market and beyond. Clinical trials are
complex experiments which are designed through clinical research to answer specific
questions about biomedical or behavioral interventions, including new treatments and
known interventions that warrant further study and comparison. A purpose of phase III
clinical trials is to obtain information on the performance of the competing treatments.
It involves large-scale trials in which a new treatment is compared with one or more
standard treatments in terms of its safety and efficacy .
Patients usually arrive sequentially in a clinical trial and are assigned to one of
the competing treatment arms. Information about the performance of the competing
treatments accrues sequentially as results become available on an increasing number of
patients. There has been extensive research in establishing the superiority of a treat-
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ment early in the trial. Adaptive designs play an important role in effectively utilizing
the sequential information and serving the purpose. Adaptive allocation procedures are
sequential designs in which the method of allocation of treatments to patients are mod-
ified based on the results obtained in the previous stage until a particular treatment is
declared to be a clear winner over the others.
The past several years have witnessed significant contributions on the development
adaptive designs for the effective comparison of treatments. These involve the devel-
opment of balanced allocation schemes such as restricted randomization or covariate-
adaptive randomization designs. Restricted randomization balances the patient alloca-
tion based on only the history of the previous allocations, whereas covariate-adaptive
randomization considers the patient heterogeniety as well while balancing the distri-
butions of the covariates across treatment arms. However, since clinical trials involve
human patients, there is an ethical concern to treat as many patients as possible in
the trial with the best treatment without compromising much on the power to test
for the treatment differences. Covariate-adjusted response-adaptive (CARA) designs
serves this purpose by allocating more subjects to the better-performing treatment arm
thus far in the trial, and, at the same time, estimate with high efficiency any differ-
ence in the covariate-adjusted treatment effects while maintaining the randomness in
treatment assignment. The patient allocation to a treatment arm for CARA designs is
based on the history of previous patient treatment assignments, the response history,
the covariate profiles of the previous patients and also the covariate information of the
incoming patient. Such designs are especially used when a non-linear, heteroscedastic
model determines the relationship between the covariate profiles of the patients and
their responses to a treatment. It is also useful when the effect of a treatment sig-
nificantly varies among the levels of the covariates of the patients and when multiple
experimental objectives such as the ones mentioned in Section 3.4 are being pursued.
There has been very little work on developing CARA designs for survival trials.
Those that have accounted for survival trials explored right-censored time-to-event re-
sponses with a single cause of failure. However, real-life clinical trials often face complex
situations where an individual may experience events from different causes. Competing
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risks arise in studies where the failure of an individual may be classified into one of the
various mutually exclusive causes of failure such as death from different causes. This
makes the usual survival analysis techniques inappropriate, as specialized methods are
needed to account for multiple causes of failures. Competing risks are events whose
occurrence either precludes the occurrence of another event or fundamentally alters the
probability of the occurrence of this other event. For example, while measuring the time
to relapse of chronic myeloid leukemia due to the increase of BCR-ABL1 oncopotein in
human bone marrow, patients may die due to cardiovascular disease. This is because
the interventions known to treat chronic myeloid leukemia are also known for QT pro-
longation and ventricular tachycardia. Therefore, monitoring such information could
be vital, not only for informing patients of the risks that they face in certain situations,
but also for making decisions about which treatment to assign a patient, how best to
allocate health resources and for understanding the longer-term outcomes of chronic
conditions. Handling such information during the design phase of a clinical trial along
with that about the patient heterogeneiety would make the design more applicable in
real-life clinical trials. In this chapter, CARA designs have been developed for survival
trials with competing risk scenarios without relying on any parametric distributional as-
sumptions about the survival responses of the patients. The various CARA designs for
survival trials with competing risks are developed and the performance of such designs
has been validated using simulation. An existing clinical trial has also been re-designed
using the derived methodologies.
An outline of the chapter is as follows. The background material relating to regres-
sion models for survival trials with competing risks is explained in Section 4.2. Section
4.3 proposes the various semi-parametric CARA randomization procedures for a sur-
vival trial with competing risks. The validation of the findings of Section 4.3 is detailed
in Section 4.4 using extensive simulation studies. The results obtained from applying
the proposed CARA designs to re-design a real-life clinical trial are presented in Section
4.5. The conclusions of the findings with a discussion and an outline of some future
research in this direction are discussed in Section 4.6.
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4.2 Regression Models for Competing Risk Prob-
lems
Often in real-life clinical trials, failure for a person may be due to several distinct
causes. It may be desirable to distinguish different kinds of events that may lead to
failure and treat the patients differently during the design phase of a clinical trial .
For example, to evaluate the efficacy of heart transplants, one would certainly want to
treat deaths due to heart failure differently from deaths due to other causes, such as
accidents and cancer. These different causes of failure are considered competing events,
which introduce competing risks. Thus, problems arising in a clinical trial with multiple
causes of failure are commonly referred to as competing risk problems. Treating failures
due to other causes as censored observations would not account for the fact that these
patients have already faced an event which is of a different cause. This would severely
bias the calculation of the risk set of the partial likelihood estimation of the model
parameters from the experiment. Therefore, it would result in biased estimates of the
model parameters. Figure 4.1 below simulates a cohort of competing events, where the
event of interest can be considered as cancer but its observations are made impossible
for patients 6 and 8 by a preceding competing event.
Figure 4.1: Scenario for competing risk
An approach to handling competing risk problems assumes the existence of c failure
times, one for each possible type of failure. In a clinical study, one then observes the
minimum of the latent failure times (T ) and the corresponding cause of failure (C). This
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means that, if the times to the events from c different causes are Tj for j = 1, ....c, then in
a clinical trial one observes T = min(Tj). The problem with this approach is that neither
the joint distribution of the failure times nor the correspondng marginal distributions
are identifiable from the observed data without additional assumptions, such as the
independence of the different latent failure times. Another approach focuses on using
the proportional hazards model to identify significant prognostic or risk factors when
competing risks are present. This approach considers the joint distribution of failure
time T and the cause of failure C for the covariate vector z. The jth cause-specific
hazard at time t is defined by
hj(t|z) = lim
∆t→0
P (t ≤ T < t+ ∆t, C = j|T ≥ t; z)
∆t
. (4.1)
This is the instantaneous failure rate of cause j at time t given z in the presence of
all other causes of failure. The overall hazard h(t|z) from any cause is the sum of the
cause-specific hazards over each failure type.
The cumulative incidence function (CIF) can also be used to handle competing risk
problems. Using the CIFs instead of the cause-specific hazards helps a clinician to have
a direct interpretation in terms of survival probabilities for the particular failure type.
This gives the marginal failure probabilities for a particular cause, which are intuitively
appealing and more easily explained to non-statisticians. The risk factors which have
a significant effect on the cause-specific hazards may not have an effect on the CIFs
for that cause. This is because as shown in (4.2) below, the CIF for each cause is a
function of the overall survivor function which considers a sum of the hazards for all
the different causes. The CIF is a function of the cause-specific hazards and is given by
Fj(t|z) = P (T ≤ t, C = j|z) =
∫ t
0
[
hj(u|z) exp
{
−
∫ t
0
c∑
i=1
hi(w|z)dw
}]
du. (4.2)
It represents the probability that an event of type j has occurred by time t for patients
with covariate z. In the presence of competing risks, the complement of the Kaplan-
Meier estimator overestimates the cumulative incidence function of cause j. That is, if
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Sˆj(t|z) is the estimator of the survivor function for events of cause j given covariates
z, then 1 − Sˆj(t|z) ≥ Fˆj(t|z). It is possible that the sum of the complements of the
Kaplan-Meier estimators at time t over all possible causes of failure is greater than 1,
which is impossible, as this sum is the cumulative probability for failure from any cause.
Strategies for regression modelling in survival trials with competing risks can be
formed by modelling the cause-specific hazards or the cumulative incidence functions.
When the aim is to assess the effect of the risk factors on the risk of failure due to a
certain cause, the Cox proportional hazards model can be used for each cause-specific
hazard to analyse these seperately by treating individuals failing from other causes
as censored observations. However, when the failure times are dependent and when
interest lies in assessing the effect of the risk factors on the incidence of a given cause,
the cumulative incidence functions can be modelled using the Fine and Gray (Fine and
Gray, 1999) approach.
The classical regression analysis of competing risks establishes a Cox proportional
hazards model (Prentice et al., 1978) for each cause-specific hazard given by
hjk(t|z) = h0jk(t)eβTjkz for j = 1, 2, ...., c, (4.3)
where z is a p× 1 vector of covariates and βjk is a p× 1 vector of regression coefficients
for cause j and treatment arm k = A,B. The effect of the covariates is assumed to act
multiplicatively on an unknown baseline hazard function h0j(t), which is considered to
be a nuisance parameter in the model. Estimation of the regression parameters βjk is
based on the partial likelihood approach. If Cik denotes the censoring time for the i
th
patient on treatment arm k, then the partial likelihood function is defined only for the
event times, yielding
Lk(β1k,β2k, ........,βck) =
nk∏
i=1
c∏
j=1
(
eβ
T
jkzi∑
l∈Ri e
βTjkzl
)δijk
(4.4)
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for k = A,B, where the risk set is Ri = {l : tl ≥ ti} and δijk = I(Tijk < Cik, C = j). The
risk set can be diminished by the occurrence of an event from any cause. Maximizing
each factor of the partial likelihood function in (4.4) provides an estimator βˆjk which
is consistent and asymptotically normal under regularity conditions. Given βˆjk, the
generalized Nelson-Aalen estimates (Njamen-Njomen and Ngatchou-Wandji, 2014) for
the cause-specific baseline cumulative hazards are given by
Hˆ0jk(t) =
∑
i:ti≤t
(
δijk∑
l∈Ri e
βˆTjkzl
)
, for j = 1, 2, ...., c, for k = A,B.
.
A drawback of modelling the cause-specific hazards is that, in order to estimate the
overall survival
S(t|z) = exp
{
−
∫ t
0
c∑
i=1
hi(w|z)dw
}
,
models need to be fitted for all types of events. The Fine and Gray model on the
other hand relates the cumulative incidence functions more directly to the covariates
and enables a clinician to assess the effects of the risk factors on the probability of an
event of a particular type. The method makes use of the sub-distribution hazard, which
is a function of the cumulative incidence for the corresponding cause of failure. The
sub-distribution hazard is defined as
hsubj (t|z) = lim
∆t→0
P{t ≤ T < t+ ∆t, C = j|T ≥ t ∪ (T < t, C 6= j); z}
∆t
. (4.5)
This would be the hazard obtained from the cumulative incidence function. Unlike
the Cox proportional hazards model for the cause-specific hazards, the Fine and Gray
model does not treat individuals failing from other causes as censored observations.
The risk set at time t for the latter model includes not only patients who have not yet
experienced the event of interest, but also those who have failed from other causes before
t. Fine and Gray (1999) pointed out that patients who have failed from causes other
than the event of interest remain at risk for the cause of interest. They established
a semi-parametric proportional hazards model for the sub-distribution hazard of the
event of interest given by
111
hsubjk (t|z) = hsub0jk(t)eβ
T
jkz (4.6)
for j = 1, 2, ...., c, where hsub0jk(t) is the baseline sub-hazard and is treated as a nuisance
parameter in the model. This does not address the probability of failure from any cause.
However, it directly relates to the cumulative incidence function through
hsubjk (t|z) = −
d
dt
log{1− Fjk(t|z)} (4.7)
for j = 1, 2, ...., c. Parameter estimation for the model depends on the right-censoring
mechanism. It has been assumed throughout that the patients experience generalized
type I right censoring, and therefore the censoring time is known, even for those who
fail for other causes before the administrative censoring time. The partial likelihood
approach is used to estimate the model parameters. For survival trials with right-
censored observations, Fine and Gray (1999) developed a weighted score function to
deal with dependent censoring. For a sample size of n patients, if δijk is the censoring
indicator as before for the ith patient on treatment k from cause j, the partial likelihood
is defined by
Lk(β1k,β2k, ........,βck) =
nk∏
i=1
c∏
j=1
(
eβ
T
jkzi∑
l∈Rsubi wile
βTjkzl
)δijk
, (4.8)
where the risk set for cause j at time ti is R
sub
i = {l : {tl ≥ ti} ∪ {tl < ti, C 6= j}}.
Fine and Gray (1999) justified that the subjects experiencing a competing event before
ti remain at risk from the main cause of failure. The weights for the Fine and Gray
model can be calculated as
wil =
1 if tl ≥ tiGˆ(ti)
Gˆ(min(tl,ti))
if tl < ti, C 6= j,
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where Gˆ is an estimate of the survivor function for the censoring distribution, that is,
the cumulative probability of still being followed up at time ti. It can be estimated by
the usual product limit method by treating the censored observations as event times.
Taking the logarithm of the partial likelihood in (4.8), the Breslow log-likelihood
function for cause j is given by
l(βjk) =
nk∑
i=1
δijk{βTjkzi − log(
∑
l∈Rsubi
wile
βTjkzl)}.
Therefore, the partial score function for cause j and treatment k = A,B is given by;
∇l(βjk) =
nk∑
i=1
δijk
(
zi −
∑
l∈Rsubi zlwile
βTjkzl∑
l∈Rsubi wile
βTjkzl
)
.
The Hessian matrix of the partial log likelihood for patients with the jth cause of
failure from treatment k = A,B is
∇2l(βjk) = −
nk∑
i=1
δijk
{∑
l∈Rsubi zlz
T
l wile
βTjkzl∑
l∈Rsubi wile
βTjkzl
−
(
∑
l∈Rsubi zlwile
βTjkzl)(
∑
l∈Rsubi zlwile
βTjkzl)T
(
∑
l∈Rsubi wile
βTjkzl)2
}
.
Let,
z¯(ti,β
T
jk) =
∑
l∈Rsubi zlwile
βTjkzl∑
l∈Rsubi wile
βTjkzl
=
∑
l∈Rsubi
zlwl,
where;
wl =
wile
βTjkzl∑
l∈Rsubi wile
βTjkzl
is the weight that is proportional to the hazard of the patient experiencing the event
for a specific cause j due to treatment k. Therefore, z¯(ti,βjk) can be interpreted as
the weighted average of the covariate vectors among those individuals still at risk from
cause j at time ti from treatment k with weights wl. The quantity,
V sub(ti,βjk) =
∑
l∈Rsubi
{zl − z¯(ti,βjk)}{zl − z¯(ti,βjk)}Twl
can be interpreted as the weighted covariance matrix of the covariates among those
individuals still at risk from cause j at time point ti. If {V subss (ti,βjk)}ps=1 are the di-
agonal entries of the matrix V sub(ti,βjk), then V
sub
ss (ti,βjk) ≥ 0. Therefore the log
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partial likelihood function has a unique maximizer, which can be obtained by equat-
ing the score function to zero and solving for βjk. So the weighted covariance matrix
of the covariates among those individuals at risk from cause j and treatment k at
time ti is positive definite. Hence, the observed information matrix for βjk, given by
Jk(sub)(βjk) =
∑nk
i=1 δijkV
sub(ti,βjk), is also positive definite. When there are p covari-
ates, the p-dimensional vector βˆjk of the estimated regression coefficients converges to
a multivariate normal distribution with mean βjk and covariance matrix J
−1
k(sub)(βjk).
Since Jk(sub)(βjk) is positive definite, its unique inverse exists and is also positive defi-
nite. This is the basis of the Wald test, which is used for treatment comparisons in the
presence of the concomitant information of the patients.
4.3 Proposed CARA Designs Based on Competing
Risk Models
Information on patients accrues sequentially in a clinical trial as they are assigned to
a treatment arm based on the design plan which the trial follows. Since clinical trials
handle human patients, there is always an ethical concern of treating more patients with
the better performing treatment arm during the trial phase. However, while comparing
different competing treatments, this skewness of patient allocation should not affect
the power of the Wald test for a treatment difference. Therefore, a design is needed
which balances these two requirements. The CARA designs serves this purpose quite
well. Now, often in survival trials patients do not fail due to a single cause. During
the design phase of the trial, ignoring the information about the causes of failures of
patients would severely bias the results of the experiment as well as the analysis. It is
therefore appropriate to develop a CARA design which accounts for such information.
The designs introduced in this section are semi-parametric in nature. This means
that they are free from any distributional assumption on the survival responses, but
a lighter assumption about the proportionality of the sub-distribution hazards or the
proportionality of the cumulative incidence functions between the two treatment arms
has been made. Proportionality here refers to the ratio of the sub-distribution hazard
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functions for patients or their cumulative incidence functions for a specific cause between
the two treatment arms at a given point of time in the trial not being dependent on
time. The censoring scheme assumed throughout this chapter is generalized type I
right censoring , where the recruitment period is of length R > 0 and D is the overall
duration of the clinical trial. At time D, the subjects who have not experienced the
event or have not already been right censored are considered to be generalized right
censored of type I.
At the beginning of the trial, patients are equally allocated between the treatment
arms using some kind of restricted randomization scheme. This is performed to collect
initial data to estimate the unknown model parameters. After the initial allocation, one
computes the partial likelihood estimates of the model parameters. From this stage,
onwards, when a new patient enters the trial with his/her covariate information, he/she
is randomly allocated to the better treatment arm found thus far in the trial in regards
to the events due to the primary cause of interest. This decision of allocating the
incoming patient to a particular treatment arm is based on the history of treatment
assignments, responses, and covariate vectors of the previous patients, and also the
covariate information of the incoming patient. Appropriate allocation functions are
thus derived here which skews the patient allocation towards the better treatment arm
for the main cause without compromising much on the power of the Wald test for a
treatment difference. If the recruitment phase is sufficiently long and the number of
accumulating responses during this phase is substantial, then it is possible to facilitate
CARA randomization.
4.3.1 Semi-Parametric CARA Designs with Target for Com-
peting Risks Models
One approach to derive CARA designs is to establish a suitable target allocation pro-
portion and then use a randomization procedure to target the derived alloccation pro-
portions. Survival trials are considered where patients experience the event due to
multiple causes. Therefore, the causes of failure needs to be considered when deriving
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the suitable target allocation proportions. These allocation proportions are functions of
the Fine and Gray model paramters, which are estimated sequentially using the partial
likelihood method with the arrival of every new patient in the clinical trial. Thus, it is
useful to construct a CARA design based on the sub-distribution hazard function.
Let jk(z;βjk) be the probability of an event from the j
th cause before censoring for
a patient on treatment k and with covariate vector z. Then,if Ci denotes the censoring
time for the ith patient, we have jk(z;βjk) = P(Tik ≤ Ci | z; βjk , C = j).To meet
most of the multiple experimental objectives in a clinical trial, one can minimize the
overall sub-distribution hazard for a patient failing due to a specific cause and with
a given set of covariates subject to the constraint of keeping the asymptotic variance
of the difference between the estimated sub-distribution hazard functions for the two
treatment groups achieved constant. This is by minimizing
nAjh
sub
jA (t|z) + nBjhsubjB (t|z),
subject to : zT{zTJ−1k(sub)(βjk)z}ze2β
T
jkz + zT{zTJ−1k(sub)(βjk)z}ze2β
T
jkz = k > 0.
If V ajk{hˆjk(t|z)} = zT{zT V¯ −1sub(t,βjk)z}ze2βTjkz denotes the variability adjustment
factor for treatment k and cause j, and qjk(z;βjk) = jk(z;βjk)h
sub
jk (t|z), the optimal
allocation proportion for treatment A is given by:
piGA1j(βAj,βBj, z) =
√
qjB(z;βjB)V ajA{hˆjA(t|z)}√
qjB(z;βjB)V ajA{hˆjA(t|z)}+
√
qjA(z;βjA)V ajB{hˆjB(t|z)}
.
(4.9)
For having a design with high power, the Neyman allocation function minimizes
nAj + nBj,
subject to : zT{zTJ−1k(sub)(βjk)z}z
2βTjkz
e + z
T{zTJ−1k(sub)(βjk)z}ze2β
T
jkz = k > 0.
The optimal allocation proportion for treatment A is given by:
piGA2j(βAj,βBj, z) =
√
jB(z;βjB)V ajA{hˆjA(t|z)}√
jB(z;βjB)V ajA{hˆjA(t|z)}+
√
jA(z;βjA)V ajB{hˆjB(t|z)}
.
(4.10)
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In order to have a direct interpreation in terms of the probability of an event, one can
also minimize the overall cumulative incidence functions for each cause subject to the
asymptotic variance of the difference between the estimated cumulative incidence rates
for the two treatments being constant. It is shown in Appendix F by an application of
the delta method that
V ar{Fˆjk(t|z)} = (tzT )V ar{hˆsubjk (t|z)}(tz)(exp[−2
∫ t
0
{hsubjk (u|z)}du]),
for k = A,B. Therefore minimize
nAjFjA(t|z) + nBjFjB(t|z),
subject to : V ar{FˆjA(t|z)}+ V ar{FˆjB(t|z)} = k > 0.
Let
V rjk(βjk, z) = (tz
T )V ajk{hˆjk(t|z)}(tz)(exp[−2
∫ t
0
{hsubjk (u|z)}du]).
If q′jk(z;βjk) = jk(z;βjk)Fjk(t|z). The optimal allocation proportion for treatment A
for cause j is given by
piGA3j(βAj,βBj, z) =
√
q′jB(z;βjB)V rjA(βjA, z)√
q′jB(z;βjB)V rjA(βjk, z) +
√
q′jA(βjA, z)V rjB(z;βjk)
. (4.11)
The derivation of (4.11) is detailed in Appendix G.
One can also minimize the overall sample size for events from a specific cause subject
to the asymptotic variance of the difference between the estimated cumulative incidence
rate for the two treatments being constant. This yields the Neyman allocation given
by
piGA4j(βAj,βBj, z) =
√
jB(z;βjB)V rjA(z;βjA)√
jB(z;βjB)V rjA(βjA, z) +
√
jA(z;βjA)V rjA(βjA, z)
. (4.12)
4.3.2 Rules to Target the Derived Allocation Proportions
The dervied allocation proportions are functions of the competing risk model parameters
which are estimated sequentially using the partial likelihood method. As soon as a new
patient enters the trial, their covariate information is recorded. This is used along
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with the treatment allocation history, response history and the covariate profile history
to allocate the incoming patient to the better performing treatment arm for a given
cause of failure, using a randomization procedure with low variability . An appropriate
randomization procedure needs to be used which approaches the derived allocation
proportions in the long run.
The covariate-adjusted doubly-adaptive biased coin design (CADBCD) serves this
purpose well. This is a continuous allocation function that targets the derived allocation
proportions. After m patients are randomized, on the arrival of the (m + 1)th patient
with covariate vector zm+1, let pˆimj = piAj(βˆAj,m, βˆBj,m, zm+1) represent the estimate of
piAj(βAj,βBj, z) based on the responses observed from the m patients, adjusted for the
covariate zm+1 of the incoming patient. Let {ρˆAmj =
∑m
i=1 piAj(βˆAj,m, βˆBj,m, zi)/m} be
an estimate of the average target allocations for treatment A based on the data for the
first m patients. Using the CADBCD procedure, the (m+ 1)th patient can be assigned
to treatment A with probability jm+1[{NAj(m)/m}, pˆimj, ρˆAmj], where {NAj(m)/m} is
the proportion of patients with events from cause j who have been assigned to treatment
A after m allocations. Therefore, the mathematical form of the allocation rule for the
(m+ 1)th patient entering the clinical trial with covariate vector zm+1 is
jm+1
{
NAj(m)
m
, pˆimj, ρˆAmj
}
=

pˆimj{ρˆAmj/
NAj(m)
m
}α
pˆimj{ρˆAmj/
NAj(m)
m
}α+(1−pˆimj){(1−ρˆAmj)/(1−
NAj(m)
m
)}α
, if 0 <
NAj(m)
m
< 1,
1− NAj(m)
m
, if
NAj(m)
m
= 0 or
NAj(m)
m
= 1.
(4.13)
If the clinician decides to have an ethical design with minimum variability, then the
covariate-adjusted efficient randomized adaptive design (CAERADE) may be suitted
better than the CADBCD. This is a discrete allocation function and is given by
jm+1
{
NAj(m)
m
, pˆimj, ρˆAmj
}
=

α′pˆimj if
NAj(m)
m
> ρˆAmj,
pˆimj if
NAj(m)
m
= ρˆAmj,
1− α′(1− pˆimj) if NAj(m)m < ρˆAmj,
(4.14)
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In the above allocation rules, for CAERADE, 0 ≤ α′ < 1 is a constant that reflects
the degree of randomization, whereas for CADBCD the degree of randomization is
determined by 0 ≤ α <∞. Both the CADBCD and the CAERADE helps the observed
allocation proportion approach the target allocation proportion for a given cause, in
the long run. However, the CAERADE is first-order efficient and therefore attains the
Cramer-Rao lower bound. Efron’s biased coin design with α′ = 2/3 is a special case
of it. For the CADBCD, α = 0 corresponds to the most random case of the allocation
rule, whereas α = ∞ is the most deterministic scenario. On the other hand, for the
CAERADE, it is considered that α′ = 0 is the most random scenario and α′ = 1 is the
most deterministic rule. Note that the theory of the CADBCD and the CAERADE
are based on parametric assumptions on the responses. There is currently no work on
semi-parametric case. These can however be checked using simulations.
4.4 Simulation Results
A comparison of the different derived CARA randomization procedures is made by
considering a two-arm survival trial with 800 patients who are failing due to two different
causes. A patient’s arrival time here is simulated from a uniform (0,365) distribution.
The response time of a patient is added to the recruitment time of the patient and
patients whose outcomes have not been observed by the pre-specified study time are
said to be generalized type I right censored. The recruitment period here has been
considered to be 365 days, and the overall trial duration is taken to be 581.66 days. A
covariate structure of two independent covariates has been generated, which are gender
(Bernoulli, p = 0.381) and age (Uniform(40,80)). The censoring time of the patients is
simulated from a uniform (0,581.66) distribution. The survival time of a patient with
covariate vector z = (1, z1, z2)
T in treatment group k is simulated from the Weibull
distribution with scale parameter µk(z) =exp(β
T
k z) and shape parameter γk = 2.48 for
patients failing from cause 1 and γk = 0.53 for patients failing from cause 2. Three
choices of the treatment effects vector have been considered in this case, which are
neutral effect of either treatment, positive effect of treatment A and negative effect of
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treatment A. The effects of the corresponding covariates for the simulation model µk(z)
=exp(βTk z), are summarized in Table 4.1 below :-
Model Treatment Covariate Effects Covariate Effects
Cause 1 Cause 2
β0 β1 β2 β0 β1 β2
Neutral A 3.803 0.810 0.06 2.535 0.001 0.06
B 3.803 0.810 0.06 2.535 0.001 0.06
Negative A 0.429 0.810 0.06 - 1.024 0.001 0.06
B 3.803 0.810 0.06 2.535 0.001 0.06
Positive A 7.176 0.810 0.06 6.094 0.001 0.06
B 3.803 0.810 0.06 2.535 0.001 0.06
Table 4.1: Values of model parameters
In Table 4.1 the neutral treatment effect refers to the hypothetical experimental
scenario where treatments A and B are equally effective. In the case of comparing
a new treatment with a control, this scenario refers to the situation where the new
treatment is as good as the existing control. The positive treatment effect refers to the
hypothetical experimental scenario where treatment A is more effective than treatment
B, or the new treatment performs better than the control.The negative treatment effect
refers to the hypothetical experimental scenario where treatment B is more effective
than treatment A, or in the case of comparing a new treatment with a control,this means
that the new treatment is not as effective as the control. The procedure used here is
a fully sequential one that recalculates the treatment effects using the Fine and Gray
regression model after the arrival of every new patient and there are 5000 simulation
runs. The competing randomization procedures and the corresponding designs number
is listed in Table 4.2.
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Design Competing Randomization Procedures
I Completely randomized design
II Efron’s biased coin design with p = 2/3
III CARA DBCD with (4.9) as the target
IV CARA DBCD with (4.10) as the target
V CARA DBCD with (4.11) as the target
VI CARA DBCD with (4.12) as the target
VII CARA ERADE with (4.9) as the target
VIII CARA ERADE with (4.10) as the target
IX CARA ERADE with (4.11) as the target
X CARA ERADE with (4.12) as the target
Table 4.2: List of the Competing Designs
For the implementation of the designs in Table 4.2, for the ith patient′s randomiza-
tion, only data from those patients who have responded before the ith patient’s arrival
are used in computing the randomization probability for the ith patient. Initially 2m0
patients have been equally allocated to the two treatment arms using Efron’s biased coin
design. Here, m0 is a positive number and 2m0 is chosen to be 220, which is sufficiently
large for the restricted randomization procedure to accurately estimate the model pa-
rameters. After the model parameters are estimated from the initial stage of the design
using a Fine and Gray model, a randomization probability is calculated after each new
patient who arrives sequentially into the trial. This randomization probability can be
based on any one of the derived allocation functions. For the implementation of the
CARA designs, at each stage of the trial, the number of events from each causes from
the previous stages is recorded. The incoming patient is then assigned to a treatment
arm according to the derived allocation proportion of the primary cause of interest in
the clinical trial. A pseudo-random number generator is then used to draw a uniform
random number between 0 and 1. If the derived randomization probability is greater
than or equal to this random number, the patient is assigned to treatment A or else the
patient is assigned to treatment B. The procedure described is repeated for the sub-
jects entering the trial in the future. For the CADBCD designs in Table 4.2, it must
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be noted that following Zhang and Hu (2009) and Rosenberger and Hu (2004), the
trade-off parameter for randomness is taken to be α = 2, whereas, for the appropriate
implementation of the CAERADE designs, α′ is chosen to be 0.55. This number is a
balance between 0.4 and 0.7 which have been set as the boundaries by Burman(1996).
The completely randomized design and Efron’s biased coin design have been consid-
ered as the traditional balanced randomization procedures to be compared against the
derived CARA designs. The performances of the competing randomization procedures
in Table 4.2 for patients experiencing the event from cause 1, when the treatment effects
between the arms do not differ, can be analysed from their operating characteristics
in Table 4.3. For each experimental design, the significance level of the Wald test for
testing the treatment difference has been set to 0.05.
Model Design NA
n
(SE) Event Type I Error
Neutral I 0.500 ( 0.033) 0.60 0.05
II 0.50 ( 0.020) 0.60 0.05
III 0.50 (0.030) 0.60 0.04
IV 0.50 (0.040) 0.60 0.04
V 0.50 (0.030) 0.60 0.04
VI 0.50 (0.038) 0.60 0.04
VII 0.50 ( 0.037) 0.60 0.04
VIII 0.50 (0.022) 0.60 0.04
IX 0.50 (0.037) 0.60 0.05
X 0.50 (0.022) 0.60 0.04
Table 4.3: Performance of the Competing Designs for Cause 1 when Treatment Effects
are Similar
It can be seen from Table 4.3 that, when there is no differences between the treat-
ment effects, all of the procedures allocate equal numbers of patients to the treatment
arms. The proportion of patients experiencing events from the main cause of interest
is the same for all the designs. Since the trial consists of patients experiencing events
122
due to multiple causes, and the main interest is in the primary cause, therefore the
proportion of patients experiencing events due to cause 1 has been considered here An
important observation here is that the simulated type I error rate is slightly conservative
for the derived CARA designs, apart from design IX. The standard errors for the type I
error rates of the Wald test for treatment comparisons for the proportion of events are
about 0.025. They are all around 0.003. The implementations of the integral function
for the designs V, VI, IX and X are taken as summation of the sub-hazard fucntion
upto time t. The performances of the competing designs for patients experiencing the
event from cause 1 when the treatment effects between the arms differ significantly, can
be analysed from their operating characteristics in Table 4.4.
On an average, the CARA designs with delayed responses result in a slight reduction
in the proportion of events from the main cause of interest when there is any difference
between the treatment effects, the standard errors being 0.025. This is because, unlike
the balanced randomization procedures, the CARA designs result in more patients
being allocated to the better treatment arm. This ethical gain is achieved by the
derived CARA designs without compromising much on the power of the Wald test for
treatment comparisons. The variability of the power is the lowest for Efron’s biased
coin design and CARA design X. Most of the powers for the CARA designs have the
standard errors of 0.004, but those for designs I, VII, VIII and IX are 0.002. It can
also be seen that, when targeting the Neyman allocation proportions, the CADBCD
procedures are more variable than the corresponding CAERADE ones but this is not
the case while targeting the other allocation proportions. This inconsistency in the
performance of the randomization procedures may arise because the CADBCD and the
CAERADE procedures are theoretically well defined for parametric resonses. Designs
VIII and X are the most powerful CARA designs considered
The boxplots given in Figure 4.2 depicts the performances of the competing designs
in the individual trials.
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Models Design NA
n
(SE) Event Power
Positive I 0.50 (0.031) 0.65 0.98
II 0.50 (0.019) 0.65 0.99
III 0.65 (0.031) 0.63 0.95
IV 0.69 (0.039) 0.63 0.92
V 0.61 (0.031) 0.63 0.96
VI 0.62 (0.037) 0.63 0.91
VII 0.64 (0.035) 0.63 0.93
VIII 0.68 (0.022) 0.63 0.96
IX 0.62 ( 0.032) 0.63 0.95
X 0.63 (0.022) 0.63 0.97
Negative I 0.50 (0.032) 0.62 0.98
II 0.50 ( 0.020) 0.62 0.99
III 0.34 (0.031) 0.59 0.93
IV 0.31 (0.041) 0.59 0.90
V 0.39 (0.031) 0.59 0.94
VI 0.39 (0.039) 0.59 0.90
VII 0.35 (0.037) 0.59 0.91
VIII 0.32 (0.022) 0.59 0.97
IX 0.40 (0.034) 0.59 0.92
X 0.37 (0.022) 0.59 0.97
Table 4.4: Performance of the Competing Designs from Cause 1 when Treatment Effects
Differ Significantly
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Figure 4.2: Performance of the Competing Designs based on the primary cause in the
Individual Trials
The distribution of the observed allocation proportions appear to be very close
to a symmetric distribution, but with different means and with different variability.
When there is no difference between the treatment effects, all of the competing designs
allocate equal numbers of patients on an average to the two treatment arms. On the
other hand when there is a difference in the treatment effects the derived CARA designs
allocate more patients to the better performing treatment in relation to the main cause
of interest. As expected, Efron’s biased coin design, which is a special case of the
CAERADE designs, is the most efficient. This is because the asymptotic variability
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of this design converges to zero. After taking care of the other risks due to competing
events, in the presence of a difference between the treatment effects, the CARA designs
allocate more patients to the better treatment arm for the main cause of interest. This
ethical objective of a clinical trial is achieved without compromising much on the power
of the Wald test for treatment differences.
4.5 Re-designing a Clinical Trial Using the Derived
Procedures
The performance of the derived methodologies can be assessed after applying them
to an existing clinical trial. Follicular cell lymphoma data from Pintilie (2007) can
be considered which consists of 541 patients with early disease stage follicular cell
lymphoma and treated in a 1:1 ratio with radiation alone (chemo = 0) or a combination
treatment of radiation and chemotherapy (chemo = 1). Disease relapse or no response
and death in remission are the two competing risks that are considered in this trial. The
concomitant information of the patients that was recorded is their age (age: mean = 57
and sd = 14) and haemoglobin levels (mean = 138 and sd = 15) recorded. The median
follow-up time was recorded to be 5.5 years. Out of the 541 patients, 272 experienced
events due to the disease, with 76 competing risk events (death without relapse) being
recorded and the rest were censored individuals.
A simulation study with 5,000 replications was conducted to compare four random-
ization designs: complete randomization, Efron’s biased coin design,the CADBCD with
target (4.9), and the CAERADE with target (4.9), have been considered. Based on data
from Pintilie (2007), the parameters were chosen as follows : R = 365 days, D = 2007.5
days, age is uniformly distributed between 31.752 and 81.248 and the haemoglobin lev-
els is uniformly distributed between 112.02 and 163.98. For each of these designs, the
aim is to assess their performance in terms of treatment allocation and efficiency. The
survival time of a patient with covariate vector z = (1, z1, z2)
T in treatment group k is
simulated from the exponential distribution with mean µk(z) =exp(β
T
k z), for k = A,B
. Based on the reported overall median survival times, the covariate-adjusted treatment
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effects have been set to 2.79 for the main cause of interest and to 1.72 for death without
relapse the covariate adjusted haemoglobin effect has been set to 1.16 and the covariate
adjusted effect of age is 4.12 for the main cause of interest, and these are 0.0127 and
0.09, respectively, for death without relapse. The intercept term from the exponential
model is estimated to be 3.29 for the disease and 8.62 for the competing risk event.
For appropriate implementation of the derived CARA designs 140 patients have been
initially equally randomized to the two treatment arms using Efron’s biased coin design
before the adaptive randomization process started. The existing design has been com-
pared with Efron’s biased coin design and the CADBCD and CAERADE with target
(4.9). The results are given in Table 4.5.
Designs I II III VII
NA/n (SE) 0.50(0.035) 0.50(0.018) 0.66(0.032) 0.67(0.035)
Event Proportion 0.503 0.501 0.458 0.469
Power 0.95 0.96 0.91 0.89
Table 4.5: Comparison of the original study design with the derived CARA designs
It can be seen from Table 4.5 above that using the CARA designs instead of the
completely randomized design or the Efron’s biased coin design, results in more patients
being allocated on an average to the better performing treatment. The balanced designs
equalize the patient allocations between the two treatment arms. As a result, the CARA
design has, on average lesser proportion of events for relapse after accounting for the
other caues of events occuring in the trial, as compared to the balanced randomization
procedures. It can be seen that the average power using the CARA designs are not
significantly reduced as compared to the balanced randomization procedure. After
performing a simulation study with 541 patients assuming that the treatment effects to
be identical, the simulated type I error rates of the four procedures were between 0.04
and 0.05. Note that the standard errors for the proportions of events are no more than
0.06.
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4.6 Discussion
This chapter has proposed new CARA randomization procedures for two-arm survival
trials with competing risks. When patients are failing due to competing causes, an
appropriate design needs to consider the causes of failure while allocating a patient
to a particular treatment arm. Therefore, an attempt has been made here to develop
methods to allocate patients to a particular treatment arm based on the main cause of
failure after taking care of the other causes which exists in the trial.
CARA designs have been developed here based on on two distinct approaches to
optimality: the CADBCD and the CAERADE, which targets various derived allo-
cation proportions. These allocation proportions are derived by formal optimization
techniques to achieve the ethical criteria of a clinical trial, but not at the cost of com-
promising on the efficiency. The target allocation proportions are derived for a model
without covariates and their covariate-adjusted versions are used for the sequential
allocation of patients.
The operating characteristics of the proposed CARA designs have been compared
with two balanced randomization designs through simulation for a two-arm survival trial
with two predictive covariates, right-censored delayed responses and staggered entry. It
has been found that the proposed CARA designs generate skewed allocations according
to covariate-specific treatment differences and result in fewer events in the trial for
the main cause of failure, while having similar statistical properties to the balanced
randomization designs. The proposed CARA designs achieve modest reductions in the
proportion of events due to the main cause of interest in the study.
When comparing CARA designs based on the CADBCD and the CAERADE proce-
dures, it has been seen that, when targeting some of the derived allocation proportions,
the CADBCD gives the more efficient designs than the CAERADE. This is because
the theoretical properties of the DBCD and the ERADE procedures were derived based
on parametric assumptions on the responses. There is hardly any reference to their
theoretical properties for the semi-parametric case. Simulation results here shows that
when dealing with more complicated semi-parametric models such as the competing risk
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Fine and Gray models, the usual properties of these designs do not hold. Therefore,
an extended scope of this research work might be to develop the theoretical properties
of these designs when the parameter estimates are not based on maximum likelihood
procedures.
Another important area of potential application of CARA randomization procedures
is competing risk survival trials with more than two treatment arms. Noted that the
target allocation proportions derived here are based on optimal allocation for a model
without covariates and then using its covariate-adjusted version for the sequential allo-
cation of patients. Therefore, the information on the covariate history of the patients
already enrolled in the trial is not taken into account when deriving this allocation
proportion. It is only accounted for while calculating the Fine and Gray regression
coefficient estimates, which the estimated covariate-adjusted allocation proportions are
a function of. A useful alternative which can be explored in the future might be to
derive an allocation proportion using some information about the distribution of the
covariate profile of the previous patients and taking an integral function with respect to
the covariate history of the product of the joint density function of the covariate history
and the estimated covariate-adjusted version of the target allocation proportion.
It should be noted that our proposed designs are only appropriate for survival tri-
als with long recruitment periods where the majority of patients contribute towards
outcome data during the recruitment phase. The number of covariates in the model
impacts sequential estimation at the design stage. Implementation of CARA designs
should be considered only with a limited number of predictive baseline covariates.
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Chapter 5
Discussion
5.1 Summary of the Main Conclusions
The thesis presented herewith reflects an attempt made to develop covariate-adjusted
response-adaptive designs for phase III clinical trials for treatment comparison, with a
view towards enhancing its scope of applications beyond what has been already con-
sidered. The clinical trials considered here are the ones which records time to event
outcomes of patients who are administered to a particular treatment arm. This often
occurs in oncology trials where the primary endpoints considered are often duration of
remission, progression free survival, overall survival or event free survival of patients
following a treatment or complete remission (CR). In such cases reducing the number
of events during the trial phase becomes very important. This makes the clinical trial
more ethically attractive.
Addressing the ethical criteria of a clinical trial has become imperative in every
clinical trial experiments nowadays. The World Health Organization (WHO) has ap-
pealed to the pharmaceutical industries to adopt measures based on the ethical criteria
as appropriate as possible, and monitor and enforce their standards. They mentioned
that ethical criteria for drug promotion should lay the foundation for proper behaviour
concerning the promotion of medicinal drugs, consistent with the search for truthfulness
and righteousness. While the focus of ethical clinical trial conduct has been on proto-
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col review in advance of the research, there has been a huge emphasis on monitoring
subject welfare during the conduct of research.
Clinical research involving humans should be scientifically sound and conducted in
accordance with basic ethical principles, which have their origin in the Declaration of
Helsinki. The Good Clinical Practice (GCP) standard is followed by the FDA and the
clinical domain maintains an international ethical and scientific quality for standard
of designing, conducting, recording, and reporting reporting trials that involve the
participation of human subjects.This is the reason why the primary principle of the
WHO about GCP is to maintain ethical conduct during the process of a clinical trial.
They emphasized three basic ethical principles with equal importance, namely respect
for people, beneficence, and justice, that permeate all other GCP principles.
The clinical trials, specially conducted in the oncology theraputic area, which records
time to event of patients thus become very attractive if it reduces the number of events
during the process of clinical trial. This may be achieved by skewing the patient allo-
cation towards the better performing treatment arm, during the course of the trial, by
making use of the sequential arrival of patients. However, since clinical trials deal with
human patients, they differ based on their personal characteristics. Such heterogene-
ity needs to be accounted for while skewing the patient allocation towards the better
performing treatment arm.
The idea behind the traditional balanced randomization procedures has been to com-
pare treatments with highest statistical efficiency. However while tending to achieve the
balance, such designs allocates almost half the patients in the worse treatment arm, thus
making the clinical trial ethically not very attractive. Also when the responses of the
patients to a treatment arm follow a non-linear and heteroscedastic model, balanced
allocation may not always give optimum results. The covariate-adjusted response-
adaptive designs developed throughout this thesis balances these competing goals of
addressing the ethical objective of the trial by skewing the patient allocation towards
the better treatment arm, without compromising much on the statistical efficiency for
treatment comparison. Such designs are specifically useful when the responses of the pa-
tients follow a heteroskedastic non-linear model and when the degree and the direction
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of the treatment effect differs across patient subgroups. While allocating an incom-
ing patient in the clinical trials to a particular treatment arm the covariate-adjusted
response-adaptive designs considers the history of previous treatment assignments, re-
sponse history of patients during the trial phase, the history of covariate information
of patients already admitted in the trial, and also the covariate information of this in-
coming patient in the trial. Throughout the thesis the arrival of the patients has been
considered to be fully sequential. For the implementation of the derived covariate-
adjusted response-adaptive designs, initially certain number of patients are equally
allocated to the two competing treatment arms using a balanced randomization proce-
dure. After the superiority of a treatment arm is established in this interim stage of
the trial, patients who arrive sequentially in the trial are allocated to the better treate-
ment arm according to the derived covariate-adjusted response-adaptive randomization
procedure. This process continues until a treatment is declared to be a clear winner.
Throughout this thesis the overall sample size in the clinical trial is considered to be
fixed, while performing the adaptation process.
Very limited research work exists in the literature about developing covariate-adjusted
response-adaptive designs for surival trials. Sverdlov, Rosenberger and Ryznik (2013)
developed such designs considering the survival responses of the patients to be expo-
nentially distributed. The work in this thesis extends the applicability of such designs
beyond the boundary of exponential survival responses, making it more appealing in
real-life clinical trials. After pointing out the limitations of the applicability of the
designs based on exponential survival responses due to its constant hazard property,
covariate-adjusted response-adaptive designs have been developed for Weibull surival
responses. It is known that Weibull distribution is categorized with an extra shape
parameter which determines the shape of the hazard function. Exponential distriution
is a special case of the Weibull model when the shape parameter is unity. Thus con-
sidering the development of covariate-adjusted response-adaptive designs for Weibull
responses, enhances the scope of application of such designs in real-life clinical trials
when the hazard of the patients to an event is non-constant.
The covariate-adjusted response-adaptive designs for Weibull distributed survival
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responses are based on two distinct approaches to optimality: the covariate-adjusted
doubly adaptive biased coin design (Zhang and Hu 2009) and the covariate-adjusted
efficient randomized adaptive design (CAERADE) and also a non-optimality based
approach : the glink function. The design based on the glink function is derived based
on the cumulative distribution function of a Gumbel model whose location parameter
is calculated as the reciprocal of the scale paramenter of the Weibull accelerated life
model calculated from the covariate information of the incoming patient and its scale
parameter is calculated by the inverse of the shape parameter calculated from the
Weibull accelerated life model based on the information based on the previous patients.
This bridges the past allocation, response histories and the present allocation pattern
after allowing for the incorporation of prognostic factors. The Gumbel model being
asymmetric and light-tailed, provides more weight to the available data, and tends
to allocate more patients to the better treatment. Moreover, when the response of
the patients follow a Weibull distribution, the design based on Gumbel model is more
appropriate as compared to other continuous models because the theoretical errors
in the Weibull Aceelerated Life regression model follow a Gumbel distribution. The
arbitrariness of choosing a value for the tuning parameter T present in the design
based on the probit link function by Bandyopadhyay and Biswas (2001) is not present
in the design based on the glink function. Scaling the the estimated covariate adjusted
treatment difference by its standard error plus the estimated hazard ratio makes this
design more consistently applicable.
After comparing the operating characteristics of the derived designs along with the
response-adaptive and the traditional balanced randomization designs it is found that
all the proposed covariate-adjusted response-adaptive designs generate skewed alloca-
tions towards the better treatment, according to covariate-specific treatment effects and
thus result in fewer events in the trial, without compromising much on the statistical
efficiency as compared to the balanced randomization designs. The degree of skewness
also varies according to the background model the design is based on. It has been es-
tablished that the ethical gain of allocating more patients to the better treatment arm
persists for Weibull survival responses based designs, without heavily compromising on
the statistical power of the Wald test for the difference of covariate adjusted treatment
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effects. It has been established that when there is a significant treatment difference,
among all the derived allocation proportions, it is the Neyman allocation proportion
that assigns more patients to the worse treatment and therefore is not ethically quite
attactive as compared to the other competing designs. The Taylor series expansion
of the random non-centrality parameter of the asymptotic Wald test for the difference
of covariate adjusted treatment effects estalishes the inverse proportionality between
its power and the variance of the random observed allocation proportions. It is this
relation which has been heavily used for comparing the derived designs.
It has been seen that when the survival responses of the patients follow a Weibull dis-
tribution, the CAERADE being the asymptotically most efficient, increases the power
or treatment comparison as compared to the corresponding covariate-adjusted Doubly
Adaptive Biased Coin Design (CADBCD). However, sometimes the CAERADE does
not converge to the target allocation proportion as fast as the CADBCD does. This
is mainly because the allocation probabilities in the CAERADE are not stable. The
allocation function being discrete, they always jump from one value to another. A
continuous allocation function like the CADBCD can make the allocation probabilities
stable and speed up the convergence of the sample allocation proportions. Therefore if
the requirement of the clinician is to solely have an efficient CARA design, the CAER-
ADE should be the best choice among all the covariate-adjusted response-adaptive
randomization procedures. However in a real-life clinical trial, ethical considerations
would appear to be quite unavoidable. Thus the CADBCD is the best achievable bal-
ance between ethics and efficiency when the survival responses conform to a Weibull
model.
Often in real-life clinical trials the response of patients fail to conform to a parametric
model. However, parametric assumption enhances the robustness and efficiency of the
parameter estimates. Therefore to strike a balance between robustness and practicality,
attempt has also been made to develop covariate-adjusted response-adaptive designs
for survival responses following a semi-parametric model. Here designs are developed
obviating any parametric assumptions about survival responses of the patients but
only considering that the hazard of patients at any given time-point is proportional
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to each other. The underlying model used to develop such kind of covariate-adjusted
response-adaptive designs is the Cox proportional hazard model. Here the derived
designs are a function of the Cox regression coefficients which are used to obtain the
partial likelihood estimate of the treatment effect in order to allocate more patients to
the better performing treatment arm during this course of the trial. As in the case of
the derived covariate-adjusted response-adaptive designs for Weibull survival responses,
here the designs are derived optimally by fixing the asymptotic variance of the covariate
adjusted treatment difference to a constant value. This helps the statistical efficiency
of the design not to get compromised much while achieving the ethical objective of
skewing the patient allocation to the better performing treatment arm. Various optimal
allocation proportions are derived minimizing the overall hazard during the trial and
also by minimizing the overall trial size which gives the Neyman allocation. As with the
designs for Weibull distributed survival responses, the CADBCD and the CAERADE
are also used here to target the derived optimal allocation proportions.
Among the other optimality approach, the weighted optimality approach (Atkinson
and Biswas, 2005) has also been considered. By appropriately choosing the tradeoff pa-
rameter η, the weighted optimality CARA designs also gives skewed allocations towards
the better treatment arm and balances the objectives of statistical efficiency and ethics.
However judiciously selecting the parameter depends on the experimental crteria of the
clinician and the obejective of the clinical trial.
Apart from the optimal designs, the cumulative distribution function of the normal
model with mean zero and standard deviation determined by the covariates of the in-
coming patient, has also been used to derive the covariate-adjusted response-adaptive
designs for survival responses following a semi-parametric model. The design is devel-
oped making the cumulative distriution function of such a normal model depend on
the partial likelihood estimate of the covariate adjusted treatment difference obtained
from the sequentially fitted Cox regression model. The probit link function being an
increasing function of the covariate adjusted treatment difference make this allocation
procedure favour the treatment doing better at the particular stage of the clinical trial.
The design scales the covariate adjusted treatment differences according to the hazard
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ratio between the two treatments and the standard error of the treatment difference for
the mth patient. This means that if the hazard of an event for a particular treatment
group is greater than the other, there would be less chance of allocating the next pa-
tient to that particular treatment arm. The probit link function here thus bridges the
past history to the present allocation pattern for patients whose responses belong to
the Lehmann family.
Apart from using a link function or a formal optimization procedure, CARA designs
can also be developed by the method of treatment effect mapping similar to Rosenberger
and Sheshaiyer (1997). The score function of the sth covariate in the Cox regression
model has been used to develop a mapping onto [0,1] that exceeds 0.5 if treatment
A has been doing better thus far, and is less than 0.5 if treatment B has been doing
better. The idea is similar to that of Rosenberger (1993) in dealing with immediate
continuous outcomes using a nonparametric rank test.
When comparing CARA designs based on covariate adjusted optimal targets, the
results obtained were very similar to the ones obtained for Weibull distributed survival
responses. However the score based design tends to have the lowest power for treatment
comparison as compared to other designs and therefore is not recommended. The design
based on the probit link is ethically most attractive as it allocates more of the patients
to the better treatment arm. However, when there is no treatment difference it has a
over-inflated type I error rate. Therefore it is also not recommended. The covariate-
adjusted response-adaptive designs based on optimality approach thus stands out and
is a suitable alternative to the traditional balanced randomization procedures for semi-
parametric survival responses of the patients.
Often in medical research response to a treatment can be classified in terms of fail-
ure from disease processes and/or non-disease-related causes. In such cases, time to
the event of interest cannot be observed because of a preceding event i.e. a competing
event occuring before. An example can be of an event of interest being a specific cause
of death where death from any other cause can be called a competing event. Such
scenarios in survival analysis is termed as competing risk. When patients are failing
due to competing causes, an appropriate design needs to consider the causes of failure
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while allocating a patient to a particular treatment arm. The underlying model used to
develop such kind of covariate-adjusted response-adaptive designs is the Fine and Gray
sub-distribution hazard model. Here the derived designs are a function of the Fine
and Gray regression coefficients which are used to obtain the partial likelihood esti-
mate of the treatment effect in order to allocate more patients to the better performing
treatment during this course of the trial. New covariate-adjusted response-adaptive
randomization designs have been proposed for two-arm survival trials with competing
risks. CARA designs for competing risk scenario have been developed here based on on
two distinct approaches to optimality: the CADBCD and the CAERADE, which tar-
gets various derived allocation proportions. Operating characteristics of the proposed
CARA designs have been compared with two balanced randomization designs through
simulation, for a two-arm survival trial with two predictive covariates, right-censored
delayed responses, and staggered entry. It has been seen that the derived CARA designs
are a suitable alternative to the traditional balanced randomization designs. However
it has been seen that while targeting some of the derived allocation proportions, the
CADBCD gives the most efficient designs. This is because the theoretical properties
of the CADBCD and the CAERADE procedures were derived based on parametric
assumption of the responses. There is hardly any reference about the theoretical prop-
erties for semi-parametric alternative of these procedures. Simulation results reveals
that while moving to more complicated semi-parametric models than Cox regression
model, such as the competing risk models, the usual properties of these designs does
not hold. Therefore an extended scope of this research work might be to develop these
designs when the parameter estimates are not based on maximum likelihood procedures.
It should be noted that our proposed designs are only appropriate for survival trials
with long recruitment periods where majority patients contribute towards outcome
data during the recruitment phase. The number of covariates in the model impacts
sequential estimation at the design stage. Implementation of CARA designs should be
considered only with a limited number of the predictive baseline covariates.
The idea behind developing covariate-adjusted response-adaptive randomization de-
signs in this thesis has been to make such designs more fruitfully applicable in survival
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trials in industrial enterprise. Such trials are primarily conducted in oncology related
clinical trials. This studied inadequacy may be attributed to a desire to enable even
a non-expert in the field of adaptive designs, to have a fairly adequate understanding
about the development of this area of research.
5.2 Critical Evaluation
In recent years, the use of adaptive design methods in pharmaceutical research and
development has become popular due to its flexibility and efficiency for identifying po-
tential signals of clinical benefit of the treatment under investigation. The flexibility
and efficiency, however, increase the risk of operational biases, resulting in decrease in
the accuracy and reliability for assessing the treatment effect of the treatment under
investigation. This is because fully sequential strategies require outcomes from all pre-
vious allocations prior to the next allocation. This can prolong an experiment unduly.
Thus there has been a lot of research going on for establishing a suitable delayed re-
sponse model. Hardwick,Oehmke and Stout (2006) proposed a delayed rate response
bandit model where they showed that except when the delay rate is several orders of
magnitude different than the patient arrival rate, the delayed response bandit is nearly
as efficient as the immediate response bandit. However such model does not take care
of individual heterogeneity of patients.
The biggest challenge in applying such designs in real-life clinical trials is that it
faces a lot of logiistical issues. Specially in survival trials, one needs to wait until a
long period of time until they obseve an event or a censoring. Thus in fully sequential
trial we are not always in a position to observe the previous response when the next
patient arrives. This may have a disadvantage of dampening the convergence of the
randomization procedure to its target. A possible way out of this problem is to obtain
a surrogate endpoint in survival trial and build the design on the surrogate endpoint
instead of the real clinical enpoint.
In clinical trials, a surrogate endpoint is a measure of effect of a specific treat-
ment that may correlate with a real clinical endpoint but does not necessarily have
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a guaranteed relationship. Surrogate endpoints are used when the primary endpoint
is undesired, or when the number of events in the trial is very small, thus making it
impractical to conduct a clinical trial to gather a statistically significant number of end-
points. The FDA and other regulatory agencies will often accept evidence from clinical
trials that show a direct clinical benefit to surrogate endpoints. Surrogate endpoints
can be obtained from different modalities, such as, behavioural or cognitive scores, or
biochemical biomarkers. A correlation does not make a surrogate. It is a common
misconception that if an outcome is correlated with the true clinical outcome, it can be
used as a valid surrogate end point. However, proper justification for such replacement
requires that the effect of the intervention on the surrogate end point predicts the effect
on the clinical outcome. Progression Free Survival (PFS) is a prominent example of a
surrogate endpoint in oncology contexts. However there are examples of cancer drugs
(eg: Avastin) approved on the basis of progression-free survival, failed to show subse-
quent improvements in overall survival in subsequent studies. There have also been a
number of instances when studies using surrogate endpoints have been used to show
benefit from a particular treatment, but later, a repeat study looking at endpoints has
not shown a benefit, or has even shown harm.
As pointed out by Rosenberger and Lachin (2002), a common argument against
practically implementing response-adaptive designs or even covariate-adjusted response-
adaptive designs is that the ethical advantage gained using such experimental designs
are on an average over several trials. It does not guarantee such success rate in every
single experiment.
In order to make the derived covariate-adjusted response-adaptive designs more
applicable for implementation in real-life clinical trials, building these designs or more
complicated survival models makes the interim phase of the clinical trial significantly
long before the actual adaptation may start. These are the major issues for which
the Food and Drug Administration (FDA) has shown extremely reserved approach in
implementing adaptive randomization procedure in real-life clinical trials.
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5.3 Directions for Future Research
Despite various reservations from the FDA about implementing adaptive randomization
procedures, active research on developing covariate-adjusted response-adaptive designs
has continued to be a hot topic of discussion in variours symposiums and conferences
across the globe. The interest of researchers on developing such designs have signifi-
cantly grown in order to give it more applied look so that it eventually gets applied in
real-life clinical trials.
A significant step forward in developing covariate-adjusted response-adaptive de-
signs for real-life clinical trials would be on building a theoretical model for estimation
of the size of the interim stage given the theoretical model the design would be based
on when the adaptation would start. Till now very limited discussion exists in the
literature about this point and the ones which do, relies on simulation procedure to
determine the size of the interim stage for equal allocation of patients. Building a theo-
retical model for estimating the size of the interim stage for equal allocation of patients
to the competing treatment arms would enhance the stance of the statisticians to have
a more robust justification to the clinicians about the waiting period before the model
based adaptation process would start.
The exponential distribution is a special case of the Weibull model, but the Weibull
model belongs to a wider class of two-parameter location-scale survival distributions,
that encompasses distributions such as log-normal and log-logistic. When considering
the development of CARA designs for survival responses belonging to the parametric
family of distributions, the ambit of applications of the CARA designs can be enhanced
further if the derived CARA designs based on Weibull model can be developed to
include all models in the two-parameter location-scale class of distributions.
If the shape parameter of the Weibull distribution is known beforehand, the rela-
tionship between the exponential and the Weibull distribution can be used to simplify
the results in Chapter 2. The Weibull distributed random variable can be raised to the
power of the value of this known shape parameter and as a new patient sequentially
arrives in a clinical trial, the CARA designs based on the exponential distribution can
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be applied on the transformed response after considering all the information which a
CARA design conditions on while calculating the randomization probability.
Often in clinical trials hazards of an event are non-proportional. However often
the odds of surviving beyond a given time-point is proportional between treatment
groups. Conceptually, instead of considering the proportionality of the hazard rate of
individuals from the two treatment groups, one can also use the proportionality of the
odds of survival of patients from the two treatment groups as the basis for development
of CARA randomization procedures.
The essence of using CARA designs in real-life clinical trials becomes slightly more
prominent when more than two competing treatment arms are considered. Instead of
considering the overall sample size to be fixed, one can develop a suitable stopping
rule which would help dropping a treatment arm in the trial before all patients are
randomized. This would make the clinical research more cost effective.
Often in real-life clinical trials one observe patients dropping out due to efficacy
related causes of a treatment under consideration. Such cases are known as infor-
mative censoring. In this case, the survivor function of the event time is a power
function of that of the censoring time. Very little work has been done till date on devel-
oping covariate-adjusted response-adaptive designs for survival responses considering
informative censoring. A possible and fruitful area of exploration might be to develop
Covariate-adjusted response-adaptive designs for all the types of different survival mod-
els considered in this thesis but considering informative censoring instead of generalized
type I right censoring.
In all the CARA designs developed till date using a formal optimization method,
the derived target allocation proportions are based on optimal allocation for a model
without covariates. The covariate-adjusted version of these derived target allocation
proportion are then used for the sequential allocation of patients. Therefore the in-
formation of the covariate history of the patients already enrolled in the trial is not
taken into account while deriving this allocation proportion. An useful alternative
which can be explored in the future might be to derive an allocation proportion using
141
some information about the distribution of the covariate profile of the previous patients
and marginalizing the distribution of this covariate profile over the covariate adjusted
version of the target allocation proportion. This would make the designs more ethi-
cal as well as it would fit the best within the actual definition of covariate-adjusted
response-adaptive designs.
Finally, more research has to be put into the development of a robust random-
ization procedure to target the derived allocation proportions when the distribution
of the survival responses move away from conforming to a parametric model. It has
been seen through simulation that while obviating any parametric assumption about
the distribution of the survival responses, when the underlying model becomes more
complex than the usual Cox proportional hazard model, the usual properties of the
CADBCD and the CAERADE does not hold true. As pointed out before, in real-life
clinical trials survival responses rarely follow a parametric form of distribution. More-
over non-proportionality of hazard is an active area of discussion in various industrial
research. Therefore the adequacy of a robust randomization procedure to target the
formally optimized target allocation proportion seem to be an important ingredient of
research for developing covariate-adjusted response-adaptive designs. In practice, ap-
plied researchers do not only want to be protected from adhering to a model based on
a parametric assumption on survival responses , but they also want to obtain a robust
randomization procedure which would be effficient in all practical scenario. Therefore
finding such semi-parametric or non-parametric randomization procedures which would
target the allocation proportions derived by formal optimization methods might be a
big step forward in the development of covariate-adjusted response-adaptive designs for
its future application in real-life clinical trials.
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Appendix A
Deriving the variance of the Weibull
distribution parameter estimates
Consider two random samples (tik,δik), (where k = A and B) from Weibull distribu-
tions with parameters {µA(z), γA} and {µB(z), γB}. Therefore two such distributions
corresponding to treatments A and B can be compared using the Wald test. To test
the hypotheses,
H0 : log{µA(z)} = log{µB(z)}
HA : log{µA(z)} 6= log{µB(z)},
the Wald test statistic
Tn =
log{µˆA(z)} − log{µˆB(z)}√
var[log{µˆA(z)}] + var[log{µˆB(z)}]
can be used, where Tn
d−→ N(0,1), and µˆA(z) and µˆB(z) are the maximum likelihood
estimators of µA(z) and µB(z) respectively. Let γˆk be the maximum likelihood estimator
of γk . The MLE of log{µk(z)} and (1/γk) can be obtained by numerically solving the
equations (2.12) and (2.13). The Fisher information matrix is obtained by finding
the Hessian matrix from equations (2.12) and (2.13) and taking the expectations after
changing the sign of the entries in the Hessian matrix. The Fisher information matrix
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here is
I[log{µk(z)}, (1/γk)] =
nkk(z;βk, γk)γ2k nkE(ςikeςik)γ2k
nkE(ςike
ςik)γ2k nkk(z;βk, γk)γ
2
k + nkE(ς
2
ike
ςik)γ2k
 ,
where, ςik = (γk)[yik − log{µk(z)}] , k(z;βk, γk) is the probability of an event before
censoring, and nk is the number of patients in treatment k (k= A,B). The determinant
of the matrix I[log{µk(z)}, (1/γk)] is given by
det I[log{µk(z)}, (1/γk)] = n2kγ4k{2k(z;βk, γk) + k(z;βk, γk)E(ς2ikeςik)− E(ςikeςik)2}.
Hence the variance-covariance matrix of log{µk(z)} and 1/γk can be obtained from
M = I−1[log{µk(z)}, 1/γk] which is given by
M =
 1nkγ2k k(z;βk,γk)+E(ς2ikeςik )2k(z;βk,γk)+k(z;βk,γk)E(ς2ikeςik )−E(ςikeςik )2 − 1nkγ2k E(ςikeςik )2k(z;βk,γk)+k(z;βk,γk)E(ς2ikeςik )−E(ςikeςik )2
− 1
nkγ
2
k
E(ςike
ςik )
2k(z;βk,γk)+k(z;βk,γk)E(ς
2
ike
ςik )−E(ςikeςik )2
1
nkγ
2
k
k(z;βk,γk)
2k(z;βk,γk)+k(z;βk,γk)E(ς
2
ike
ςik )−E(ςikeςik )2
 .
Now, equation (2.16) gives the mathematical form of Gk. Therefore, M can be written
as
M =
 Gknkγ2k − 1nkγ2k E(ςikeςik )2k(z;βk,γk)+k(z;βk,γk)E(ς2ikeςik )−E{ςikeςik}2
− 1
nkγ
2
k
E(ςike
ςik )
2k(z;βk,γk)+k(z;βk,γk)E(ς
2
ike
ςik )−E(ςikeςik )2
1
nkγ
2
k
k(z;βk,γk)
2k(z;βk,γk)+k(z;βk,γk)E(ς
2
ike
ςik )−E(ςikeςik )2
 .
Therefore,
σˆ2 = v̂ar[log{µˆk(z)}] = Gk
nkγˆ2k
,
and,
v̂ar((1/γˆk)) =
1
nkγˆ2k
ˆk(z;βk, γk)
ˆ2k(z;βk, γk) + ˆk(z;βk, γk)E(ς
2
ike
ςik)− E(ςikeςik)2
=
σˆ2ˆk(z;βk, γk)
ˆk(z;βk, γk) + E(ς2ike
ςik)
.
144
Appendix B
Derving the Analytical Form for
k(z;βk, γk)
It is known that k(z;βk, γk) = P ( Tik ≤ Cik |z;βk, γk) and Tik = min(Tik, Cik).
The survival outcomes are assumed to conform to a Weibull distribution with scale
parameter µk(z) and the shape parameter γk and the right censored times Cik are
assumed to follow uniform distribution with parameters 0 and D. D is considered to
be the trial duration. Let A be a set such that A = (tik : Tik ≤ Cik). Therefore,
k(z;βk, γk) = P { (Tik, Cik),∈ A } or,
k(z;βk, γk) =
∫ D
0
∫ cik
0
f(tik, Cik)dtikdCik,
substituting the joint density function of the event times and the censored times we
get,
k(z;βk, γk) =
∫ D
0
1
D
∫ cik
0
γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dtikdCik.
(Assuming that the survival times and the right censored times are independent);
Performing a change of coordinates in the set A,
k(z;βk, γk) =
∫ D
0
1
D
∫ D
tik
γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dCikdtik.
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Integrating with respect to Cik we get,
k(z;βk, γk) =
1
D
∫ D
0
(D − tik) γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dtik.
Opening up the brackets,
k(z;βk, γk) =
1
D
∫ D
0
D
γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dtik
− 1
D
∫ D
0
tik
γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dtik.
Cancelling out the contants in the numerator and the denominator,
k(z;βk, γk) =
∫ D
0
γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dtik
− 1
D
∫ D
0
tik
γk
µk(z)
{tik/µk(z)}(γk−1)e−{tik/µk(z)}(γk−1)dtik.
Therefore,
k(z;βk, γk) =
∫ D
0
f(tik)dtik − 1
D
∫ D
0
tikf(tik)dtik.
Therefore,
k(z;βk, γk) = P (tik ≤ D)− 1
D
E{tikI(tik≤D)}.
This gives,
k(z;βk, γk) = F (D)− 1
D
E{tikI(tik≤D)},
where F(D) is the distribution function of the Weibull model at D and I(tik≤D) is the
indicator function such that;
I{tik≤D} =
1; if tik ≤ D,0; if tik > D.
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Now E{tikI(tik≤D)} can be approximated by the average of all the observed event time
for a particular treatment arm. Let’s call this x¯ik. Therefore, the estimate of k(z; βk, γk)
can be written as;
ˆk(z;βk, γk) = F (D)− 1
D
x¯ik.
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Appendix C
Deriving the Asymptotic Variance
of the Hazard Ratio
From the theory it is known that (βˆ − β)→ Np{0, J−1(β)}.
According to the Cox proportional hazard model,
log{h(t|z)} = log{h(t|z = 0)}+ βTz.
Here, h(t|z = 0) is the baseline hazard function and is treated as a nuisance parameter
in the model.
Therefore, to fit the Cox proportional hazard model to a set of survival data, the
fitted model can be written as
log{hˆ(t|z)} = βˆTz.
this is because the baseline hazard function is treated as a nuisance parameter and
cannot be estimated in the Cox proportional hazard model.
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Therefore,
V ar[log{hˆ(t|z)}] = V ar(βˆTz)
. Which means,
V ar[log{hˆ(t|z)}] = zTJ−1(βˆ)z.
According to the multivariate version of the delta method, if (βˆ−β) d−→ N{0, J−1(β)},
then for f being a one-one continuous function of the estimator βˆ,
{f(βˆ)− f(β)} d−→ Np[0,∇{f(β)}TJ−1(β)∇f(β)].
Now, log{hˆ(t|z)} being the partial likelihood estimator of log{h(t|z)},
[log{hˆ(t|z)}] d−→ N(log{h(t|z)}, V ar[log{hˆ(t|z)}]).
Therefore,
V ar(exp{log[hˆ(t|z)]}) = ∇[exp(βTz)]TV ar[log{hˆ(t|z)}]∇[exp(βTz)].
Which means,
V ar{hˆ(t|z)} = zTV ar[log{hˆ(t|z)}]z exp(2βTz).
For each treatment arm k,
V ar{hˆk(t|z)} = zT{zTJ−1k (βk)z}z exp(2βTk z).
Now, Jk(βk) =
∑nk
i=1 δikV (t(i),βk). The law of large numbers can be used to estimate
Jk(βk) in order to get the variance estimate of the hazard ratio. Therefore,
E{Jk(βk)} = E
{
nk∑
i=1
δikV (t(i),βk)
}
.
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This can also be written as
E{Jk(βk)} =
nk∑
i=1
E{δikV (t(i),βk)}.
This can also be written as
E{Jk(βk)} =
nk∑
i=1
E{δik]V (t(i),βk).
Which deduces to
E{Jk(βk)} =
nk∑
i=1
k(z;βk)V (t(i),βk).
This can be written as
E{Jk(βk)} = nkk(z;βk)V¯ (t,βk).
Thus,
V ar{hˆk(t|z)} = zT
{
zT
V¯ −1(t,βk)
k(z;βk)nk
z
}
z exp(2βTk z),
where k = A,B.
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Appendix D
Deriving the Optimal Allocation
Proportion for minimizing the Total
Cumulative Hazard Function
The total cumulative hazard at time D > 0 can be minimized subject to the asymptotic
variance for the covariate adjusted treatment difference remaining fixed to a constant.
This yields the optimal allocation proportion of (2.18) as follows :
min: nA
{
DγA
µγAA (z)
}
+ nB
{
DγB
µγBB (z)
}
subject to :
{
GA
nAγ2A
}
+
{
GB
nBγ2B
}
= k > 0
Re-arranging the constraint we get
k−
{
GB
nBγ2B
}
=
{
GA
nAγ2A
}
,
Re-arranging the constraint further we get
knBγ
2
B −GB
nBγ2B
=
{
GA
nAγ2A
}
,
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Solving for nA we get;
GAnBγ
2
B
knBγ2Bγ
2
A −GBγ2A
= nA.
The ethical objective here is to minimize,
nA
{
DγA
µγAA (z)
}
+ nB
{
DγB
µγBB (z)
}
.
However
GAnBγ
2
B
knBγ2Bγ
2
A −GBγ2A
{
DγA
µγAA (z)
}
+ nB
{
DγB
µγBB (z)
}
can be minimized in order to achieve the ethical objective.
To achieve the minimum value of the objective function
∂
∂nB
[
GAnBγ
2
B
knBγ2Bγ
2
A −GBγ2A
{
DγA
µγAA (z)
}
+ nB
{
DγB
µγBB (z)
}]
= 0.
Differentiating with respect to nB we get
{
DγB
µγBB (z)
}
+
{
DγA
µγAA (z)
}
−GAGBγ2Aγ2B
(knBγ2Bγ
2
A −GBγ2A)2
= 0.
This can be further re-arranged to obtain{
DγA
µγAA (z)
}
GAGBγ
2
Aγ
2
B
(knBγ2Bγ
2
A −GBγ2A)2
=
{
DγB
µγBB (z)
}
.
This can be further re-arranged to obtain{
DγA
µγAA (z)
}
GAGBγ
2
Aγ
2
B = (knBγ
2
Bγ
2
A −GBγ2A)2
{
DγB
µγBB (z)
}
.
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Taking the positive square-root on both sides we get√√√√{ DγA
µγAA (z)
}
GAGBγ2Aγ
2
B = (knBγ
2
Bγ
2
A −GBγ2A)
√√√√{ DγB
µγBB (z)
}
.
Substituting for k we get√√√√{ DγA
µγAA (z)
}
GAGBγ2Aγ
2
B =
{
GAnBγ
2
B
nA
− GBnBγ
2
A
nB
−GBγ2A
}√√√√{ DγB
µγBB (z)
}
.
Simplifying we get
√√√√{ DγA
µγAA (z)
}
GAGBγ2Aγ
2
B =
nB
nA
GAγ
2
B
√√√√{ DγB
µγBB (z)
}
.
Solving for nB
nA
we get
nB
nA
=
√√√√{ DγA
µ
γA
A (z)
}
GAGBγ2Aγ
2
B√√√√{ DγB
µ
γB
B (z)
}
GAγ2B
.
Now,
piWA0(βA,βB, γk, z) =
nA
nA + nB
.
Dividing the numerator and the denominator in the right hand side of the equation
by nB we get
piWA0(βA,βB, γk, z) =
nA/nB
1 + nA/nB
.
Substituting for nA
nB
we get
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piWA0(βA,βB, γk, z) =
√√√√{ DγB
µ
γB
B (z)
}
GA
γ2A√√√√{ DγB
µ
γB
B (z)
}
GA
γ2A
+
√√√√{ DγA
µ
γA
A (z)
}
GB
γ2B
.
Re-arranging this we obtain
piWA0(βA,βB, γk, z) =
γB
√{1/(µB(z)}γBDγBGA
γB
√{1/(µB(z)}γBDγBGA + γA√{1/(µA(z)}γADγAGB .
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Appendix E
Deriving the Optimal Allocation
Proportion for minimizing the
Overall trial size for
Semi-parametric Survival Models
The overall trial size can be minimized subject to the asymptotic variance for the
difference in the covariate adjusted hazard ratios for the two treatment arms with the
baseline hazard to remain fixed to a constant. The variance of the covariate adjusted
hazard ratio for a treatment arm k with respect to the baseline hazard is;
V ar{hˆk(t|z)} = zT
{
zT
V¯ −1(t,βk)
k(z;βk)nk
z
}
z exp(2βTk z),
where k = A,B.
Therefore the objective is to
min: nA + nB
subject to : V ar{hˆA(t|z)}+ V ar{hˆB(t|z)} = k > 0.
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Re-arranging the constraint we get,
k− zT
{
zT
V¯ −1(t,βB)
B(z;βB)nB
z
}
z exp(2βTBz) =
zT
{
zT
V¯ −1(t,βA)
A(z;βA)nA
z
}
z exp(2βTAz).
This can also be written as
kB(z;βB)nB − zT{zT V¯ −1(t,βB)z}z exp(2βTBz)
B(z;βB)nB
=
zT
{
zT
V¯ −1(t,βA)
A(z;βA)nA
z
}
z exp(2βTAz).
Solving for nA we get
nA =
zT{zT V¯ −1(t,βA)z}z exp(2βTAz)B(z;βB)nB
kA(z;βA)B(βB, z)nB − A(βA, z)zT{zT V¯ −1(t,βB)z}z exp(2βTBz)
.
The objective here is to minimize nA + nB. Therefore,
min :
zT{zT V¯ −1(t,βA)z}z exp(2βTAz)B(z;βB)nB
kA(z;βA)B(z;βB)nB − A(z;βA)zT{zT V¯ −1(t,βB)z}z exp(2βTBz)
+ nB
is the objective.
Let V ak{hˆk(t|z)} = zT{zT V¯ −1(t,βk)z}z exp (2βTk z) denote the variability adjust-
ment factor for treatment k.
To achieve the minimum value of the objective function,
∂
∂nB
[
V aA{hˆA(t|z)}B(z;βB)nB
kA(z;βA)B(z;βB)nB − A(z;βA)V aB{hˆB(t|zm)}
+ nB
]
= 0.
Differentiating both sides with respect to nB and re-arranging we get,
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{V aA{hˆA(t|z)}B(z;βB)}{kA(z;βA)B(z;βB)nB − A(z;βA)V aB{hˆB(t|z)}}
{kA(z;βA)B(z;βB)nB − A(z;βA)V aB{hˆB(t|z)}}2
−
{V aA{hˆA(t|z)}B(z;βB)nB}{kA(z;βA)B(z;βB)}
{kA(z;βA)B(z;βB)nB − A(z;βA)V aB{hˆB(t|z)}}2
= −1.
Simplifying the expression we get,
A(z;βA)B(z;βB)V aA{hˆA(t|z)}V aB{hˆB(t|z)} =
{kA(z;βA)B(z;βB)nB − A(z;βA)V aB{hˆB(t|z)}}2.
Taking the positive square-root on both sides we get,√
A(z;βA)B(z;βB)V aA{hˆA(t|z)}V aB{hˆB(t|z)} =
kA(z;βA)B(z;βB)nB − A(z;βA)V aB{hˆB(t|z)}.
Substituting for k we get,√
A(z;βA)B(z;βB)V aA{hˆA(t|z)}V aB{hˆB(t|z)} =
V aB{hˆB(t|z)}A(z;βA) + V aA{hˆA(t|z)}B(z;βB)nB
nA
− A(z;βA)V aB{hˆB(t|z)}.
Solving for nB
nA
we get,
nB
nA
=
√
A(z;βA)B(z;βB)V aA{hˆA(t|z)}V aB{hˆB(t|z)}
V aA{hˆA(t|z)}B(z;βB)
.
Which can also be written as
nB
nA
=
√
A(z;βA)V aB{hˆB(t|z)}√
V aA{hˆA(t|z)}B(z;βB)
.
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Now,
piSA2(βA,βB, z) =
nA
nA + nB
.
Dividing the numerator and the denominator in the right hand side of the equation
by nB we get,
piSA2(βA,βB, z) =
nA/nB
1 + nA/nB
.
Substituting for nA
nB
we get,
piSA2(βA,βB, z) =
√
V aA{hˆA(t|z)}B(z;βB/
√
A(z;βA)V aB{hˆB(t|z)}
1 +
√
V aA{hˆA(t|z)}B(z;βA)/
√
A(z;βA)V aB{hˆB(t|z)}
.
This can be written as
piSA2(βA,βB, z) =
√
V aA{hˆA(t|z)}B(z;βB)√
A(z;βA)V aB{hˆB(t|z)}+
√
V aA{hˆA(t|z)}B(z;βB)
.
This can be further written as
piSA2(βA,βB, z) =√
zT{zT V¯ −1(t,βA)z}ze2βTAzB(z;βB)√
A(z;βA)zT{zV¯ −1(t, βB)z}ze2βT z +
√
zT{zT V¯ −1(t,βA)z}ze2βTAzB(z;βB)
.
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Appendix F
Deriving the Asymptotic Variance
of the Cause Specific Cumulative
Incidence Function
From (4.7) the relationship between the subdistribution hazard hsubjk (t|z) for cause j at
treatment k and the corresponding cumulative incidence function Fjk(t|z)) is given by
hsubjk (t|z) = −
d
dt
log{1− Fjk(t|z)}, for j = 1, ...., c.
Therefore,
log{1− Fjk(t|z)} = −
∫ t
0
{hsubjk (u|z)}du, for j = 1, ...., c.
This can also be writted as
Fjk(t|z) = (1− exp[−
∫ t
0
{hsubjk (u|z)}du]), for j = 1, ...., c.
Now, hˆsubjk (t|zi) being the partial likelihood estimator of hsubjk (t|zi),
hˆsubjk (t|z) d−→ Np[hsubjk (t|z), V ar{hˆsubjk (t|z)}].
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Also,
V ar{hˆsubjk (t|z)} = zT
{
zT
V¯ −1(t,βjk)
k(z;βjk)nk
z
}
z exp(2βTjkz),
where k = A,B.
Therefore,
Fˆjk(t|z) d−→ Np[Fjk(t|z), V ar{Fˆjk(t|z)}],
where
V ar{Fˆjk(t|z)} = ∇(1−exp[−
∫ t
0
{hsubjk (u|z)}du])TV ar{hˆsubjk (t|z)}∇(1−exp[−
∫ t
0
{hsubjk (u|z)}du]).
This can be written as
V ar{Fˆjk(t|z)} =
{∫ t
0
∇hsubjk (u|z)du
}T
V ar{hˆsubjk (t|z)}
{∫ t
0
∇hsubjk (u|z)du
}
(
exp
[
− 2
∫ t
0
{hsubjk (u|z)}du
])
,
which mean
V ar{Fˆjk(t|z)} = (tzT )V ar{hˆsubjk (t|z)}(tz)(exp[−2
∫ t
0
{hsubjk (u|z)}du]),
for k = A,B.
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Appendix G
Deriving the Optimal Allocation
Proportion for minimizing the
Overall Cumulative Incidence
Function for a given Cause
The overall cumulative incidence function for cause j can be minimized subject to the
asymptotic variance for the difference in the covariate adjusted cumulative incidence
function for the two treatment arms to remain fixed to a constant. This means,
min : nAjFjA(t|z) + nBjFjB(t|z),
subject to : V ar{FˆjA(t|z)}+ V ar{FˆjB(t|z)} = k > 0
Re-arranging the constraint we get,
k− (tz
T )V ajB{hˆjB(t|z)}(tz)(exp[−2
∫ t
0
{hsubjB (u|z)}du])
jB(z;βjB)nBj
=
(tzT )V ajA{hˆjA(t|z)}(tz)(exp[−2
∫ t
0
{hsubjA (u|z)}du])
jA(z;βjA)nAj
.
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This can also be written as
kjB(z;βjB)nBj − (tzT )V ajB{hˆjB(t|z)}(tz)(exp[−2
∫ t
0
{hsubjB (u|z)}du])
jB(z;βjB)nBj
=
(tzT )V ajA{hˆjA(t|z)}(tz)(exp[−2
∫ t
0
{hsubjA (u|z)}du])
jA(z;βjA)nAj
.
Solving for nAj we get
nAj =
(tzT )V ajA{hˆjA(t|z)}(tz)(exp[−2
∫ t
0
{hsubjA (u|z)}du])jB(z;βjB)nBj
kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)(tzT )V ajB{hˆjB(t|z)}(tz)(e[−2
∫ t
0 {hsubjB (u|z)}du])
.
The objective here is to minimize nAjFjA(t|z) + nBjFjB(t|z). Let
V rjA(βjA, z) = (tz
T )V ajA{hˆjA(t|z)}(tz)(exp[−2
∫ t
0
{hsubjA (u|z)}du])
and
V rjB(βjB, z) = (tz
T )V ajB{hˆjB(t|z)}(tz)(e[−2
∫ t
0 {hsubjB (u|z)}du]).
Therefore,
min :
V rjA(βjA, z)jB(z;βjB)nBj
kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(βjB, z)FjA(t|z) + nBjFjB(t|z)
is the objective.
To achieve the minimum value of the objective function,
∂
∂nBj
[
V rjA(βjA, zi)jB(z;βjB)nBj
kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(βjB, zi)FjA(t|zi)+nBjFjB(t|zi)
]
= 0.
Differentiating both sides with respect to nBj and re-arranging we get,
{V rjA(βjA, z)jB(z;βjB)FjA(t|z)}{kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(betajB, z)}
{kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(βjB, z)}2 −
{V rjA(βjA, z)jB(z;βjB)FjA(t|z)nBj}{kjA(z;βjA)jB(z;βjB)}
{kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(βjB, z)}2 = −FjB(t|z).
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Simplifying the expression we get,
jA(z;βjA)jB(z;βjB)FjA(t|z)V rjA(βjA, z)V rjB(βjB, z) =
FjB(t|z){kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(z;βjB)}2.
Taking the positive square-root on both sides we get,√
jA(z;βjA)jB(z;βjB)FjA(t|z)V rjA(βjA, z)V rjB(βjB, z) =√
FjB(t|z){kjA(z;βjA)jB(z;βjB)nBj − jA(z;βjA)V rjB(βjB, z)}.
Substituting for k we get,√
jA(z;βjA)jB(z;βjB)FjA(t|z)V rjA(βjA, z)V rjB(βjB, z) =[√
FjB(t|z)V rjB(βjB, z)jA(z;βjA)+
√
FjB(t|z)V rjA(βjA, z)jB(z;βjB)nBj
nAj
−
√
FjB(t|z)jA(z;βjA)V rjB(βjB, z)
]
.
Solving for
nBj
nAj
we get,
nBj
nAj
=
√
jA(z;βjA)jB(z;βjB)FjA(t|z)V rjA(βjA, z)V rjB(βjB, z)√
FjB(t|z)V rjA(βjA, z)jB(z;βjB)
.
Which can also be written as
nBj
nAj
=
√
jA(z;βjA)FjA(t|z)V rjB(βjB, z)√
FjB(t|z)V rjA(βjA, z)jB(z;βjB)
..
Now,
piGA3j(βAj,βBj, z) =
nAj
nAj + nBj
.
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Dividing the numerator and the denominator in the right hand side of the equation
by nB we get,
piGA3j(βAj,βBj, z) =
nAj/nBj
1 + nAj/nBj
.
Substituting for
nAj
nBj
we get,
piGA3j(βAj,βBj, z) =
√
FjB(t|z)V rjA(βjA, z)jB(z;βjB)/
√
jA(z;βjA)FjA(t|z)V rjB(βjB, z)
1 +
√
FjB(t|z)V rjA(βjA, z)jB(z;βjB)/
√
jA(z;βjA)FjA(t|z)V rjB(z;βjB)
.
This can be written as
piGA3j(βAj,βBj, z) =
√
FjB(t|z)V rjA(βjA, z)jB(z;βjB)√
FjB(t|z)V rjA(βjA, z)jB(βjB, z) +
√
jA(z;βjA)FjA(t|z)V rjB(z;βjB)
.
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